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ABSTRACT
Worldwide, breast cancer is the most common cancer in women. In Scotland, there aie 
currently over 3,000 women diagnosed with the disease each year and the incidence 
continues to rise. Despite some major advances in the treatment of breast cancer, with 
the discovery of tamoxifen and the on-going development of cytotoxic drugs, only 60% 
of women are still alive after five yeai's, many of whom have a relapse at some later 
stage.
Against that background, the main aims of this thesis are to interpret the findings of a 
survival analysis of cases of breast cancer in Scotland; to investigate whether the 
method of including extra categories for unknown values in factors in that analysis is 
appropriate; and to check whether the assumption of proportional hazai'ds is valid. 
Chapter 1 provides a general introduction, whilst Chapter 2 examines the burden that 
breast cancer places on the National Health Service in Scotland and throughout the 
world. The risk factors for getting the disease and the different strategies available for 
treatment of the cancer are also presented.
To identify how women with breast cancer in Scotland were managed, Chapter 3 
outlines some background to a national retrospective audit of all cases of invasive breast 
cancer in the years 1987 and 1993. Analyses of a subgroup of the 1987 cohort 
constitute the majority of this thesis.
Chapter 4 examines the associations among the variables included in the survival 
analysis. The patterns among the missing values in four' of the prognostic factors are 
also investigated, using log-lineai' modelling. The method employed in analysing this 
cohort of women was to create extra categories to represent unknown values in each of 
the factors. Other teclmiques available for handling missing values in models are 
discussed, along with a summary* of the methods used in other relevant studies of breast 
cancer survival. ..
Chapter 5 presents a survival analysis of the cohort, including a discussion of the 
findings in relation to other relevant studies. Model checking is performed on the best 
fit model to assess the adequacy o f the fit of it and to validate the assumption of 
proportional hazards. The remainder of the chapter focuses on a comparison of the 
results from fitting Cox models using the additional categories and the complete cases 
methods. This investigates whether different inteipretations would be concluded from 
these models.
In Chapter 6, simulated datasets are generated using exponential distributions to 
investigate whether the proportional hazards assumption is valid when additional 
categories are used to extend two factors at two levels to three levels in an exponential 
regression model. The extent of any biases for the parameter estimates is examined.
Chapter 7 provides a summary of the key conclusions and highlights areas of future 
research.
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SECTION A :
BACKGROUND
CHAPTER 1 INTRODUCTION
1.1 SURVEY OF BREAST CANCER IN SCOTTISH WOMEN IN 1987 AND IN 
1993
‘Audit Report’. This detailed the preliminary results of a national population-based 
study of all women diagnosed with invasive breast cancer in Scotland in these two 
years.
The main aims of the audit were:
• to identify how women diagnosed with invasive breast cancer in Scotland in 
1987 and in 1993 were managed;
• to investigate whether there had been any changes in the patterns of care 
between the two study years, during which time a national breast screening 
programme had been introduced;
• to examine how many women were managed according to best practice;
• to identify the factors affecting various outcome measures for the 1987 cohort 
only.
The cohorts were based on all women registered with the national Scottish Cancer 
Registry (SCR) for these two years of diagnosis. However, rather than limit the analysis
1
:
In 1996, the Scottish Breast Cancer Focus Group (SBCFG), the Scottish Cancer Trials 
Breast Group and the Scottish Cancer Therapy Network (SCTN) produced a report for
the Chief Scientist and Clinical Resource and Audit Group in Scotland, entitled
3‘Scottish Breast Cancer Audit 1987 & 1993’ (SBCFG et al, 1996), known here as the |
11
;l
to data collected and held on the national register, specially trained Data Managers from 
the SCTN sought all of the case notes relating to the breast cancer for these women.
They re-examined the contents of them and collected a large amount of supplementary 
data to augment that from the SCR records. This additional information relates to 
refeiTal patterns; initial staging of the tumour at the clinic; the surgical procedures 
performed; other forms of treatment given; pathology details, including extra staging 
information; and follow-up and outcome details.
This dataset provides two national ‘snap-shots’ of the management o f breast cancer in 
Scotland. The Audit Report gives analyses of the quality of the data collected; the effect 
of the breast screening programme; refeiTal patterns, including surgical case load and 
time for referral between presentation and diagnosis; pathological information collected; 
the management of women who did not undergo any surgery; the management of 
women who had surgery, with and without radiotherapy; the use o f systemic adjuvant 
treatment; survival of those women undergoing surgery in 1987; and finally entry into 
clinical trials for breast cancer.
Subsequent to the Audit Report, to date, three peer-reviewed papers (Twelves et al,
1998a; Twelves et al, 1998b; Dewar et al, 1999) and a letter to the BMJ (Twelves et al,
1999) based on the data collected in the Audit have been published. These relate to the 
survival from breast cancer of women undergoing surgery in the 1987 cohort; factors y
affecting clinical trial entry for breast cancer in Scotland for both cohorts; the increase in 
workload of oncologists due to increased use o f radiotherapy and adjuvant systemic 
therapy between the two years; and factors which determined whether a woman moved 
out o f her Health Boai d of residence for her surgery respectively.
1.2 AIMS OF THE MSC
The idea of the project for this thesis came from my heavy involvement in some of the 
analyses of the Breast Cancer Audit data, especially the survival analysis of the 1987
cohort; both for the preliminary report (SBCFG et al, 1996) and for the publication by 
Twelves et al (1998a).
One of the problems encountered during analysis of the retrospective Audit data was the 
large extent of unloiown information for some variables. This was due to looking back 
at case notes, rather than collecting the information prospectively as women are
"I
diagnosed with breast cancer. For example, for some women in the 1987 cohort, the :d
case notes were eight years old when they were examined. Whilst some of the case 
notes simply could not be found, some of the information was not available because it 
just had not been recorded. How to deal with the missing values in the survival analysis 
was an issue. For both publications, the decision was taken to include additional 
categories for the unknowns in each of the factors, so as to avoid throwing away a large 
number of cases and losing information about other variables for these women.
a
The first aim of this thesis is, therefore, to examine whether using these additional 
categories gives different results from those that are obtained when only those women 
with complete information are retained in the analysis. This will discuss whether 
different implications, in terms of political and organisational structures, could be drawn 
from the results.
T
T
From this initial aim, others follow naturally. These include looking at simple 
frequency distributions of the factors to determine the full extent of the missingness; 
investigating whether there are any patterns or associations between the missing values; 
and researching other possible techniques for handling missing data to try to identify any 
which could be applied to the Breast Cancer Audit data.
One final aim is to examine whether it is likely that including the additional categories 
for the unknowns in the survival analysis of the Audit data violates the assumption of 
proportional hazards imposed by fitting a Cox regression model. This will be 
researched using various randomly generated simulated datasets constructed from 
Imown theoretical distributions.
CHAPTER! BREAST CANCER
This chapter provides some background information about breast cancer - how common 
it is, what factors increase the chances a woman will get the disease, how it is usually 
treated and the survival chances for women who have breast cancer.
2.1 DESCRIPTIVE EPIDEMIOLOGY OF BREAST CANCER
Breast cancer is the most common cancer in women worldwide (Parkin et al, 1993). In 
Scotland in 1995 there were 3,156 new cases registered with the national Scottish 
Cancer Registry, representing 26% of all malignant neoplasms in females (Figure 2.1). 
Current estimates suggest that 1 in 12 women in the UK will get breast cancer during 
their lifetime (Evans et al, 1994).
Relative frequencies of nine most common sites 
for females in Scotland, 1995
Breast
26%
Malignant Melanoma of Skin 
3%
Non-Hodgkin's Lymptioma 
3%
Large Bowel
Bladder
Stomach
Uterus
Other Sites
Figure 2J: Relative frequencies offemale cancers in Scotland in 1995.
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2.1.1 CANCER REGISTRATION IN SCOTLAND
1947 -1996
Information about new cases of cancer in Scotland has been collected on a national basis 
since 1947, although computer records only date back to 1958. The file was tumour- 
based with each new malignancy as the basis o f a new record. The Scottish Cancer 
Registry, based at the Information & Statistics Division (ISD) of the NHS in Scotland 
(NHSiS), manages the data centrally.
Data were either collected manually using Scottish Morbidity Record 6 (SMR6) paper 
forms or electronically from vaiious databases held independently within hospital or 
pathology departments. The data were sent to ISD via five regional registries. Basic 
information included name, date of birth and postcode of the patient; date of birth; the 
hospital where the cancer was registered; and the Mate treatment commenced’. There 
were also details about the site code of the cancer to 4 digits, based on the ninth revision 
o f the International Classification of Diseases (lCD-9) (World Health Organisation, 
1977); whether the patient had had previous tumours; whether the current diagnosis was 
histologically verified and if it was, the morphology code, based on the International 
Classification of Diseases for Oncology (lCD-0) (World Health Organisation, 1976).
Derived fields, such as Health Board of residence (based on postcode) and age at 
diagnosis, were then attached to the record. A regular record linkage using probabilistic 
matching (Kendrick & Clarke, 1993) between the cancer file and the death records 
supplied by the General Registers Office (GRO) enabled follow-up of cancer patients %from diagnosis to death.
;,iî!
1997 ONWARDS
The SMR6 scheme was replaced by a fiilly computerised system, known as SOCRATES 
(Scottish Open Cancer Registration And Tumour Enumeration System), in 1997.
The aim of SOCRATES is to identity possible new cases of cancer from multiple 
sources of records. These include hospital discharge records (SMRl), GRO death i
records and pathology and oncology departmental records. SOCRATES links 
information obtained from the various sources and automatically creates a provisional 
cancer registration. The information held on SOCRATES is patient-based, rather than 
tmnour-based.
After allowing six months for treatment details to accumulate, a trained Cancer 
Registration Officer (CRO) scrutinises medical case notes relating to the provisional 
registration. The registration is then confirmed or deleted if  invalid. The CRO 
supplements the basic details with information about the management of the cancer 
including whether surgery was performed, chemotherapy or radiotherapy were given, 
and the initial stage of the tumour is recorded. For breast cancer, pathological 
information about axillary node status and the size of tumour are also noted. All of the 
additional data will be useful for clinical audit and will allow extra prognostic factors to 
be included in survival analyses. These factors were not available from the old SMR6 
files.
The computer records from the SMR6 scheme were appended to SOCRATES to enable 
epidemiological studies of incidence and mortality over time. Therefore, the 
SOCRATES system has records dating back to 1958, now linked by patients rather than 
tumours.
The validity of performing epidemiological studies on the Scottish Cancer Registration 
database is supported by the long collection period, and also more importantly, because 
the information is widely recognised to be of a high standard in terms of both accuracy 
and completeness (Brewster et al, 1994; Brewster et al, 1997). In general, high accuracy 
is reflected by a high percentage of registrations based on tumours having a microscopic 
verification (%MV). The %MV for breast cancer in Scotland in 1995 was 89.6%.
Completeness of ascertainment describes the proportion of cases which are registered 
out of those which should have been registered. This can be indirectly assessed from 
the percentage of registrations made on the basis of a death certificate only (%DCO) 
which occurs when this is the only record supporting the diagnosis of cancer. For these 
records, the date of diagnosis entered onto the cancer registry file is the date of death 
from the death certificate. These DCO cases are usually excluded from survival
analyses as they have zero survival time and provide no other details relating to the 
cancer. A high %DCO rate suggests that incidence rates may be underestimated. In 
1995, the %DCO for breast cancer in Scotland was low at 2.8%, suggesting high 
completeness.
2.1.2 INCIDENCE OF BREAST CANCER
There are approximately 720,000 new cases of breast cancer in the world each year 
(Parkin et al, 1993) with 34,500 cases registered in 1991 in the UK (Cancer Research 
Campaign, 1996). The number of cases registered with the Scottish Cancer Registry for 
the years 1986-1995 are given in Table 2.1.
Year of Number of Women
Registration with Breast Cancer
1986 2617
1987 2684
1988 2680
1989 2775
1990 2969
1991 3171
1992 3233
1993 3110
1994 3071
1995 3156
Table 2.1: Numbers o f cases registered in 
Scotland, 1986-1995.
This table shows an increasing trend in the annual number of reported cases with a 
marked jump around 1990-1992. Although the increase in numbers of cases may imply 
an increase in incidence, it is important to consider the population at risk and the rate of 
disease. To allow for population changes in age distribution over time, it is preferable 
to study age-specific rates (Boyle & Parkin, 1991; Sharp et al, 1993).
I
■ ■ " l i
Age is the most important known risk factor for breast cancer, with the elderly, in 
general, being the high risk group (Henderson et al, 1996). The most dramatic increase 
for all countries is between the age-bands 30-34 to 50-54, between which the rate more 
than doubles. This can be seen in Figure 2.2 which gives the age-specific incidence 
rates per 100,000 population for breast cancer for Scotland and four other countries 
from the developed world.
For the Western World countries, the increase in the age-specific rate slows down for 
postmenopausal women but it is still present. In contrast, for Japan, the ciu've reaches a 
plateau and remains almost constant after the age of menopause. Hoel et al (1983) 
observed that the level of oestrogen in postmenopausal Japanese women is probably not 
very high as they have low body weight and not many excess fat cells (see Section 
2 .2 . 1).
Age-specific rates per 100,000 population, 
selected countries, selected years
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Figure 2.2: Age-specific rates for various countries for breast cancer (Parkin et al, 
1997).
The increase in the number of registrations in 1990-1992 seen in Table 2.1 is primarily 
due to an increase in the age-specific rates for the screening age group 50-64 shown 
below in Figure 2.3 and is probably due to the introduction of the Scottish Breast 
Screening Programme. This was phased in throughout Scotland from 1988, attaining 
national coverage in 1994 (Scottish Breast Screening Programme Central Co-ordinating
Unit, 1997) and led to detection of a lai'ger number of small early breast cancers. In 
1995, 546 (17.6%) of cases of breast cancer were screen-detected.
Age specific breast cancer incidence rates by year, Scotland 1974-95
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Figure 2.3: Age-specific rates in Scotland, 1974-1995, by age group (Scottish Breast 
Screening Programme Central Co-ordinating Unit, 1997).
Another important risk factor for breast cancer is the country in which the women grew 
up (Parkin et al, 1993), although this may in part be due to reproductive risk factors; for 
example, the age of menarche can be affected by temperature, climate and social welfare 
conditions in a country (see Section 2.2.2). To allow comparisons of incidence figures 
for countries with different age structures, the populations are usually standar dised to an 
arbitrary standard population. Often this is either the World Standard Population (WSP) 
or the Eur opean Standard Population (ESP), both of which were first detailed by Doll et 
al (1966). Figure 2.4 shows the variation in World age-standardised rates (WASR) 
across several regional registries, countries and racial groups (Parkin et al, 1997) and it 
is clear that there is a six-fold variation in the rates, although the differences have been 
decreasing gradually over time (Lipworth, 1995).
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Figure 2.4: World age-standardised incidence rates for various countries (Parkin et al,
1997).
Doll et al (1966) point out that probably the most important bias when comparing 
incidence data from different countries is due to different methods of collection used to 
report the cancers. Some incidence rates may be low simply because known cases are 
not registered; alternatively, rates may be artificially higher because cases are registered 
without being verified pathologically to confirm the diagnosis.
Studies of migrants from Japan to the US have shown that these women have a 
marginally increased incidence rate compared with women of similar ages who have 
remained in Japan (Buell, 1973). However, Japanese women born in the US (i.e. 
descendants of these migrants) have veiy similar incidence rates to those of white US 
women (Shimizu et al, 1991), although this is not so obvious from Figure 2.4 for the 
period 1988-1992 in women in San Francisco. These findings indicate that 
environmental and social factors may be more important than genetic factors in altering 
the risk of getting breast cancer.
Breast cancer is also known to be a disease of the affluent, with a much higher incidence 
in women resident in areas of low deprivation or women in high social class (Sharp et 
al, 1993; Henderson et al, 1996). However, this pattern is not observed in either
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mortality or survival rates where both a higher mortality rate and worse survival figure 
are associated with a greater extent of social deprivation in some (Karjalainen & 
Pulckaia, 1990; Scluijvers et al, 1995; Carnon et al, 1994) but not all (Twelves et al, 
1998a) studies (see Section 5.2.3).
Figure 2.5 below shows the association between the risk of breast cancer and the 
Carstairs deprivation index (Carstairs & Morris, 1991). This measure of deprivation is 
often used for Scottish health statistics. The Carstairs classification of socio-economic 
deprivation was adapted to represent quintiles from the total Scottish population, based 
on the 1981 Census and updated for the 1991 Census. This measui'e is area-based and 
assigns to the populations living within small areas a score to reflect not readily 
measurable quantities, such as material well-being or poor access to amenities.
Age standardised (World Standard Population) Incidence rates for 
Scotland,1986-95 by deprivation category
65.0
60.0
0.0
-
77.6
-
--
- -
--
--
•-
- -
Least Dep 2 3 4
Deprivation Category In five quintiles based on the 1991 Census
Most Dep
Figure 2.5: World age-standardised incidence rates in Scotland by deprivation 
category.
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2.1.3 MORTALITY FROM BREAST CANCER
For the whole of the UK, breast caiicer is the most common cause of female cancer 
mortality, representing 20% of all female cancer deaths (Cancer Research Campaign, 
1996). Breast cancer was the cause of death for 3.9% of the 31,709 women who died in 
1995 in Scotland (General Register Office for Scotland, 1996). Although breast cancer 
is more common in older women, it has the highest impact on mortality on women aged 
35-54 (Figure 2.6). In this age range, breast cancer accounted for 15% of all female 
deaths, not just those due to cancer, during 1995 in Scotland compared to 13% due to 
ischaemic heart disease (ICD-9 410-414) and 8% due to lung cancer (ICD-9 162).
Percentage of deaths due to breast cancer out of all female deaths 
Scotland 1995
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Figure 2.6: Percentages o f deaths due to breast cancer by age group.
Scotland has one of the highest rates of breast cancer mortality and can be compared to 
those in other countries (Table 2.2; World Health Organisation, 1996).
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World age-standai’dised mortality rates per 
100,000 population from breast cancer, 
selected countries, most up-to-date years
Netherlands (1994) 26.7
England & Wales (1994) 25.8
Scotland (1995) 25.2
Israel (1993) 24.5
US (1992) 21.4
Australia (1993) 20.4
France (1993) 19.8
Italy (1992) 19.8
Norway (1993) 19.4
Estonia (1994) 17.8
Finland (1994) 16.1
Japan (1994) 7.1
China, various urban (1994) 6.2
China, various rural (1994) 3.6
Table 2.2: World age-standardised mortality rates per 
100,000 population from breast cancer for selected 
countries for the most up-to-date years.
One of the main aims of introducing the Scottish Breast Screening Programme (Scottish 
Breast Screening Prograimne Central Co-ordinating Unit, 1997) was to try to reduce 
mortality from breast cancer in the screened age group, 50-64 years old. Figure 2.7 
shows the European age-standardised mortality rates per 100,000 for Scotland for 1950- 
1995 (Brewster et al, 1996a).
Age-standardised {European standard population) mortality rates, cancer 
of the female breast (ICD-9 174), Scotland 1950-95
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Figure 2.7: European age-standardised mortality rates for Scotland.
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Mortality from breast cancer in Scotland has risen gradually since 1950, although it may 
now be levelling out, or even falling (Brewster et al, 1996a). A fall in mortality is 
supported by data for the whole of the UK (Quinn & Allen, 1995; Peto, 1998). These 
thi'ee studies suggest that the widespread introduction of adjuvant tamoxifen is the 
probable reason for this reduction in mortality. Death rates may be expected to fall 
further as benefits of screening are unlikely to have become fully apparent yet.
2.1.4 SURVIVAL FROM BREAST CANCER
In contrast to mortality, survival depends only on the number of deaths from the disease 
(or from any cause) among patients with the disease and therefore does not depend on 
the incidence (Berrino et al, 1995). Due to this difference, reduction in mortality should 
be the aim of any treatment (cui'ative or preventative) or early diagnosis scheme, such as 
screening. However, treatment effects can best be assessed by examining survival.
CRUDE AND RELATIVE SURVIVAL
The relative survival figure for breast cancer tries to adjust the crude sui'vival from 
breast cancer to correct for other causes of death. It does this by comparing the 
observed survival with the expected survival, based on the general mortality life tables 
for a population with the same age structure, for the same time period (Ederer et al, 
1961). Relative survival is therefore age adjusted but does not allow for any variations 
in the numbers of deaths expected in the different deprivation categories, or Health 
Boards, say.
In Scotland, the crude and relative 5-year survival figures for all ages (0-84) have 
steadily improved since 1968 (Table 2.3). The figures are from Black et al (1993) and 
Harris et al (1998), except the 1988-1992 crude survival figure, which was calculated 
separately as this has not yet been published.
1
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Period Crude 5-year 
suiwival (%)
Relative 5-year 
survival (%)
1968-1972 49.5 56.4
1973-1977 52.0 59.7
1978-1982 55.1 63.1
1983-1987 56.3 64.3
1988-1992 63.8 70.1
Table 2.3: Crude and relative 5-year survival in Scotland.
Crude and relative survival figures may vary by age. For example, 5-year relative 
survival for the 35-44 group was 95.3% compared to 71.3% for the 55-64 group and 
only 18.2% for the 75-84 age group for the 1983-1987 cohort (Black et al, 1993).
Survival figures can also vary by country. Figure 2.8 shows 5-year relative survival 
values for the period 1981-1982 for twelve countries in the EUROCARE study (Berrino 
et al, 1995), for women diagnosed with breast cancer in the period 1978-1985. The 
1981-1982 figures are shown because information was not available for all countries for 
the other years. Sant et al (1998) modelled these data and found variation by age, year 
of diagnosis and country, possibly due to variations in the quality of the data collected, 
or in the quality of the treatment women receive in the different countries (Sant et al, 
1998; Berrino et al, 1995).
5-year relative survival {%) for countries/registries In the 
EUROCARE study, 1981-1982
60 T 77 Average = 68%
Country I  Registry
Figure 2.8: 5~year relative survival (%) for the EUROCARE countries /  registries, 
1981-1982. Note that only Denmark, Estonia, Finland and Scotland are national 
registries.
15
INTERPRETATIONS OF SURVIVAL FROM BREAST CANCER
Identification of prognostic factors for breast cancer survival (Miller et al, 1994) can:
• aid the decision of which treatment to give to a particular patient;
• allow treatments given to groups of patients with similar risks of recurrence or 
death to be compared;
• enliance understanding of breast cancer, which may lead to new treatments or 
strategies being developed;
• assess health education, to encourage earlier presentation;
• help evaluate the impact of the screening programme.
Differences in sui'vival may be due to differences in case mix, by age, region, 
deprivation or variables associated with service provision from the National Health 
Service in Scotland, such as surgical case load. However, it is necessaiy to remember 
that case mix can vary for different levels of these variables as well as any treatment 
effects. That is, the case mix of a group of women may affect the survival chances for 
that group, irrespective of the treatment the women in the group receive. Thus, 
prognostic factors can influence the overall survival prospects o f a group of women, as 
well as affecting the chances of an individual surviving.
For example, it may appear that a group of women detected by the screening 
programme, and therefore treated at a specialist centre (see Section 2.3.1), have better 
survival chances than women treated elsewhere. However, this group of screen-detected 
cases will almost certainly have a higher percentage of women with small, node 
negative tumours (see Section 2.3.2) and will, therefore, inherently have better survival 
prospects than the group of non screen-detected cases, notwithstanding the fact that 
these women may also receive superior treatment having been seen at a specialist centre.
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2.2 AETIOLOGY OF BREAST CANCER
Some basic biological details relating to cancer in general, and specifically to breast 
cancer, are given in Section 2.2.1, whilst knovwi and possible risk factors for developing 
the disease are discussed in Section 2.2.2.
2.2.1 BASIC BIOLOGICAL DETAILS
Normal cells in an organ, such as the breast, are continuously growing, reproducing and 
dying to allow normal function of the organ. Breast cell turnover is under partial control 
o f circulating oestrogens, a group of female hormones. It appears that both oestrogen 
(Henderson et al, 1985) and progesterone stimulate cell division in the breast (Ferguson 
& Anderson, 1981; Henderson et al, 1996). As well as being produced by the ovaries in 
premenopausal women, oestrogen is also produced in smaller amounts from the 
conversion of the adrenal androgens to oestrogen in fat cells. Virtually all o f the 
circulating oestrogens in postmenopausal women are produced via this route.
Cancer is the term used to describe the occurrence of a growth when this continual birth 
and death process goes wrong and abnormal cells develop and become invasive. If 
DNA in a cell becomes transformed, this leads to altered regulation of cell turnover, 
which then leads to cancer. The term malignant tumour or malignant neoplasm can also 
be used for cancer. The majority of breast cancers form in the epithelial cells lining the 
milk ducts in the breast (Henderson et al, 1996).
Boyle & Leake (1988) point out that breast cancer is not one disease, but several and 
prognosis and survival depend on various factors. Firstly, the tumour can be hormone 
sensitive or independent, which affects a woman’s response to hormonal treatment. 
Secondly, tumours can be aggressive in nature or can be slow growing, and finally, that
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the tumour will either remain as a disease of the breast, being controlled locally, or it 
can metastasise very quickly; that is, the ability to ‘‘spread from the site o f origin to 
distant tissues” (Souhami & Tobias, 1995). This is the main attribute which sets 
cancerous cells apart from normal cells. This spread of the cancer occurs when tumour 
cells invade local tissues, or are carried via blood or lymphatic systems to other organs 
throughout the body. Common secondary cancers from the breast include bone, the 
liver, the lungs and skin (Souhami & Tobias, 1995). In the case of breast cancer, it is 
usually the métastasés that kill patients, not growth confined to the local tissue.
2.2.2 RISK FACTORS FOR BREAST CANCER
Oestrogens appear to play an important role in aetiology of breast cancer and may 
mediate the apparent effects of age and geography (Section 2.1.2). Other risk factors 
can be split into those related to reproductive life and those umelated to it.
RISK ASSOCIATED WITH REPRODUCTIVE LIFE
Four risk factors which can be thought of as the natural reproductive factors (i.e. those 
linked to exposure to oestrogen and also to progesterone occumng naturally in the body) 
are age at menarche, length of menstrual cycle, age at menopause and age at first 
pregnancy. Two other factors: use of oral contraceptives and use of hormone 
replacement therapy are artificial reproductive factors. Table 2.4 overleaf gives the 
levels associated with higher risk of developing breast cancer for these factors.
OTHER POSSIBLE RISK FACTORS
Other known or possible factors for breast cancer are now discussed.
Height, weight and body mass index (BMI): Obesity is often measured using the 
Body Mass Index, defined as weight divided by height^, measured in kg/m^.
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Vatten (1996) found strong evidence that height, weight and BMI are all positively 
associated with breast cancer risk for postmenopausal women. The relationship of 
height and weight with breast cancer risk is not so clear for premenopausal women, 
although there is some evidence to support the argument that being obese decreases the 
risk of getting breast cancer for premenopausal women.
Risk Factor Higher Risk References
Age at Menarche Early age.
Two year delay: relative risk 
0.9 (95% Cl: 0.85, 0.94).
Hsieh et al (1990); 
Titus-Ernstoff et al (1998)
Length of Menstrual 
Cycle
Short cycle.
28 day vs 33 day cycle: twice 
the risk
Henderson et al (1985)
Age at Menopause Late age.
Aged 55 vs under 45: twice 
the risk.
Hsieh et al (1990); 
Trichopoulos et al (1972)
Pregnancy Nullparity.
Nulliparous vs parous: 1.5 
times the risk.
Late age at pregnancy.
Aged over 35 vs <18 years: 3 
times the risk.
MacMahon et al (1970); 
Henderson et al (1996); 
Tavani et al (1997)
Use of Oral 
Contraceptives
Currently taking the Pill.
Relative risk 1.24 (95% Cl: 
1.15, 1.33)
Within 10 years of stopping 
use.
Relative risk 1.07 (95% Cl: 
1.02, 1.13).
The Collaborative Group on 
Hormonal Factors in Breast 
Cancer (CGHFBC, 1996)
Use of Hormone 
Replacement 
Therapy (HRT)
Currently taking HRT or 
within 5 years of stopping 
taking it.
For each year of use, risk 
increases by factor 1.02 (95% 
Cl: 1.01, 1.04)
CGHFBC (1997)
: 1 ,
Table 2.4: Risk factors for breast cancer due to reproductive life.
Family history: Evans et al (1994) showed that there is an increased risk of getting 
breast cancer if  there is a history of breast cancer or other associated cancers (ovary, 
prostate, colon) in the family. This risk is even higher if  these cancers occuiTed at an 
early age in the relative. Most of the cases related to family histoiy occur at early age so
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that virtually all breast cancer cases that are diagnosed in women over the age of 60 are 
not due to inlierited gene mutations.
Benign breast disease: This is a general term that is given to several different types of 
non-cancerous diseases that can affect the breast. There is some evidence to suggest an 
increased risk of developing malignant breast cancer for women who had benign breast 
disease compared to women who do not have any previous breast disease (Cancer 
Research Campaign, 1996).
Radiation: Tokunaga et al (1994) examined the incidence of breast cancer among the 
atomic bomb survivors of Hiroshima and Nagasaki in Japan. They found a strong linear 
dose response relationship of radiation exposure with breast cancer risk. This was much 
stronger for women aged under 20 years at the time of the exposure than for women 
aged 40 and over at the time of the bombings. Radiation given as chest x-rays searching 
for tuberculosis showed similar increased risk for getting breast cancer (Lipworth,
1995).
1-
Diet: Many studies have examined whether there is any relationship with breast cancer 
risk and diet. These studies are difficult to conduct as it is hard to know what 
‘exposure’ there was from food and energy levels ought to be taken into account. Since 
diet varies between individuals, across countries and across socioeconomic 
backgrounds, several components have been examined for their links with breast cancer 
risk. No firm evidence has been found to support the link between dietary fat (Cassidy, 1
1996); dietary fibre (Howe et al, 1990; Stoll, 1996) and vitamins A, C and E (Cassidy,
1996; Bohlke et al, 1999) with breast cancer risk.
Alcohol intake and smoking: A recent meta-analysis by Longnecker (1994) showed 
some evidence o f a positive association of breast cancer risk with alcohol consumption, 
both in terms of some versus none and the amount of alcohol consumed. There does not 
appear to be much evidence to link breast cancer risk with smoking (Henderson et al,
1996). A weak inverse association between circulating levels o f oestrogens and 
smoking are discussed by Michnovicz et al (1986).
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2.3 MANAGEMENT OF BREAST CANCER
Whilst there have been some major brealcthroughs in the treatment of breast cancer and #'
the development of drugs which attack the cancer in an effort to prevent it spreading 
tlii'oughout the body, only about 60% of women survive for five yeai’s, many of whom 
have a relapse at some point. The organisation of breast cancer services in Scotland; the 
wide range of treatments available for breast cancer and the importance of participation 
in clinical trials are discussed in this chapter.
2.3.1 ORGANISATION OF BREAST CANCER SERVICES IN THE 
NATIONAL HEALTH SERVICE IN SCOTLAND
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%Traditionally breast surgery was not a separate sub-specialisation but was performed by
most surgeons. Increasingly, treatment is now focused at a Breast Unit or one of the ■IScreening Centres, with surgery being performed by a breast specialist. A policy 
document from the Chief Medical Officers of England and Wales (Expert Advisory 
Group on Cancer, 1995), kno’wn as the ‘Calman/Hine’ report, detailed plans of a 
network between primary care through Cancer Units at district hospitals to Cancer itCentres for the provision of cancer services in England and Wales. One of the main 
points was that breast cancer can be managed at Cancer Units at district hospitals, but 
with Cancer Centres providing expertise in the management of all cancers and having 
additional specialist diagnostic and therapeutic resources, such as radiotherapy.
The Scottish Cancer Co-ordinating and Advisoiy Committee (SCCAC) proposed a 
similar network for Scotland (SCCAC, 1996). The Cancer Centres were identified as 
the locations where radiotherapy is given, namely: Raigmore Hospital in Inverness plus 
the four large teaching hospitals: Aberdeen Royal Infirmary; Ninewells Hospital and 
Medical School in Dundee; Western General Hospital (which in 1987 included the
Longmore Breast Unit, now closed) in Edinburgh and the Western Infirmary/Beatson
I
Oncology Centre in Glasgow. In Scotland, 15 Health Boards provide health care for 
residents within their defined areas. The five Health Boards containing the Cancer 
Centres are Highland, Grampian, Tayside, Lothian and Greater Glasgow respectively.
1
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These Cancer Centres are the bases for non-snrgical oncology with many of the 
oncologists based at them visiting Cancer Units to aid decisions about the prescription 
of chemotherapy. Women are referred from the Cancer Units to the Cancer Centres for
their radiotherapy. There is an increasing acceptance of the need for a multidisciplinary 
approach at specialist Breast Units with specialist surgeons, radiologists, breast care 
nurses, pathologists, oncologists and plastic surgeons.
Richards et al (1997) describe how the implementation of the Calman/Hine proposals 
has worked so far in the West Midlands. Dewar et al (1999) examined the increase in 
the use of radiotherapy and chemotherapy between the years 1987 and 1993 in Scotland 
(based on the Breast Cancer Audit data). They found that there had been an increase in 
the number of patients being referred to an oncologist from 1076 (50% of Audit 
population in 1987) to 1634 (64% of Audit population in 1993), which is a 52% 
increase. The number of patients receiving adjuvant radiotherapy and chemotherapy 
increasing by 72% and 215% respectively. However, there was only an increase from 
32 to 37 consultant oncologists (16% increase) between the two years. Whilst the 
increase in the use of adjuvant therapy is necessaiy to ensui'e appropriate treatment for 
women with early breast cancer (see next section), there must be enough staff with the 
expertise needed to deliver this service. Richai'ds & Pairott (1996) showed that 
oncologists currently only see half of the patients with cancer in Britain. The SCCAC 
report can only serve to increase the workload of these oncologists further.
The main purpose of both the Calman/Hine and SCCAC reports are that all women 
should have uniform access to high levels of specialist care to provide optimal 
treatment. Twelves et al (1999) point out that there were inequalities in determining 
whether or not a woman moved Health Board for her treatment (that is, she was treated 
at a hospital that is not within her Health Board of residence). They found that younger 
women and women living in affluent areas were more likely to move Health Boards for 
their treatment than more elderly or women living in social deprivation.
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MSeveral papers have shown a benefit from women being managed by specialist |
surgeons, and more importantly by a multidisciplinary team (Sainsbmy et al, 1995a;
Sainsbury et al, 1995b; Gillis & Hole, 1996; Twelves et al, 1998a; Twelves et al, 1998b) 
in terms of receiving more appropriate treatment, entering clinical trials and improving
.survival from breast cancer. ii!I■4Ji;
2.3.2 TREATMENT OF BREAST CANCER
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INTRODUCTION
By the time the woman presents, the cancer may already have spread from the breast 
tissue into the lymph nodes, or formed secondary cancers in other organs. The 
management and prognosis of women with no evidence of métastasés at presentation is 
veiy different to that for women where the cancer has spread. Figure 2.9 shows the 
Kaplan-Meier survival curves (see Section 5.1.1) for these two groups of women based 
on all o f the women (n=2148) included in the Breast Cancer Audit in Scotland in 1987 
(Scottish Breast Cancer Focus Group et al, 1996). The non-metastatic group has been 
broken down into those who underwent surgery and those who did not.
O f the 8% of women who had métastasés at presentation, only about 10% of them were 
still alive at five years. The 16% of women who did not undergo sui'gery despite having 
no evidence of métastasés at diagnosis had a better outlook, with approximately 35% of 
them surviving at 5 years. These women were mainly elderly and may have been 
deemed too unfit to have an operation. Alternatively, the tumour may have been too 
large, growing too quickly, or the women may simply have refused surgery. The 
remaining 76% of women did not have métastasés at presentation and did undergo 
surgery. This is the subgroup that was included in all subsequent analyses, as this is the
only group where there is a realistic chance of cure.
Survival functions for the different patient groups
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Figure 2.9: Estimated survival curves for the different types o f breast cancer.
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) define early breast 
cancer to mean any cancer which is confined to the breast (or to the lymph nodes) and 
which can be removed surgically. Thus, disease that has metastasised beyond the breast 
and axilla (metastatic cancer) and tumours that are too large, too aggressive or located in 
an awkward location in the breast such that it cannot be excised (locally advanced 
cancer) are not included in the definition of early breast cancer. The two non-metastatic 
groups above (surgery and no surgery) fall roughly into the early and locally advanced 
categories respectively, although the non-surgical group may have included women 
whose disease was technically early, but who were too unwell with concomitant 
diseases to survive surgeiy or those who refused such treatment.
The EBCTCG have drawn together data from a large number of clinical trials for early 
breast cancer from around the world and have published several overviews. The 
Scottish Intercollegiate Guidelines Network (SIGN), in collaboration with the Scottish 
Cancer Therapy Network (SCTN), recently published clinical guidelines (SIGN/SCTN,
1998) for the management of breast cancer in Scotland (not only for early breast cancer.
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but also for locally advanced and metastatic breast cancer). How a woman is treated 
depends largely on her prognosis when she presents at the clinic.
DETERMINATION OF THE DISEASE AND OPTIMAL MANAGEMENT 
When a woman has been referred to a breast clinic with a suspected breast tumour, 
usually fine needle aspiration followed by a biopsy is used to check whether the cells in 
the lump are malignant. Once the diagnosis has been confirmed, some basic staging 
investigations aie performed. These include a blood test to check blood cell count and 
liver function, a chest x-ray and a clinical examination. The clinical stage and
Cancers can be described in terms of clinical stage and metastatic status. The clinical 
stage describes the state of advancement of the disease. One widely used system is the 
four category TNM classification (UICC, 1987) which depends on the clinical tumour 
(T) size measured, whether there is any nodal (N) involvement (obtained by palpation) 
or any evidence of distant métastasés (M). The metastatic status can also be 
determined by imaging techniques such as bone isotope, MRI and ultrasound scans.
The presence of métastasés means that the cancer is incurable and the survival prospects 
are therefore very poor.
If there is evidence of métastasés then treatment is generally palliative (see below). If 
no secondary deposits can be found then the initial priority is local treatment to deal 
with the cancer in the breast.
TREATMENT FOR EARLY BREAST CANCER
The choice of treatment for eaiiy breast cancer should be made on the basis of the risk 
of recun ence of the disease, the menopausal status of the woman and the wishes of the 
patient. However, the initial management is normally surgery, either conservative 
(where only the lump is excised) or a mastectomy (where the whole breast is removed). 
The surgeon often removes some or all of the lymph nodes in the axilla (axillaiy sample 
or clearance), both for diagnostic and therapeutic purposes. Usually when only the lump
metastatic status are determined hom  results of these simple tests.
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is excised, radiotherapy (RT) is given to the breast, although it can also be given to the 
chest v^all after a mastectomy or to the axilla to try to control the disease locoregionally.
The single most important prognostic factor is pathological node status. This is 
obtained hom  tissue removed from the axilla. The tissue is examined to determine how 
many of the total number of nodes examined show tumour involvement. The status is 
often just given as positive or negative. Nodal involvement is often an indicator that the 
disease has micrometastasised, with tumour cells already spread into the blood supply 
but have not yet infiltrated other tissue and so cannot be detected. In general, if  no 
nodes are positive, the prognosis is good. The outlook worsens as the number of 
positive nodes increases.
Miller et al (1994) show that sui'vival decreases as the number of nodes involved 
increases, with 10-year survival rates being 65%, 38% and 13% for none positive, 1-3 
nodes positive and > 4 nodes positive, respectively. Alternatively, any nodal 
involvement had 10-year survival rate of 25%.
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EBCTCG (1995) showed that there was no survival benefit from performing a 
mastectomy as opposed to lump excisions plus RT for tumours <4cm in size. The 
results from this overview are based on approximately 28,000 women, entered into trials 
for surgery with or without RT, which began randomisation before 1985. In this case 
(size <4cm), the decision for surgery type should depend on factors such as the ratio of
o-'-'the size o f the tumour to the size of the breast, the age of the patient and the patient’s
choice. I
'iAlthough most women do not have clinical evidence of métastasés at diagnosis, surgery f
is not usually sufficient because undetectable micrometastases may already be in the 
blood. These may lay dormant for a number of years until they develop into a clinically
f.detectable recurrence which may eventually kill the patient. It is, therefore, necessary to 
identify the risk of relapse to guide the choice of adjuvant systemic treatments given at 
the same time as surgery. The aim of these therapies is to treat the whole body to try to Éj
prevent the disease recurring or spreading. The factors which identify the risk of relapse 
also, therefore, affect the overall prognostic chances of survival for a woman.
Î
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Another important prognostic factor is pathological tumour size, as measured by the 
pathologist. Ewertz et al (1991) found an increasing risk of death with tumour size, as
M,.did Miller et al (1994), Newman et al (1997) and Gordon et al (1992). When compared 
to tumours < 2cm, the hazard ratios of dying for tumours of size 2. l-5cm and >5cm 
were 1.43 (95% Cl: 1.09, 1.88) and 2.13 (1.33, 3.43) respectively (Newman et al, 1997).
However, Carter et al (1989) reported an interaction between pathological size and
.■pathological node status. That is, the effect on survival was larger for node status 
negative compared to node positive, when tumour size was large than when tumour size 
was small. Conversely, the survival effect was larger for small tumour size compared to :large, when node status was positive rather than negative. They showed that in 71% of 
women with tumour size > 5cm, at least one node is expected to have involvement. #
Tumour differentiation or grade measures the degree o f differentiation of the cells in 
the tumour. That is, how similar the cancer cells are in appearance, shape and structure 
compared to the normal cells in the breast. Miller et al (1994) showed that the grade of 
the tumour affects the survival figures. Grade I (well-differentiated) tumours had a 10- 
year survival of 85% compared to poorly-differentiated tumours (Grade III) having a 
40% survival at 10 years. Ewertz et al (1991), Freedman et al (1979) and Sainsbury et 
al (1995a) all found a similar relationship of smwival with grade.
Age is another factor which is both prognostic for survival and may influence choice of 
treatment. Some of the studies demonstrate a linear decrease of survival with age 
(Freedman et al, 1979; Karjalainen & Pukkala, 1990; Sainsbury et al, 1995a). However, 
other studies showed an increased hazard of death for women aged under 35 compared 
with the group of women aged over 35 (Miller et al, 1994; Richards et al, 1996) and 
under 40 (Newman et al, 1997) compared to 40-49, with the risk then increasing for the 
age groups greater than 40-49.
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Clinical stage is not really used to determine choice of adjuvant treatment for early #
breast cancer, but it is another prognostic factor, since one of its components is the 
presence of métastasés. Several staging methods have been included in reported 
survival analyses, some use the TNM staging method (UICC, 1987), whilst others use
I
the extent o f disease: local (no nodes or métastasés), regional (nodal involvement) or 
métastasés.
Shek & Godolphin (1988) found that survival decreased as the clinical stage increased.
Sainsbmy et al (1994) show that the survival at five years for Stages I, II, III and IV 
were 84%, 71%, 48% and 18% respectively. Stage IV disease represents metastatic 
breast cancer. Clinical stage obtained from the TNM system is not always reliable 
because the measurements are based on clinical assessment and not pathological details 
(Sainsbury et al, 1994). Hundred et al (1994) suggest that true prognostic information 
can only be achieved by histopathological assessment of the nodes removed from the 
axilla because only 70% of involved nodes can be detected clinically. Brewster et al 
(1996b) showed that there was poor agreement between clinical and pathological 
staging information. Sainsbury et al (1995a) and Schrijvers et al (1995) used extent of 
disease to stage the tumour with Sainsbury et al (1995a) quoting an increased hazard of 
death for nodal involvement of 1.99 (95% Cl: 1.89, 2.09) and an even higher one for
.A
metastatic disease (4.39; 95% Cl: 3.98, 4.85) when compared to local disease after ;ï
adjusting for age, grade, deprivation, period of treatment and combination of treatment 
given. Schrijvers et al (1995) reported similar findings.
Oestrogen receptor (ER) status gives a measurement about the presence or absence of 
oestrogen receptors in the cells of the sample of tissue excised. Several ways of 
reporting the ER status mean that scores given by different labs cannot be directly 
compared. The scores are on a continuous scale, with a cut-off selected to separate 
negative from positive. Often only the binary variable is reported and used in statistical 
analyses, irrespective of the method used to obtain it.
IThe ER status of the woman is determined at the age when the transformation of the I
DNA in the cell takes place and not the age at diagnosis. Pujol et al (1998) found that 
67% of peri- & postmenopausal group had ER positive tumours compared to 59% of
premenopausal women. Souhami & Tobias (1995) suggest similar figures for 
postmenopausal (65% ER positive) but only 30% ER positive for premenopausal 
women. In general, having an ER negative tumour implies a poorer prognosis than 
having an ER positive tumour (Newman et al, 1997), with a hazard ratio for ER 
negative vs ER positive of 1.76 (95% Cl: 1.35, 2.29). Similar findings were observed
Î
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by Gordon et al (1992), Hawkins et al (1996) and Shek & Godolphin (1988). However,
Miller et al (1994) suggest that the effect of ER status on survival weakens over time.
They also point out that ER status and tumour grade are often correlated and give the 
example that most Grade III tumours are ER negative. Gluffrida et al (1992) observed
'.:Sthat ER status was significantly associated with body mass index, with obese women 
more likely to have ER positive tumours in both pre- and postmenopausal women.
I
The importance o f ER status is considerable for guiding whether or not hormone 
treatment would be useful. Endocrine therapy aims to prevent the cancer cells getting 
the hormones that they need to grow and survive. The usual drug of first choice is 
tamoxifen which is an anti-oestrogen, but endocrine therapy also includes aromatase 
inhibitors, which block the production of oestrogen from the fatty tissue in 
postmenopausal women.
Two EBCTCG overviews (EBCTCG, 1992; EBCTCG, 1998a) have examined the 
prescription of tamoxifen and the results are based on roughly 37,000 women in 55 
trials. The annual reduction in the odds of recurrence in the two overviews were 25%
(standard deviation (SD) 2) and 26.4% (SD 1.5) respectively. Similarly, there was an 
aimual reduction in the odds of death of 17% (SD 2) and 14.5% (SD 1.7) for use of 
tamoxifen versus none for all ages. From the earlier report (EBCTCG, 1992), the 
corresponding 10-year survival figures for all deaths were 58.8% for the use of 
tamoxifen and 52.6% for none, which gives a veiy highly significant difference of 6.2%
(SD 0.9). The benefits increased with longer duration of tamoxifen (i.e. use of drug for 
five years instead of two years) and SIGN/SCTN (1998) recommend that it be given for 
at least five years.
Ovarian ablation is another form of endocrine therapy. The purpose is to stop the
v:;
normal function of the ovaries. This can be achieved surgically by removal of both of 
the ovaries; by irradiation of the ovaries; or by drugs which suppress their control of the 
menstrual cycle, hence altering the levels of oestrogen and progesterone circulating in 
the blood. Ovarian ablation can be used for early, locally advanced or metastatic breast 
cancer.
Two overviews (EBCTCG, 1992; EBCTCG, 1996) examined the results for about 3,000 
women given ovarian ablation in total, rouglily 2,000 of whom were under 50 years in 
age. The major finding was that ovarian ablation only provided a benefit in women 
aged under 50 years (a surrogate for premenopausal women), with an overall reduction 
in mortality per year of 18% (SD 5.7) for the under 50 group in the latter report. This 
was equivalent to a 15-year survival difference of 6% (SD 2.3) of 45.0% vs 39.0%.
An alternative systemic treatment is chemotherapy (CT), used to kill cancer cells, both 
in the breast and the metastatic cells thi'oughout the body. Chemotherapy is the term 
given to one or more cytotoxic drugs prescribed for this sole purpose and can be used 
for women with early, locally advanced or metastatic breast cancer. It can cause partial 
or complete ovarian suppression in premenopausal women (EBCTCG, 1996).
Two overviews examine the use of chemotherapy (EBCTCG, 1992; EBCTCG, 1998b) 
and are based on approximately 18,000 women. Chemotherapy was given either as 
single agents or in combinations and data are available from over 100 trials. The largest 
benefit was gained from giving polychemotherapy (multi-agents) for a prolonged period, 
although no additional benefit was gained fr om extending the period beyond 3-6 months 
(EBCTCG, 1992).
For women of all ages, the odds reduction in mortality was 11% (SD 2), which was 
highly significant (EBCTCG, 1992). The 5-year survival figures showed a benefit of 
3.3% (SD 1.1) for chemotherapy vs none, and at 10 years the difference was very highly 
significant at 6.3% (SD 1.4). The benefit of giving CT was much greater for women 
aged under 50, although there was still a significant reduction observed for the 50-69 
group. The gain for use of CT was higher for node positive women compared with node 
negative disease (EBCTCG, 1998b).
The exact choice of adjuvant systemic treatment for early breast cancer depends on the 
prognostic factors for risk of relapse and age or menopausal status of the patient, but it 
is generally accepted that either endocrine therapy or chemotherapy be given, either 
alone or in combination, following surgery (Richards et al, 1994).
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TREATMENT FOR METASTATIC BREAST CANCER
This can either be for women with métastasés at presentation or those who develop them 
as secondary cancers. “Currently, patients with distant métastasés are incurable. The 
aim of treatment is therefore to maintain the highest quality of life and relieve 
symptoms” (SIGN/SCTN, 1998). Therefore, all of the treatment given at this stage is 
palliative and not curative in intent.
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TREATMENT FOR LOCALLY ADVANCED BREAST CANCER 
In a minority of patients without evidence o f metastatic disease at presentation, the 
woman cannot be operated upon because the disease has infiltrated the skin of the breast 
or chest wall; is in an awkwaid position; or is growing too rapidly. This cancer is
'Î;îlaiown as locally advanced disease and the median survival for this group of women is 
about 24-30 months, with 5-year survival between 1% to 30% (Rodger et al, 1994).
The initial treatment is radical radiotherapy, followed by systemic treatment 
(SIGN/SCTN, 1998). Rodger et al (1994) point out that it may then be possible to 
perform some surgery if  the systemic therapy reduces the bulk o f the tumoui'. Often 
surgery is only performed on locally advanced disease to attempt to remove most o f the 
tumour if it is fungating tlirough the skin (Souhami & Tobias, 1995). A large number of 
patients with locally advanced cancer will develop uncontrolled disease of the chest 
wall. Patients given standard chemotherapy regimens have lower rates of recuiTence
Î
than women not receiving CT, but they do not have improved survival.
The median survival for women with métastasés from breast cancer is about 18-24 
months, although this varies considerably, depending on the site of the métastasés, 
whether the tumour is hormone sensitive or not, and, for women with non-metastatic 
disease at presentation, the speed of progression of the métastasés. Women with 
métastasés in the bones and soft tissue (skin, other breast, lymph glands) have the best 
outlook, whereas patients with metastatic disease in the lungs, liver or brain may survive v
for as little as two months (Leonard et al, 1994).
Usually endocrine therapy is given first because it is not as toxic as chemotherapy. The 
exceptions to this are if the métastasés are in sites such as the liver, lung or brain; or if  :
I"there has only been a short interval between primary treatment (for patients without 5
métastasés at presentation) and the occurrence of métastasés. In these situations, 
chemotherapy is the first line of treatment.
In some cases, surgery is performed to remove either the primary tumour and/or some of 
the métastasés. The decision to operate or not will depend on site o f the deposit and the 
overall health of the patient.
SIGN/SCTN (1998) recommend tamoxifen (or ovarian ablation for premenopausal 
women) as the first line of treatment, with progestogens (or aromatase inhibitors for 
postmenopausal women) as second line treatment if these fail (i.e. no response to the 
treatment or an initial response followed by disease progression). Only about 30% of 
women have an objective response (complete or partial) to hormone treatment, although 
women with ER positive tumours have a much higher rate of response of about 50-60% 
(Leonard et al, 1994).
When hormonal treatments no longer appear to have any effect on the cancer, 
chemotherapy is then considered. The first line response rates to CT (40-60%) are, in 
general, higher than for hormonal therapy, although they tend not to last as long and 
have more side-effects (Souhami & Tobias, 1995). Gregory et al (1993) found that it 
was not possible to predict which patients were likely to respond, but that women who 
responded to first line CT treatment were more likely to respond to second line CT 
treatment than those who did not respond to the first line treatment (24% vs 12%; 
P=0.04).
The survival benefit due to giving CT may be several months in a few women. These 
must be balanced against the toxic effects of treating women where CT gives no 
response (Souhami & Tobias, 1995; Ramirez et al, 1998).
When standard chemotherapy regimens fail to work, Leonard et al (1994) suggest that 
experimental CT drugs can be administered (with the patient’s consent and adherence to 
the necessary guidelines for administering experimental treatments). In addition, the 
other symptoms of the cancer are treated to try to improve quality of life. Radiotherapy
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CLINICAL TRIALS FOR WOMEN WITH BREAST CANCER
There is, as described, wide variation in treatments given for breast cancer, especially 
among early, locally advanced and metastatic disease, but also within each of these three 
groups. With many new drugs becoming available, it is essential that they are tested 
both alone and in combination with other treatments. They can be assessed frilly only 
thi'ough the use of Phase III randomised controlled trials (RCTs), although experimental 
Phase I and II trials provide the guidance for setting up RCTs.
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can be given as a palliative measure for women suffering from pain due to metastatic si
disease.
Clinical trials are an integral part o f defining better treatments, providing improved 
standards of care and optimising the standard therapy. They offer the opportunity o f a 
major breaktlirough in the treatment of cancer.
The overviews mentioned above demonstrate the large number of trials that have been 
available for early breast cancer. Despite this, participation in clinical trials for breast |
cancer is low. Tate et al (1979) estimated that on average 8% of patients with breast 
cancer in the UK entered clinical trials, whilst overall, 12% of women entered clinical 
trials in Scotland in 1987 (Twelves et al, 1998b) from analysis of the Breast Cancer 
Audit data.
From that Audit, 8.4% and 8.7% of patients in 1987 and 1993 respectively entered trials 
for early or locally advanced breast cancer in Scotland (Twelves et al, 1998b). In this |
study, it was found that being treated by a ‘specialist’ surgeon or seeing an oncologist 
implied that a woman was much more likely to enter a clinical trial. They also found 
that women treated on a clinical trial were more likely to have their tumour staged more 
thoroughly. For example, only 16% of women on a trial did not have their node status 
known compared to 32% of women not treated on a trial. Thus, patients treated on a 
trial may be managed more appropriately. Ramirez et al (1998) suggested that women 
on a clinical trial may have a better prognosis than women treated outwith the trial 
setting. Twelves et al (1998b) did not find a significant suivival benefit for trial entiy, 
although with only 58 deaths in women treated on a trial in the 1987 cohort examined
This chapter has mainly focused on the risk of getting breast cancer, the optimal 
treatment available to women who do get the disease, and the survival chances for these 
women. The next chapter describes the purpose of a national retrospective audit of all 
women identified as having invasive breast cancer in Scotland in the years 1987 and 
1993. This was performed to examine what treatment these women were receiving and 
what were their survival chances.
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for survival, the lack of significance may simply be due to a lack o f power, as the hazard 
ratio suggested a benefit, 0.79 (95% CL 0.59, 1.04; P=0.10) for those women entered 
onto a clinical trial.
O f the women diagnosed with breast cancer in Scotland in 1987, only 83 of the women 
included in the Breast Cancer Audit data (n=2148) were entered into trials for metastatic 
cancer (Twelves et al, 1998b). These women represent 12.8% of the 775 (175 with 
métastasés at presentation plus 600 with non-metastatic disease at presentation, who had |
had a distant relapse by the time the data were collected) women eligible for entiy to a 
trial for women with métastasés.
It seems imperative that the number of women entering clinical trials increases. The 
reorganisation of the health service and support of trials provided by the Scottish Cancer 
Therapy Network mean it ought to be possible to achieve a similar level of participation 
for breast cancer trials in Scotland as that observed for entry of children into trials of 
acute lymphoblastic leukaemia (over 50%; Stiller, 1994). This should lead to improved 
treatments for women with breast cancer, and hopefully, ultimately lead to improved 
survival prospects.
CHAPTER 3 SURVEY OF BREAST CANCER IN SCOTTISH 
WOMEN IN 1987
3.1 AIMS OF THE STUDY, METHODS OF DATA COLLECTION AND THE 
SUBSET OF PATIENTS SELECTED FOR ANALYSIS
AIMS
The main aims of the audit were to identify how women diagnosed with invasive breast 
cancer in Scotland in 1987 and in 1993 were managed and to investigate whether there 
had been any changes in the patterns of care between the two study years, during which 
time a national breast screening programme was introduced (Section 2.1.2). This thesis 
is only concerned, however, with analysis of the 1987 cohort. Analyses relating to the 
management patterns for these women and survival analysis results are discussed in the 
text. One issue to bear in mind is that this study is only a retrospective audit and not a 
controlled randomised clinical trial. Therefore, any conclusions reached can only be 
descriptive, indicating areas where a clinical trial might be appropriate or where further 
research could be beneficial.
METHODS OF DATA COLLECTION
A list o f all women diagnosed with breast cancer in 1987 was obtained from the Scottish 
Cancer Registry.
All patients who were deemed ineligible were removed from this list. These included 
women who were DCO (death certificate only) registrations, because, by definition, only 
limited diagnostic information is held about such patients. Other women excluded were 
those who were diagnosed and treated outside Scotland; those women who in fact had
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non-invasive disease and also those women who had a previous diagnosis of breast 
cancer, identified using probabilistic record linkage (Kendrick & Clarke, 1993).
Having excluded the ineligible women, case notes were then sought for all eligible 
patients. However, not all of the case notes for these women could be found because 
some sets were either missing or had already been destroyed. From the case notes that 
were available, much additional information was collected, to supplement the data that 
had already been provided by the cancer registration system, by trained Data Managers 
from the Scottish Cancer Therapy Network (SCTN). A quality check was performed on 
a random sample of case notes to assess the accuracy of extraction of information from 
the case notes, using cross-checking of data extraction by Data Managers, and also 
checks were performed to assess the accuracy of the data entered onto the audit 
database.
NUMBERS INVOLVED IN THE 1987 COHORT
At the time that the list was drawn up from the Scottish Cancer Registry, there were 
2,581 women who were registered in 1987 as having breast cancer. Out of these 
women, 79 were excluded as they were DCO registrations. Another 101 women were 
deemed ineligible because they were diagnosed and treated outside Scotland, their 
disease was non-invasive or they had had a previous diagnosis of breast cancer. This 
left 2,401 women who were considered to be eligible for inclusion in the study.
The Data Managers were unable to find 164 sets of notes and a further 89 sets had been 
destroyed. This meant, therefore, that infonnation was available for 2,148 women in 
1987. This represented 89% of the eligible cases. Data collection was undertaken 
during the years 1994-5.
It is important to be aware of the fact that there were significantly more notes missing 
(either not located or destroyed) for elderly patients. These patients were more likely to 
have died by the time of the data collection. Notes belonging to deceased people are 
more likely to have been destroyed or archived (where there may be a problem of 
retrieval). This possible bias cannot be accounted for in any subsequent analyses and 
needs to be remembered when interpreting any results.
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ANALYSIS DATASET
Â
A  further 529 women were also excluded here. This was because only 1619 women 
were included in the cohort used in the survival analysis performed on the Breast Cancer
'IAudit data (Twelves et al, 1998a). In that study, only those women who had no 
evidence of métastasés at diagnosis and who underwent surgery were included in the 
analysis. One of the main purposes of this thesis was to investigate the effects o f the 
unknowns on the results and conclusions from that survival analysis (see Chapter 5) 
and, therefore, the cohort of 1619 women was studied here.
4The 529 women excluded were those with metastatic disease (175 in 1987), because 'Ithese women would have been treated very differently from those women with early
•y
breast cancer (Section 2.3.2), and the women whose disease was non-metastatic, but did jS
not undergo surgery (354 in 1987). This latter exclusion was because the three
important prognostic factors: pathological node status, pathological tumour size and ER
status can only be recorded if tissue is removed by surgery. Rather than perform the
analysis on factors with even greater percentages of unknowns (see Section 4.2), the
women who did not undergo surgery were not included in the analysis. It is possible
that some selection bias may have been introduced by this exclusion, say for example, if
different Health Boards had different policies for selecting women for surgery, leading
to only the better prognosis women undergoing surgeiy.
Thus, the subgroup of women included in all analyses based on the Breast Cancer Audit 
data in this thesis relate to the 1619 women who had no evidence of metastatic disease 
at presentation and who underwent surgery.
OUTCOME INFORMATION
The initial plan had been to supplement outcome information collected from case notes 
by linkage to the death records from the General Registers Office (GRO). At the time of 
the initial analysis the latest death information available for linkage was up to the end of 
1993.
It was realised that there would be a problem with the approach of using death 
information collected from case notes with data collection taking place during 1994 and
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the start o f 1995. Bias would be introduced for those case notes examined towards the 
end of collection as these women would have had a longer time in which to have died or 
still have been seen alive. This bias could be regional systematic with Glasgow (being 
the lar gest region for data collection) taking the longest time to collect all o f the 
information.
Therefore, it was decided that the most valid analysis would be to use the probability 
matching technique (Kendrick & Clarke, 1993) to link the cases with the GRO death 
records to obtain the date of death. For those women with no recorded death, the 
assmnption that the women were still alive at 31/12/93 was made. Clearly, this would 
misclassify women who had migrated out of Scotland after diagnosis and died 
elsewhere. However, these women are likely to be few in number.
3.2 VARIABLES COLLECTED AND THE SUBSET SELECTED FOR 
ANALYSIS
INTRODUCTION
The information collected from case notes for all of the women in both years of the 
audit covered the referral patterns; the initial staging information collected at the clinic; 
the surgical procedures undertaken, by which surgeon and the date of diagnosis; other 
forms of treatment given; pathology details including extra staging information; and 
follow-up and outcome details. The data collected at each of these stages of 
management are discussed separately in Appendix 1.
Only information relevant to the analyses undertaken in this thesis are discussed 
subsequently. Analyses based on variables relating to non-relevant information can be 
found in ‘Audit Report’ (Scottish Breast Cancer Focus Group (SBCFG) et al, 1996).
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VARIABLES SELECTED FOR ANALYSIS
The included variables were identified before undertaking the analysis. They fell into 
three categories: clinical, treatment and service(-related) variables. The clinical 
variables (Table 3.1) represent features of the patient and the disease at diagnosis.
These are known to influence survival from prior clinical research (Section 2.3.2). The 
treatment variables (Table 3.2) are known from clinical trials to be of significant 
importance for determining outcome (Section 2.3.2). The service variables (Table 3.3) 
were chosen because they reflect the mode of service deliveiy by the National Health 
Service in Scotland (NHSiS). A social factor, deprivation was also included in with the 
service variables.
Clinical Variables:
Variable Variable Categories
Age at diagnosis <50, 50 - 64, 65 - 79, >80 years
Clinical stage I, II, III, not known
ER status positive, negative, not known
Pathological node status positive, negative, not known
Pathological tumour size <2 cm, >2 cm, not known
Table 3.1: Clinical variables and definitions o f the factors levels used in the analyses.
Age was divided into 15-year age bands so as to include the 50-64 range (the screening 
group) as one group. There were only 33 women aged under 35 years, so the original 
groups <35 and 35-49 were merged into one <50 group and analysed together in all 
analyses.
Clinical stage was derived from TNM staging. Since Stage IV patients are those with 
métastasés, there are no Stage IV patients in the subgroup of 1619 women chosen for 
analysis.
ER status was considered positive if cytosolic protein > 20 fmoi/mg or staining > 10%, 
otherwise it was taken to be negative.
Women were classified as unknown node status for three reasons: the information was 
not known as they had no axillary surgery; it simply was missing from the case notes;
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the sample was inadequate in that it contained less than four nodes, all of which were 
negative.
The two original groups for pathological tumour size, >2-5 cm and >5 cm, were merged 
together to form one group, >2 cm, because there were only 79 women with tumours 
that were greater than 5 cm in diameter.
T r e a t m e n t  V a r ia b l e s :
Variable Variable Categories
Type of surgery mastectomy, breast conservation
Adjuvant chemotherapy given, not given
Adjuvant endocrine therapy 
(including ovarian ablation)
given, not given
Any systemic treatment given, not given
Adjuvant radiotherapy given, not given
Table 3.2: Treatment variables and definitions o f the factors levels used in 
the analyses.
As seen in Section 2.3.2, primary treatment of early breast cancer can include surgery, 
radiotherapy, chemotherapy and hormone treatments. Variables chosen for analysis are 
given in Table 3.2.
Women who had breast conservation followed by a mastectomy within three months of 
the initial surgery were coded as having had a mastectomy as their primaiy treatment.
Adjuvant endocrine therapy included both hormone treatment and ovarian ablation. The 
‘any’ adjuvant systemic treatment group consisted of patients receiving chemotherapy or 
endocrine therapy or a combination of these treatments.
Adjuvant radiotherapy can be given to tliree different sites: to the breast, for women 
who have had breast conservation; to the chest wall, for those women who have had a 
mastectomy; and to the axilla, for all women, except those who have had an axillaiy 
clearance. As explained in Section 2.3.2, radiotherapy is a treatment o f local control 
(trying to prevent local recurrences) rather than systemic control and has not been shown
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to have benefit in terms of overall survival. Therefore, in this thesis, site specific usage 
o f radiotherapy is not considered.
S e r v i c e  V a r ia b l e s :
Variable Variable Categories
Deprivation I = least deprived, II, III, IV, V = most deprived
Health board of first 
treatment
A, B, C, F, G, H, I, L, N, S, T, V, Y
Referral to oncologist 
within 3 mths of diagnosis
yes, no, not known
Surgical caseload 1 - 9  patients per year, 10-29  patients per year, member 
of team or >30 patients per year, not known
Table 3.3: Service variables and definitions o f the factors levels used in 
the analyses.
These variables represent the social background of the patient and organisational 
infrastructure of the NHSiS under which the primary treatment was administered. Table
3.3 gives the service variables chosen for analysis.
The Cai'stairs classification of socio-economic deprivation (Carstairs & Morris, 1991) 
was adapted to represent quintiles from the total Scottish population, based on the 1981 
Census (Section 2.1.2). This is an area-based measui'e of socio-economic status, derived 
from the postcode of residence at the time of diagnosis.
The Health Board of first treatment was the Health Board in which primary treatment 
was administered. Although a few patients may have had neo-adjuvant treatment, the 
decision was made to derive the Health Board of first treatment to be the Health Board 
where surgery was performed for all of those women who underwent surgery (all of the 
cases in the chosen subgroup of analysis for this thesis). Health Board of residence was 
not used because the aim of the audit (SBCFG et al, 1996) was to examine management 
patterns and the effect on survival.
Due to the small numbers o f women treated in the Health Boards covering the Islands 
(Orkney, Western Isles and Shetland), these three Health Boai’ds were grouped together 
as the ‘Islands’ to represent off-mainland treatment. Appendix 2 gives the key to the
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Health Board labels given in Table 3.3. These labels aie those used in the virtually all 
NHSiS documents.
Referral to an oncologist for primary treatment meant that women for whom the date of 
referral was unknown had to be excluded because the referral could have been for 
primary treatment or later following a recurrence. The classification ‘no’ for referral to 
an oncologist included those women who saw an oncologist after three months as it was 
assumed that this referral was not as part of the primaiy treatment. The reason for the 
majority of women seeing an oncologist would have been for the prescription of 
radiotherapy, rather than chemotherapy.
The original surgical case load breakdown was 1-9, 10-24, 25-49 and ‘team’ or >50 
patients per year. Here ‘team’ indicates a group of breast surgeons who collaborate and 
work together in a breast clinic. This was used for some of the analyses reported in the 
‘Audit Report’ (SBCFG et al, 1996). However, the brealcdown given in Table 3.3 was 
the one used in the initial suiwival analysis given in that report and also by Twelves et al 
(1998a) to allow comparisons with the recently published paper by Sainsbury et al 
(1995a). The number of cases a surgeon dealt with per year was based on the total 
number of patients with breast cancer diagnosed under their care, including those 
women who did not eventually undergo surgery. Women who were recorded as having 
had surgeiy in their case notes, but the surgeon’s name was not stated had to be 
excluded frpm analyses involving surgical case load.
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SECTION B :
ANALYSES
CHAPTER 4 DETERMINATION OF MISSING VALUES AND 
CHARACTERISATION OF VARIABLES
4.1 GENERAL CHARACTERISTICS OF VARIABLES SELECTED FOR 
ANALYSIS
INTRODUCTION
This section presents some basic descriptive statistics for the variables chosen for 
analysis in the Breast Cancer Audit. Also discussed are associations for pairs of 
variables with cross-tabulations given in Appendix 4. All of the variables used in the 
analysis were categorical.
BASIC DESCRIPTIVE STATISTICS
C l i n i c a l  V a r ia b l e s :  Table A3.1 in Appendix 3 gives the breakdown of the numbers and 
percentages of cases in the different levels for the factors for clinical variables. Figures
4.1 to 4.5 illustrate these breakdowns. Note that ‘NK’ stands for not known.
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For the 1619 surgical patients, both the mean and median ages at diagnosis were 58 
years. The youngest and oldest women receiving surgery were aged 23 and 89 years 
respectively and the interquartile range was 48 to 67 years. The largest group for age 
was the 50 to 64 age group. Most of the tumour s were clinical stage II, that is, either 
small tumours with node involvement or large tumours with no nodal involvement.
Menstrual status was collected for all hut 85 (5.3%) women. This clinical variable was 
not examined further because it was found to be non-significant in the Cox’s survival 
analysis (see Section 5.2.2).
Despite histological grade being an important prognostic factor for breast cancer (Miller 
et al, 1994), this variable was not included in the list of available clinical factors because 
53% of the women did not have this information recorded. This decision is supported 
by Schemper & Smith (1990), who state that using covariate deletion is their chosen 
option when a large percentage, say 50%, of the data are missing.
T r e a t m e n t  V a r ia b l e s :  Table A3.2 in Appendix 3 gives a corresponding breakdown of 
cases for the treatment variables. Figures 4.6 to 4.10 illustrate the percentage 
breakdowns.
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Mastectomy was the most common surgical procedure in this 1987 cohort, perhaps 
reflecting the fact that the majority of tumours were greater than 2 cm in size. However, 
the mastectomy group included the 117 women who had breast conservation, followed 
by a mastectomy within three months of the conservation sui'gery.
The majority of women getting some form of endocrine therapy received tamoxifen. 
Adjuvant chemotherapy was not widely prescribed for early breast cancer in 1987. The 
classification adjuvant chemotherapy or endocrine therapy is also known as any 
adjuvant systemic therapy in this thesis.
S e r v i c e  V a r ia b l e s :  Table A3.3 in Appendix 3 provides a breakdown of the cases for 
each of the service factors. Figures 4.11 to 4.14 illustrate these breakdowns.
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A = Ayrshire & Arran 
B = Borders 
C = Argyll & Clyde 
F = Fife
G = Greater Glasgow 
H = Highland 
I = Islands 
L = Lanarkshire 
N = Grampian 
S = Lothian 
T = Tayside
V = Forth Valley
Y = Dumfries & Galloway
The fact that 25% of women were in the least deprived group, which was derived to be a 
quintile of the Scottish population, reflected the known higher incidence of breast 
cancer among women living in the less deprived areas (Harris et al, 1998). Only three 
categories were used, instead of five, to highlight the differences between the least 
(category I) and most deprived (category V) women more clearly.
There were 278 women in the sui'geon case load grouping who managed only one to 
nine cases of breast cancer in 1987. Seventy-eight surgeons saw these women, with 23 
surgeons only seeing one patient in that year. Thus 17% of the women in the cohort 
were operated on by surgeons who were relatively inexperienced with breast cancer, 
although there might be some underestimation of the case loads of surgeons who took 
up post or retired during the year of study (likely to be few in number).
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The five Health Boai'ds containing Cancer Centres are Highland, Grampian, Tayside, 
Lothian and Greater Glasgow respectively (Section 2.3.1) and are known in this thesis 
as Cancer Centre Health Boards (CCHB). The other Health Boards are known here as 
non-Cancer Centre Health Boards.
The number of women living in a CCHB was 885. Of these women, only 477 (53.9%) 
were actually operated on at the Cancer Centre.
ASSOCIATIONS BETWEEN PAIRS OF VARIABLES
The clinical variables were examined to investigate whether these variables, which 
represent the state of the tumour the clinician was faced with at the clinic, were related. 
A selection of relationships which were deemed to be interesting from a clinical point of 
view were also investigated. Table 4.1 presents the P values for the ^  tests of 
association which were performed.
c **
E **
N * * ** **
T 0.001 ** ** **
H 0.001 ** ** ** * *
S ** ** ** 0.42 -
R ** ** - - ~ - -
D 0.24 0.32 - - “ - -
CT - - ** - - ** -
TS " - - - - 0.27 - - -
A C E N T H S R D CT
Table 4.1: P values for tests o f association for various variables. Note that '
indicates a P value <0.001; - ’ means that the association was not tested. Age is given 
by A, clinical stage(C), node status(N), tumour size(T), ER status(E), Health Board(H), 
surgeon case load(S), referral to oncologist(R), deprivation group(D), 
chemotherapy (CT) and type o f surgery (TS) respectively.
All of the clinical variables were associated with each other and also there were 
differences in the levels of these variables amongst the Health Boards. These significant 
results for Health Board could be because there were differences in the proportions 
originally selected for surgeiy in the different Health Boards (data not given). This
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could lead to different distributions of the clinical factors for the patients treated in 
different Health Boards.
Neither age nor clinical stage at presentation were associated with the deprivation 
category assigned to the postcode of residence, although there was a significant 
association between deprivation and ER status. This is discussed further in Sections 
5.2.2 and 5.2.3. Use of chemotherapy depended upon referral to an oncologist, age and 
node status. These results were expected with the majority of women receiving 
chemotherapy heing aged under 50 years with node positive disease. This is the group 
of women, subsequently shown in the overview (EBCTCG, 1992), where chemotherapy 
has a beneficial survival effect over no use of chemotherapy (Section 2.3.2). The type 
o f surgery performed was independent of the case load of the surgeon, although all of 
the clinical variables, except tumour size, were associated with surgeon case load.
Cross-tabulations of pairwise clinical variables: It is possible that some of the P 
values for the tests of association were only significant because of differences in the 
proportions of unknowns in the different levels. Tables A4.1 to A4.10 in Appendix 4 
give the percentages in the cross-tabulations of the pairs of clinical variables. To 
examine whether different proportions of unknowns caused the significant results, tests 
of association on each of the pairwise-complete pairs of variables were performed 
(Table 4.2).
c * *
E 0.001 0.13
N 0.42 0.58
T 0.09 ** 0.001 4; $
A C E N
Table 4.2: P values for Wsts o f association for
pairwise-complete clinical variables. Note that 
indicates a P value <0.001. Age is given by A, clinical stage(C), 
node status(N), tumour size(T) and ER status(E) respectively.
Therefore, the observed significant associations for the pairs of variables: age by node 
status; age by tumour size; clinical stage by ER status and ER status by node status 
appeared to be due to differences in the proportions of unknowns in the different levels
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of the factors. Here, when all of the information was complete, the hypothesis of 
independence for each of these four pairs of factors could not be rejected. However, 
there were still significant differences between the numbers observed and expected for 
the different levels for the pairs of factors: age by clinical stage; age by ER status; 
clinical stage by node status; clinical stage by tumour size; ER status by tumour size and 
node status by tumour size. Some findings from the tables for these six cross­
tabulations are now given.
From Table A4.1 in Appendix 4, there was a larger percentage of clinical stage I women 
in the under 50 age group, but a lower proportion of women with clinical stage III
Idisease in this age group, than expected. There appeared to he larger number than 
expected of these stage III women in the age group 65-79.
There also appeared to be a larger percentage of ER negative women aged under 50 
(Table A4.2 in Appendix 4) than in the older age groups. This agrees with Souhami & |
Tobias (1995; Section 2.3.2). However, there was a larger proportion of cases with ER 
status unknown for women aged over 65, especially those over 80 years.
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There were many more women with pathological node negative disease with clinical 
stage I than expected from a statistical point of view, although not from a clinical point 
of view, with clinical node status being a component of clinical stage. That is, it would 
be expected that pathological node status would be related to clinical stage. Similarly, f
there were more women with pathological node positive disease whose clinical stage 
was stage II or III, especially III. There were more women with pathological node status 
not determined for women with clinical stage I disease or with clinical stage unknown 
(Table A4.6 in Appendix 4). I
Similarly, there were many more women with pathologically small (< 2cm) tumours 
with clinical stage I than expected under the assumption of independence between these 
factors. However, with clinical tumour size being a component of clinical stage, it is not 
suiprising from a clinical point of view that clinical stage was associated with 
pathological tumour size. There were more women with large tumours (>2cm) with 
clinical stage II or III. Again, there were more women than expected who had neither of 
these factors recorded (Table A4.7 in Appendix 4). !■
' f
j
There were more women with small tmnours which were ER positive than expected and 
more women with large tumoiu’s that were ER negative. There were also differences in 
the proportions with unknown tumour size across the levels of ER status (Table A4.9 in 
Appendix 4).
There were many more women with node negative disease who had small tumours than 
expected. Similarly, there was a larger percentage of women with large tumours that 
also had nodal involvement than would he expected by chance (i.e. under the 
assumption of independence). This supported the findings of Carter et al (1989; Section
2.3.2). There were more women with both of these factors missing than expected 
(Table A4.10 in Appendix 4).
Cross-tabulations of the clinical variables with surgeon case load: The associations 
of surgeon case load with the clinical variables were then examined to investigate 
whether significant results were due to differences in the proportions in the unknowns in 
the different levels. The cross-tahulations for each of the clinical variables with surgeon 
case load are given in Appendix 4 (Tables A4.11 to A4.15), although there was no 
evidence to reject independence of surgeon case load by pathological tumour size.
These were examined because surgeon case load and specialisation has been linked to 
survival in several studies (Gillis & Hole, 1996; Sainsbury et al, 1995a; See Section
5.2.3).
There were more women aged under 65 years who were managed by a surgeon in the 
Team or 30 or more cases per year group. This group of surgeons (high case load) saw 
many more women with clinical stage II disease, but also more ER positive tumours. 
However, the most striking observation from the tables given in Appendix 4 is that this 
high surgeon case load group had much lower proportions of unknowns in the clinical 
variables. When the unknowns were excluded from the analyses, the pairs of factors 
became non-significantly associated (P=0.50 for clinical stage; 0.08 for ER status; 0.20 
for node status). This suggests that the observed differences in the levels for the known 
factors by surgeon case load were because the high case load group was managing more 
women whose disease had been better staged. The possible influences on survival are 
discussed further in Section 5.2.3.
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4.2 PATTERNS OF MISSING VALUES AND LOG-LINEAR MODELLING
The last section showed that the clinical vaiiables were inter-related. The four 
variables: clinical stage, pathological node status, pathological tumour size and ER 
status have all been shown to have prognostic importance in terms of survival from 
breast cancer (Miller et al, 1994). There were some cases where this information was 
missing for these factors, and the patterns of the missing values in these data are now 
examined, both descriptively and by log-linear modelling.
4.2.1 THE VARIABLES: CLINICAL STAGE, PATHOLOGICAL NODE 
STATUS, PATHOLOGICAL TUMOUR SIZE AND OESTROGEN-RECEPTOR 
(ER) STATUS
For the 1619 patients, Table 4.3 shows the numbers and percentages which were known 
and missing for each variable.
Table 4.3: Numbers and percentages o f known and missing values for each o f the 
four variables o f interest.
Only 578 (35.7%) of the women had all four variables known. These cases comprise 
the group known as the ‘complete cases’. The number of cases where there was only 
one, two or tlnee of the four variables missing were 546 (33.7%), 350 (21.6%) and 113 
(7.0%) respectively. There were only 32 (2%) of the 1619 women who had no 
information recorded for any of the four variables. Therefore, about 30% of cases had 
two or more of these variables missing.
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Variable Number (%) Number (%) Total
Known Missing
Clinical Stage 1302 (80.4) 317 (19.6) 1619
Pathological Node Status 1184 (73.1) 435 (26.9) 1619
Pathological Tumour Size 1287 (79.5) 332 (20.5) 1619
ER Status 990 (61.1) 629 (38.9) 1619
I
To investigate whether the missing values are related, log-linear modelling is performed. 
Some theory is now given for this technique.
4.2.2 THEORY OF LOG-LINEAR MODELLING
In the situation where several categorical variables have heen cross-classified to give a 
contingency table, it is the counts of the individuals falling into the cells of this table 
that are modelled.
Let represent the frequency of the (7 , Ar,/,m)th cell, where the four variables take
the values:
ER status (E): 7  = 1,2 
Tumour size (T): ^ = 1,2 
Node status (N): / = 1, 2 
Clinical stage (C): m = 1, 2 , 
where each factor has level 1 meaning known and level 2  meaning missing.
Also, let represent the probability that a randomly selected individual falls into cell 
(7 ,A:,/,m). Let the vectors x  and S  represent the 16 frequencies and the 16 
probabilities respectively, for simplicity.
Considering the total sample size to be fixed (« = 1619), the sampling distribution from 
which these counts are assumed to come can be shown to be multinomial (Dobson, 
1990), since the assumption is made that the original counts are from independent 
Poisson variables, but these are constrained by the total fixed sample size and are thus 
from a multinomial sampling distribution.
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The probability density function for the vector x  conditional on 2^ , is given
Jklm :i
by
with the constraints 0 < < 1 and = 1.
The expected value of a particular element of x  is given by 
E { x j u )  =  n & jt„„ . (Eq4.2.2_l)
In a log-linear model the logarithms of the expected frequencies at*e assumed to have a 
linear form
16
log e [ x ju ,„) = , (Eq 4.2.2_2)f-1
where p  is an 16 x 1 vector of unknown parameters and z  is an 16 x 1 vector of
indicator variables, z,..
where S j  =  , the marginal prohability of being in ER status level y for y = 1, 2.
klm
Therefore, if the hypothesis of global independence holds then, from Eqs 4.2.2 1 and 
4.2.2_3, the expected frequencies are given by
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jkhn %
jklm  ^  jklm  * S
jklm  ^  ^ Z _ j  ^ jk lm  ~  ^ ■ ; Î
jklm  j
One hypothesis of interest is that of complete marginal independence. When this holds,
a
(Eq4,2.2_3) |
Similarly, i9^  , i9, and i9 are the marginal probabilities for the tumour size, node 
status and clinical stage variables respectively.
This can be written in terms of a main effects log-linear model with the structure
\oq,E[xj„„) = + +Ptz^+r,z^+ô„,z„
with the appropriate constraints on the parameters and .
Similarly, the maximal (or fully-saturated) model can be written as the model with a 
constant ; four main effects; six two-way interaction terms; four thi'ee-way interaction 
terms and a four-way interaction term.
Since the sampling distribution is assumed to be multinomial with n  fixed, the log- 
linear model must include the corresponding parameter jn . In this analysis, a corner- 
point constraint is imposed, with cell (1,1,1,1) where all of the variables are known, 
taken as the reference cell. Also, all o f the terms including the first levels of the 
variables are set to be zero. Thus, = 0, = 0, = 0, = 0, = 0,
= 0  etc.
Every variable has only two levels and since all of the terms involving the first levels ar e 
set to zero, there is no need to include the subscripts on the parameter terms. Therefore, 
the unknown parameters given in Eq 4.2.2_2 can be written as:
A  P2=gc\ A  = A ;  A  ; A  A  A  = ;
A  ~  A  “  (A f ) 5 Ao ~  (A ^) 5 All — 5 Ai2 “  is^Pï) )
Ai3 = (« A ^  ; Ai4 =  ; A s = ( A / 4  ; Ao =  («A r^) ■
The main effects are represented by a  for ER status; P  for tumour size; y  for node 
status and 5  for clinical stage respectively. The two-way, three-way and four-way 
interactions are denoted, for example, by (cuy )^, [^ocPy] and respectively.
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4.2.3 RESULTS OF LOG-LINEAR MODELLING
For the four variables of interest in the Breast Cancer Audit data, the breakdown of the 
observed values in the 16 cells is given in Table 4.4.
ER Status Tumour Size Node Status Clinica stage
Known Missing
Known Known Known 578 81
Missing 133 26
Missing Known 100 30
Missing 32 10
Missing Known Known 232 73
Missing 124 40
Missing Known 65 25
Missing 38 32
Table 4.4: Observed numbers o f cases in each o f the 16 cells.
GLOBAL INDEPENDENCE
For the complete marginal independence model, the likelihood ratio statistic had a 
value of 137.12 on 11 degrees of freedom (df) with P<0.0001. Therefore, the 
hypothesis that the missing values in the variables were independent of each other could 
be rejected. Thus, examination of the interactions between the variables was necessary 
and a search was made to try to identify the ‘best’ log-linear model fitting the data.
OTHER MODELS
The teclinique of backward elimination (Armitage & Berry, 1994) was used for the 
model selection. Only hierarchical models were sought. Table 4.5 below shows the 
results of this process starting with the maximal model, but only gives the highest 
generating classes for the model fitted at each step. A generating class is a way of 
describing what terms are in the model and is best illustrated through an example.
I
f
Ï
:::::
JÏ.
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Example: Step 4 from Table 4.5 below has generating classes given by
E*T*C, T*N*C, E*N, 
where E, T, C and N stand for ER status, tumour size, node status and clinical stage 
respectively.
E^T'^C means that all of the t Q r m s [ a p ô ) , [ a l ^ X a ô ) , [ p ô ) ,  a , p , ô  and ju are 
included in the model.
T*N*C with E*T*C means that the extra terms [ p y ô ) , [ p y )  , { y S )  and y  are 
also included in the model.
E*N with both E*T*C and T'^'N^C means that the extra term(<%%) is also 
included in the model.
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Due to the hierarchical structure, only the highest order terms were assessed for removal 
at each step. Thus for example at Step 4, despite the fact that there were 13 terms in the ;
model, only the interactions [ a p â ) , [ p y â )  and ( a y )  were examined to see whether they
could be removed from the model. At each step, the term which gave the smallest non­
significant change of the likelihood ratio was removed. The model fitted (shown using 
the generating classes representation), along with the P values for removal of the highest 
order terms, are presented for each step in Table 4.5.
B E S T F I T M O D E L
Step 7 below shows that the best fit model included all of the two-way interactions, I
except for the one between node status and clinical stage. The likelihood ratio goodness 
of fit statistic for this model was 7.64 as (P value =0.266) and hence this model 
could not be rejected.
..Ï-
*
Terms examined Change in LR P Value
Step 1: Generating Class: E*T*N*C
{apyô) 2.812 0.0936 - removed
Step 2: Generating Classes: E*T*N, E*T*C, E'^ bPC, T*N*C
(aP r) 0.025 0.8755
(a p é ) 0.504 0.4778
[ayd] 0.000 0.9828 “ removed
(pyS) 1.105 0.2932
Step 3: Generating Classes: E*T*N, E*T*C, T*N*C
(a p y ) 0.024 0.8768 - removed
(a p s ) 0.509 0.4757
1.105 0.2932
Step 4: Generating Classes: E*T*C, T*N*C, E*N
{a p s) 0.498 0.4806 - removed
[Pyé) 1.157 0.2820
[a y ] 46.974 <0.0001
Step 5: Generating Classes: T*N*C, E*N, E*T, E*C
0.928 0.3353 -removed
{a y ) 46.728 <0.0001
(a p ) 7.623 0.0058
ia 5 ) 26.143 <0.0001
Step 6: Generating Classes: E*N, E*T, E*C, T*N, T*C, N*C
[a y ] 46.725 <0.0001
[ap] 7.621 0.0058
{a5) 26.141 <0.0001
(P r) 4.869 0.0273
(M 17.009 <0.0001
[rs] 3.378 0.0661 - removed
Step 7: Generating Classes 
BEST FIT MODE]
;: E*N, E*T, E*C, T*N, T*C
[a y ] 51.204 <0.0001
[ap] 7.326 0.0068
{aS) 30.619 <0.0001
[P r) 5.908 0.0151
18.048 <0.0001
T a b l e  4 .5 :  T h e  s t e p s  in  th e  b a c k w a r d  e l im in a t i o n  p r o c e s s  w i th  th e  h ig h e s t  g e n e r a t i n g  
c l a s s e s  f o r  e a c h  s e t  o f  v a r i a b l e s ,  a l o n g  w i th  th e  P  v a lu e s  f o r  r e m o v a l  o f  th e  h ig h e s t  
o r d e r  t e r m s  f r o m  m o d e l ,  b a s e d  o n  c h a n g e  in  th e  l i k e l i h o o d  r a t i o  (L R ). N o te  th a t  E  
s t a n d s  f o r  E R  s ta tu s ,  tu m o u r  s i z e ( T ) ,  n o d e  s ta tu s ( N )  a n d  c l i n i c a l  s t a g e ( C ) .
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The parameter estimates with their standard errors for the best fit model are given in 
Table 4.6. All o f the terms have 1 df. No standard error was calculated for the constant 
term because the multinomial sampling distribution was assumed and so this term was 
considered to be fixed.
Term Parameter Parameter
Estimate
Standard 
Error (se)
Constant (all loiown) P 6.3497
ER status missing a -0.9036 0.0716
Tumour size missing P -1.7418 0.0949
Node status missing 7 -1.4300 0.0837
Clinical stage missing 5 -1.8752 0.0962
ER status missing by 
tumour size missing
[a p ) 0.3495 0.1287
ER status missing by 
node status missing
[a y ) 0.8193 0.1148
ER status missing by 
clinical stage missing
{a ô ) 0.7072 0.1278
Tumour size missing by 
node status missing [P r )
0.3328 0.1355
Tumour size missing by 
clinical stage missing iP S )
0.6236 0.1437
T a b l e  4 .6 :  P a r a m e t e r  e s t im a te s  a n d  th e i r  s t a n d a r d  e r r o r s  f o r  th e  t e r m s  in  th e  b e s t  
f i t  m o d e l .
All of the parameter estimates for the interactions represented being missing compared 
with being known. Since all of these parameter estimates were positive, then this 
implied that there was a positive association between the chances of the values being 
missing in both variables in each of the two-way interactions, except for the non­
significant interaction between node status and clinical stage. Thus, it was more likely 
that the second variable was missing if  the first variable was missing than when the first 
variable was laiown.
Table 4.7 below gives the estimated fitted values from the ‘besf model for the 16 cells 
along with the observed values from Table 4.4. It can be seen that the estimated 
expected numbers of cases falling into each of the cells are fairly close to the observed 
numbers.
- ' I
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ER
Status
Tum our
Size
Node
Status
Clinical Stage
K M
K K K 0 578 E 572.30 0 81 E 87.75
M O 133 E 136.96 0 26 E 21.00
M K o 100 E 100.27 o 30 E 28.68
M o 32 E 33.47 0 10 E 9.57
M K K o 232 E 231.85 o 73 E 72.10
M o 124 E 125.89 o 40 E 39.15
M K o 65 E 57.62 0 25 E 33.43
M o 38 E 43.64 0 32 E 2532
T a b l e  4 . 7; O b s e r v e d  (O )  a n d  e x p e c t e d  (E ) n u m b e r s  o f  c a s e s  in  e a c h  o f  th e  1 6  c e l l s .  
N o t e  th a t  K  a n d  M s t a n d  f o r  k n o w n  a n d  m i s s i n g  r e s p e c t i v e ly .
LOOKING AT THE SUB-TABLES
To obtain a general pictui'e as to why the significant two-way interactions were needed 
in the model it is possible to look at the sub-tables of observed values for the pairs of 
variables (easily obtainable from Tables A4.1 to A4.10 in Appendix 4). The 
percentages for being missing in the second variable given that the first variable was 
missing compared with being missing in the second variable given that the first variable 
was known are given for the six pairs o f variables in Table 4.8. The P values for the 
differences between the proportions and for the corresponding interactions in the log- 
linear model are also given.
The associations between missing values in the pairs of variables are apparent from 
examination of the percentages. It can be seen that the proportion missing in the second 
variable when the first vaiiable was missing is always lai'ger than the proportion missing 
in the second variable given that the first variable was known. Caution is needed when 
interpreting the univariate results because the sub-tables are not derived from the log- 
linear model. The percentages are based only on the collapsed sub-tables of observed 
values for the pairs of variables and as such are only illustrative.
The reason for caution can be demonstrated by looking at the observed proportions for 
the clinical stage by node status sub-table. Simple comparison shows that the node 
status was missing in 34% of the cases when clinical stage was also missing but was 
missing in only 25% of cases when clinical stage was known. This observed difference
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was statistically significant (P=0.001) for the univariate test of differences in the 
proportions (Table 4.8). However, the interaction between this pair of variables 
dropped out of the log-linear model at Step 6, with a P value of 0.066 (Table 4.5). This 
P value is conditional on the other variables being in the multivariate model. There is, 
perhaps, some weak evidence to suggest that the missing values were related, although 
this was not statistically significant at the 5% level.
I
y..
First
variable
% Second variable 
missing given first 
variable missing
% Second variable 
missing given first 
variable known
P value test for 
differences in 
proportions
P value in log- 
lineai* model
ER status
Node status 
37
Node status 
20 <0.0001 <0.0001
ER status
Tumour size 
25
Tumour size 
17 0.0001 0.007
Node
status
Tumour size 
26
Tumour size 
19 0.002 0.015
Clinical
stage
ER status 
54
ER status 
35 <0.0001 <0.0001
Clinical
stage
Tumour size 
31
Tumour size 
18 <0.0001 <0.0001
Clinical
stage
Node status 
34
Node status 
25 0.001 0.066*
* not indue ed in the log-linear model
T a b l e  4 .8 :  P e r c e n t a g e s  m i s s i n g  in  th e  s e c o n d  v a r i a b l e  g i v e n  th a t  th e  f i r s t  v a r i a b l e  w a s  
e i t h e r  m i s s i n g  o r  k n o w n , a l o n g  w i t h  th e  P  v a lu e s  f o r  t e s t i n g  th a t  th e  p r o p o r t i o n s  w e r e  
th e  s a m e  in  th e  u n i v a r ia te  s u b - t a b l e s  a n d  P  v a lu e s  f o r  th e  te r m s ,  c o n d i t i o n a l  o n  th e  
o th e r  te r m s ,  in  th e  m u l t i v a r i a te  lo g - l i n e a r  m o d e l .
C O N C L U S IO N S
The aim of this analysis was to find out whether there were any associations among the 
missing values in the variables. The hypothesis of no association among the binary 
variables was rejected. It was found that all two-way interactions were necessary in the 
model, except the interaction of node status by clinical stage. Thus, there was pairwise 
dependence between each pair of variables, although there was no evidence to suggest 
that each two-way interaction was affected by the values of the third and fourth 
variables. This interpretation holds except for the interaction of node status with 
clinical stage. For this term, there was insufficient evidence to reject conditional 
independence between these two vaiiables, given the third and fourth variables.
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In general, a log-linear model with a significant two-way interaction of two factors, each |
at two levels, suggests that the expected numbers of cases at level 2 of factor 1 are
different for the two levels of factor 2. In this analysis, for example, there was a
significant interaction for clinical stage with ER status, both at two levels either known 
.or missing. Here the two-way interaction indicated that the expected number of cases <
with ER status missing was associated with whether clinical stage was known or
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-t.missing.
CLINICAL INTERPRETATIONS 
From a clinical point o f view, it is not entirely clear how the missing values in the 
variables are expected to be associated with one another. Having discussed this matter 
with clinical colleagues prior to the analysis, two possible opposing hypotheses were 
given:
(i) it may be argued that there will be associations among the missing values of 
the tliree pathological variables: node status, tumour size and ER status. However, no 
associations are expected between whether or not clinical stage is missing with these 
tlnee pathological variables being missing, except possibly with node status.
The reasoning behind this hypothesis is that there were three individuals involved in the 
process of recording the information about these four clinical variables in 1987. The 
sui'geon determined clinical stage in his clinic prior to surgery and may or may not then 
have entered the details onto the case notes. The pathologist examined any material p
excised during the operation and recorded the pathological features (node status and 
tumour size) of the tumoui*. Thus, it might be expected that if  one of these were 
missing, then so would the other. ER status was determined by the biochemist i f  a 
specimen was sent from the pathologist. However, there is a possibility that node status 
might be associated with clinical stage because the node status in the axilla can only be f
recorded by the pathologist i f  the surgeon actually removed some nodes from the axilla 
as part of the surgical procedure, perhaps because of the clinical node status.
1:;•r4
P(ii) it might be expected that all of the variables will be associated with one 
another in terms of the missing values.
t-:The reasoning behind this hypothesis is that institutions may have agreed protocols, or 
at least informal practice agreements, for management of women with breast cancer.
Thus, you might expect that hospitals which are less systematic in recording clinical 
information, may also have less well defined protocols for recording pathological data.
The ideal situation is where there are multidisciplinary teams involved at all stages of 
the care of the woman and where all information is recorded by all of the specialists 
involved.
4.3 GENERAL DISCUSSION OF METHODS FOR HANDLING MISSING 
VALUES IN COVARIATES
The fact that all o f the two-way interactions were significant in the model, except for the 
clinical stage by node status interaction, appears to support the second hypothesis more 
strongly than the first hypothesis. For example, it was more likely that ER status and 
tumour size were missing when clinical stage was missing than when it was known.
The non-recording of clinical stage had a strong bearing on the non-recording of the 
three pathological factors, although less so on node status. Overall, from Table 4.3 in 
Section 4.2.1, ER status was missing in 39% of cases; tumour size was missing in 21% 
of cases and node status was missing in 27% of cases. However, when only the women 
when clinical stage was not noted in the case notes (i.e. 317 cases) were included, these 
figures rose to 54%, 31% and 34% respectively, as can be seen in Table 4.8.
I N T R O D U C T I O N
'1:The last two sections examined the general characteristics of some of the variables in
,4
the Breast Cancer Audit data and also patterns of missing values in the fbur main ;|
prognostic factors. For each of the factors, extra categories to represent the cases with 
unknown values for each factor were created. This was the approach used in the
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analysis of the survival data (Twelves et al, 1998a). However, there are other 
techniques that can be used when analysing data with missing values in some of the 
covariates, as described below. Any discussions about the different techniques tend to 
focus on their applicability to analysis of survival data. Firstly, however, possible 
structures for missing values in data are reviewed. All statistical methods are likely to 
be affected when underlying assumptions made about the structure of any missing data 
are not valid.
S T R U C T U R E  O F  M IS S IN G  D A T A
Missing Completely A t Random (MCAR): The mechanism of missing values is said to 
be MCAR when the observations that are missing do not depend on any of the data, 
either those which are known or those which are missing.
Missing At Random (MAR): Data are said to be MAR when the observations that are 
missing do not depend on any of the rmobserved values, either in the variable that is 
missing or in any other variable, but may depend on observed values in other variables.
ÎNon Missing At Random (non-MAR): If, however, the probability that an observation 
is missing depends on its unobserved true value or on the true value of any other 
variable with missing information, then this mechanism for missing values is said to be 
non-MAR.
I
Patterns o f Missing Values: There may be observed patterns among the missing values
for several variables. However, this may not actually mean that the data are non-MAR. a
■a?
Vach (1997) suggests the need to examine the assumption of the data being MAR using 
sensitivity analyses, but he makes the point that it is not possible to know if this 
assumption is valid using the available data. However, background subject loiowledge 
may help to determine whether or not the assumption is reasonable.
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METHODS OF ANALYSING DATA WITH MISSING VALUES
A  number of techniques are now described. The first four are easily implemented using 
standard software. The remaining four are more complicated methods which require 
specialist software or fairly advanced programming skills.
C o m p l e t e  C a s e s  A n a l y s i s :  This method is the simplest approach o f all (Greenland & 
Tinkle, 1995). Here, only cases with complete information for all o f the covariates aie 
retained in the analysis. Cases with missing data for any of the covariates are simply 
discarded. This is very wasteful as it tlirows away information that has been recorded 
for some of the other covariates. When there is a large number of covariates, the 
number of cases that have to be excluded can be substantial, even if  there are relatively 
few missing values for each covariate.
When this method is used, it assumes that there is no bias introduced by using only a 
subgroup of cases which has all of the information known and that this subgroup is 
representative of the whole population. However, this is a strong assumption to make 
and the estimates obtained based on these cases alone may be very biased (Schemper & 
Smith, 1990). Vach & Blettner (1991) investigate the situation of missing values in 
case-control studies. Using a simple context, they demonstrate that the estimate 
obtained for the odds ratio is not biased when MCAR can be assumed to be valid, but is 
biased when the data are MAR.
The complete cases method also produces estimates which have higher than necessary 
variances (Greenland & Tinkle, 1995). The teclmique can be applied to survival 
analysis and is often the suggested method when there are only a few missing values in 
the data (Schemper & Smith, 1990). Whether the bias observed for MAR data in the 
case-control framework (Vach & Blettner, 1991) would be evident in survival analysis 
is not clear.
A v a i l a b l e  C a s e s  A n a l y s i s :  This method is another simple approach. It is described by 
Little (1992) in the context of multivariate normal data. Here the estimate of every 
element in the variance-covariance matrix is obtained separately. The value of element
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(y, Â:) is estimated using the data which are complete for both variables j  and k . One
problem with this approach, however, is that the variance-covariance matrix is not 
necessarily positive-definite. This is a problem when the covariates are highly 
correlated. It is not obvious how this available cases approach could be applied easily to 
survival data since values of parameters in a model are not independent of the other 
variables included in the model.
Using this approach in the regression problem, information is obtained for the 
regression parameters, based on the subjects with known data. Whilst the extra terms 
involving n tj are used to obtain the regression fit, the parameters obtained for them are
not reported when the results of the fit are given. Greenland & Tinkle (1995) state that 
the estimates obtained for this method can be biased.
They also point out that when only one vaiiable contains missing data, this method is 
the same as adding an additional category to represent these unknowns in the factor. 
This is the next method discussed.
Analysis Using Indicators For Missing Data: Greenland & Tinkle (1995) outline this 
simple approach where indicator variables, n i j , to indicate missing values are created
for every covariate, X j , which contains some unknown information. Both rrij and X j
are then included in the analysis in the following manner. If X j is missing then n ij = 1;
otherwise m .  = 0. Then m^ - is simply added to the model, whereas the variable X j is
replaced by the product 1^ -  . The method is described for the regression
problem, but the technique could be used in survival analysis.
Analysis Using Additional Categories For Missing Data: This method is another 
simple approach and was the one used in the survival analysis of the Breast Cancer 
Audit data. Additional levels were added to each of the factors with missing data to 
represent a category of unknowns in each variable. In their paper regarding missing 
values in case-control studies, Vach & Blettner (1991) demonstrate that the estimate for
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the odds ratio is biased for all of the different scenaiios for the missing data 
mechanisms, including MCAR and MAR. They do not discuss the implications of these 
results for other study designs.
I m p u t a t i o n  M e t h o d s :  The idea behind imputation is to estimate and assign values for 
the missing data using the known data. There are several ways of obtaining these 
estimates.
(i) The simplest approach is to replace all of the missing values for a covariate with the 
overall mean for this variable based on the known values. One problem with this 
approach is that the variance will be underestimated if many missing values are 
allocated the mean value.
(ii) A slightly improved method involves the use of conditional means. Suppose 
variable j  has some cases which are missing, but variable k  is known for those cases. 
Then different estimates o f variable j  are obtained for the different values of k  based on 
the cases where variable j  and variable k  are known. Usually, linear regression is used 
to obtain these estimates. For example, suppose age is not known for some people, but 
sex is known for all. Then the average ages for males and females would be calculated 
from the available data. Males with missing values for age would be given the average 
age for men and similarly, women with missing data on age would now take the female 
average age, obtained from those with age known.
Usually the assumption of MCAR is necessary. The theory has been developed for 
linear regression and is described in Little & Rubin (1987). The variance-covariance 
matrix is underestimated by the sample variance-covariance matrix. This method of 
imputing values based on conditional means could be used for survival analysis if  a 
suitable model can be developed for the data. This would be similar to the approach of 
Schluchter & Jackson (1989) described below.
(iii) Vach & Blettner (1991) present a simple technique of filling the cells of a 
contingency table in the case-control context. They use knowledge of the proportions
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(iv) The Probability Imputation Technique was described initially in the paper by 
Schemper & Smith (1990) and updated in Schemper & Heinze (1997). The technique is 
presented only for binaiy variables, taking values 0 or 1. Based on the data for known 
cases, the probability, n: , o f getting a 1 is calculated. The missing values are then given
covariates. It is similar to the conditional means approach.
M a x i m u m  L i k e l i h o o d  A p p r o a c h :  Here, the approach is to use maximum likelihood 
(ML) to model the known data to obtain estimates for the parameters of the model and 
hence for the missing values simultaneously. To apply ML theory, a parametric model 
must be used for the joint distribution of the covariates (Vach & Blettner, 1995). They 
note that it is not always possible to obtain this. Little & Rubin (1987) question whether
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for the known observations to impute values for the missing data. They point out that ■' 'i:
this method can only be utilised when the assumption of MAR can be made. This 
method, along with all o f those described above, is an ad hoc method, requiring 
specially derived formulae. The remaining imputation techniques and other methods
:ndiscussed relate to modelling the data. ^
:either the value \ - tc or k  , instead of 0  or 1 , depending on the values of the other
Schemper & Heinze (1997) point out that their method is only to be used with binary 
0/1 coded variables. It is not clear whether it would be possible to generalise this 
technique to categorical variables with more than two levels. Schemper & Smith (1990) 
say that the technique can he applied to the Cox model. In all situations, the method 1
needs the assumption of MAR. ](v) In Multiple Imputation, rather than using average values to fill missing data, a set of 4
imputed values is produced, possibly assuming a known distribution or conditional 
known distributions. For each of the cases with missing values, a random value is 'ç
selected from the appropriate distribution. Parameter estimates are then obtained based Î
on all cases, i.e. on the known cases and the missing cases, which have all been replaced 
by the random values. The process is then repeated many times, thus generating a set of 
parameter estimates. These are then combined in a variety of ways, details of which can 
be found in Little & Rubin (1987).
' 1
4using the information matrix to calculate standard errors is valid in this context and 
point out that large sample normality of the likelihood function may not apply as the 
data will not necessarily be an independent, identically distributed sample.
(i) The simplest application of the ML approach involves the situation where the data 
have some special patterns of missingness and the likelihood function can be factored 
into components which can be easily maximised. Little (1992) gives an example.
(ii) When there ar e no specific patterns in the data, the likelihood function camiot be 
factored and it is necessary then to use an iterative maximisation procedure. 
Possibilities include the Newton-Raphson and the EM algorithms. These methods are 
computer intensive.
Little (1992) points out that the ML approach is valid for MAR data, but can also be 
adapted for some situations involving non-MAR data. The technique does not perform 
well when there is only a small number of cases and is mainly recommended for use 
with large samples.
Little (1992) states that this method is not very useful when the covariates with missing 
values are categorical. Schemper & Smith (1990) point out that it may not be possible 
to use ML for survival analysis due to the fact that the Cox model uses partial 
likelihood. Vach (1997) also comments on this fact and makes use of a logistic model 
with grouped survival data to permit use of the ML theory.
A n  E x p l i c i t  M o d e l :  Schluchter & Jackson (1989) attempt to incorporate missing data in 
categorical covariates into a survival analysis. This paper uses ML theory. The joint 
distribution of the survival data and the covariates is modelled using a flexible log-linear 
model. The covariates are assumed to have a multinomial distribution, determining the 
probability of the observation taking a certain value, either known or missing. They 
state that they assume that the “hazard function, conditional on the covariates, is a 
stepwise function over disjoint time intervals. Thus, the survival times have piecewise 
exponential distributions”. To employ this method, the assumption that the data are 
MAR must be made.
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DISCUSSION
Not all o f the tecliniques described above could easily be applied to survival data. The 
fact that the Cox model is semi-parametric in nature means that no explicit joint 
distribution can be written down between the survival times and the covariates. That is, 
the hazard for a set of covariates can be modelled, but the underlying baseline hazai'd 
function cannot. Thus, any approach which uses ML theoiy would be difficult to adapt 
for the Cox model. The semi-parametric nature o f the Cox model also presents a 
problem for using Multiple Imputation. Schluchter & Jackson (1989) fitted a fully 
parametric model. Schemper & Heinze (1997) state that the probability imputation 
teclmique can be used with the Cox model but they also point out that only binary 
variables can be used in their method. No indication is given as to whether it would be 
possible to extend this to non-binary categorical variables.
Vach & Blettner (1991) point out that the method of additional categories is used 
extensively in published literature in many eircumstances including case-control studies, 
despite the fact that the estimates obtained for this method are biased for all missing 
data mechanisms.
For all of the methods described above, the data need to be MAR, otherwise the results 
will potentially be biased.
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4.4 POSSIBLE APPROACHES TO THE PROBLEM OF MISSING VALUES IN 
THE BREAST CANCER AUDIT DATA
then perhaps the Breast Cancer Audit data can he assumed to be MAR. It seems 
unlikely that the assumption of MCAR could be taken to be valid.
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INTRODUCTION ■1
In the last section, various methods were presented for handling missing values in 
general situations. Here, the methods used to analyse the Breast Cancer Audit survival 
data are described.
,41
The pattern of the missing values has already been presented in Section 4.2.3. It was 
shown that all but one of the two-way interactions for the four prognostic factors 
(clinical stage, node status, tumour size and ER status) were significant in a log-linear 
model describing the probability of being missing for each variable. Thus, a patient was 
more likely to have a missing value in node status when the tumoui' size was also 
missing. However, this only provided information about the structure of the missing 
data and not whether having missing data affected the survival results.
In the case of the Breast Cancer Audit survival data, it is not clear whether the missing 
information in the four main clinical prognostic covariates were MAR. If, for example, 
node status was missing because of the true unknown value of tumour size, then the data 
would be non-MAR. However, if  the data were missing in both of these variables 
because of an external policy of recording pathological information within the hospital,
In the analysis of the data presented in the paper by Twelves et al (1998a), the missing y
values were included in the analysis using the method of additional categories. The 
decision to use this method was made for two reasons. The first was that use of the 
complete cases method was thought to be unacceptable due to the large amount of 
missing data present in the four main prognostic clinical factors (64%). The second 
reason was that many other studies have used the additional categories method (these 
are discussed in the next section, along with the other techniques employed in survival 
analysis of breast cancer data). It is not clear whether the estimates obtained and
:...
The clinical reasons for looking at (i) were that node status and tumour size have been 
known to be important prognostic factors for a long time (Blarney et al, 1979) and are
reported by Twelves et al (1998a) will be greatly biased using this method for analysing 
missing data in survival analysis.
To try to address this issue, the results obtained for a complete cases analysis, the 
simplest alternative to the technique employed, were compared with those from the 
additional categories method to see if  there was any consistency between the findings 
for the two methods. The results o f this comparison are given in Section 5.4.2. The 
main objection to the complete cases analysis method, that o f wasting too much 
information, has already been stated. It is also not clear whether the subgroup of women 
with complete information would have been representative of the whole population. If 
it were not, then bias could be introduced into the estimates of hazard ratios. This 
would not be important if the survival for the women in the subgroup for a particular 
combination of factors was representative of the survival of all women in that particular 
combination. Another objection to this method of handling missing values is that there 
is the possibility of a loss of power due to the substantially reduced sample size thus 
reducing the possibility of detecting any relationships.
Another approach looked at briefly is an ad-hoc combination of the available cases, 
complete cases and additional categories methods. Here, two further subgroups of the 
1619 surgical cases included in the Breast Cancer Audit were considered (known here as 
partial-complete cases analysis). The subgroups included those cases where:
(i) both node status and tumour size needed to be known, but the other factors 
clinical stage and ER status could be either known or missing; and
(ii) all three pathological factors (ER status, node status and tumour size) had to 
be known but clinical stage could be either known or missing.
more likely to have been recorded than ER status, which is harder to determine, with 
several different methods used to analyse the specimens (Barnes et al, 1996). Indeed, 
examination of the recording of the Breast Cancer Audit data, given in Section 4.2.1, 
showed that nearly 40% of the cases did not have this information available.
;
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The subgroup of cases given by (ii) was examined because clinical stage might not have 
been recorded in the notes if the pathological information was available. Also, the «
misclassification of clinical stage is a known problem (Hundred et al, 1994) and the 
agreement of clinical and pathological findings is not always very high (Brewster et al,
1996b). It was important to obtain a model based on the more important prognostic 
pathological factors and compare the estimates from this analysis with those based on all 
1619 cases and just the ‘proper’ complete cases analysis.
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The results from fitting Cox models to these subgroups of cases were compared with 
those from the additional categories and the complete cases analyses and are reported in 
Section 5.4.2.
It was decided that it was not feasible in the time available to apply the other methods 
discussed in the last section to the Breast Cancer Audit survival data. The main reason 
was the complexity and the need for specialist software. It is not certain that any of the 
techniques, other than the probability imputation technique (PIT; Schemper & Smith, 
1990) could be applied to the Cox model. The PIT seems to require that all o f the 
variables with missing information are binary. Thiee of the four clinical factors with 
missing information are indeed binary (ER status, node status and tumour size), but 
clinical stage is not, although it could be made binaiy. However, the technique still 
needs the missing data to be MAR. Whether this assumption is valid for the Breast 
Cancer Audit data remains unclear. However, this method would probably be the most 
appropriate to try to implement if the computer softwai’e and time were available.
No easy solution exists to the issues of missing data. However, analysis of retrospective 
cancer audit data still needs to be performed to provide some idea of the survival 
chances of the people with cancer in Scotland and the variation in survival across levels 
of treatment and other factors, such as Health Board. Therefore, it is necessary to move 
forward tentatively, and provide a set of results to inform decision making. Of course, 
any proposed solution must be interpreted cautiously in light of the potential bias, due to 
the imperfect nature of the data. In the next section, how other relevant literature dealt 
with missing values in survival data is discussed. J
4.5 EXAMINATION OF HOW OTHER BREAST CANCER STUDIES DEALT 
WITH MISSING VALUES
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INTRODUCTION
To investigate how data with missing values were analysed in other studies of survival 
from breast cancer, 14 papers were examined. These papers highlight known prognostic 
factors for breast cancer, and support the findings of the survival analysis of the Breast 
Cancer Audit data (Twelves et al, 1998a). Any references that are not discussed here, 
but which are mentioned in sections 2.3.2 and 5.2.3, do not directly involve any analysis 
of survival data.
Eleven of the 14 papers are retrospective studies, similar in nature to the Breast Cancer 
Audit. Two of the studies (Gordon et al, 1992; Haybittle et al, 1997) involve clinical 
trial data. These papers reported the effects of socioeconomic data on survival rather 
than the primary results of the trial. One study (Hawkins et al, 1996) was a prospective 
study for prognostic factors. Both this study and Gordon et al (1992), have no missing 
information, except for tlnee cases in Gordon et al (1992) and are, therefore, not 
discussed further. The data in Haybittle et al (1997) do contain missing information in 
variables not used as part of the randomisation process. The approaches to dealing with 
missing information in the 12 studies is now detailed.
The first observation is that none of the papers included a discussion about the 
assumption of the structure of the missing data, and whether or not the data are assumed 
to be MAR. Several of the studies which used the Complete Cases (CC) method did 
compare the characteristics of the CC subgroup with all of the cases or with the 
excluded cases (Gillis & Hole, 1996; Newman et al 1997; Shek & Godolphin, 1988). 
Most of the studies concluded that the CC were representative of the whole population 
because the proportions in the levels of each of the factors were similar for all cases 
versus complete cases. Thus, the implicit assumption was made that the unknowns that 
would also be in the same proportions across the levels of the factors and, therefore, that 
the data are MAR. However, the important fact is whether or not the survival of the 
women in CC for a particulai' combination of factor levels is representative of the 
survival of all women in that particular combination, although this cannot be known.
Several of the papers explicitly state that they have used the CC analysis, by reporting 
that women with missing information were excluded from the analysis. The percentages 
of cases dropped in these studies (Haybittle et al, 1997; Ewertz et al, 1991; Carter et al,
66% respectively. This last figure is almost identical to that in the Breast Cancer Audit 
data.
Two of the papers (Basnett et al, 1992; Gillis & Hole, 1996) do not explicitly say what 
they did with the missing values, although it appears that the cases were dropped and 
CC analyses performed. Basnett et al (1992) only had missing information for stage, 
which was unknown in only 9% and 4% of cases seen in teaching and non-teaching 
districts respectively. Gillis & Hole (1996) had a much higher percentage of missing 
information, with 31% and 22% missing for tumoui’ size for non-specialist surgeons 
(non-spec) and specialist surgeons (spec) respectively. Similarly, 38% and 17% of 
women had no node status recorded for non-spec and spec respectively. Gillis & Hole 
(1996) quote crude survival figures for each of the factors separately, based on the cases 
where information was known in each of the factors, and also for the women with 
missing information. It is not clear, however, whether the adjusted hazard ratios 
obtained from the Cox regression model were based only on a CC analysis or whether 
additional categories were used for the unknowns.
The remaining five studies adopted the same method as used by Twelves et al (1998a); 
that is, the additional categories method. The percentages of cases with missing values 
that would otherwise have been lost, had a CC analysis been performed instead, were 
9% (Karjalainen & Pukkala, 1990); 11% (Richards et al, 1996); 20% (Schrijvers et al, 
1995); 47% (Sainshury et al, 1995a); and 70% (Freedman et al, 1979).
Therefore, from this limited sample of papers chosen as suitable references for 
prognostic factors, it appears that none of the sophisticated techniques, such as Multiple 
Imputation, the Probability Imputation Technique or Maximum Likelihood methods are 
being used for the analysis of survival data with missing information. Instead, the only 
two techniques used were CC analysis and the additional categories method. Which of 
these methods, if  either, is the more appropriate remains unclear.
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.1989; Shek & Godolphin, 1988; Newman et al, 1997) were 12%, 18%, 26%, 26% and
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CHAPTER 5 SURVIVAL ANALYSES
5.1 INTRODUCTION TO SURVIVAL DATA AND METHODS OF ANALYSIS
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=4IN T R O D U C T I O N  T O  S U R V IV A L  D A T A
Data which represent time from a definite origin to a particular event, or end-point, are |
known as survival data. Ofren, as with the Breast Cancer Audit data, the end-point of
interest is death. f
The survival times are assumed to be observations from a random variable T . Since 
time to an event is always positive, the distribution of the data is not symmetrical, but is 
generally positively-skewed. Therefore, the standai'd techniques for modelling normally 
distributed data cannot be used and so other techniques for modelling survival data have 
been developed.
:# 
IT H E  S U R V IV O R  F U N C T I O N  A N D  T H E  H A Z A R D  F U N C T I O N  
The survivor function is defined as the probability that an individual survives up to or 
beyond time t . Thus,
S { t )  =  P { T > t )  =  \ - F ( t ) ,  
where F { t )  is the cumulative distribution function. The probability density function of 
T  is therefore given by
- T -
The instantaneous death rate of an individual sui'viving to time t  is given by the 
probability than an individual dies at time t , given that they survived to that time. This 
is known as the hazard function and can be wiitten as (Collett, 1994):
^  --^{log^C /)) from E q5.1_l.
Thus, S { t )  = Q x p { H ( t ) }  or H { t )  = - lo g 5 ( / ) , (Eqs 5.1_2)
I
where JT(r) = ^ h (u )  d u .
0
H { t )  is the cumulative hazard. Note that h { t )  is not a probability density flmction.
METHODS OF ANALYSIS
The analysis of observed survival times provides estimates of both the survivor and 
hazard functions. Parametric, non-parametric or semi-parametric methods can be used 
to obtain estimates of these functions.
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CENSORING
Survival analysis needs to take into account subjects for whom the end-point does not 
occur before the end of the period o f observation of the study. Rather than discarding 
data for such subjects, the information that an event did not occur is retained in the 
analysis by a method known as censoring. There are several types of censoring, but only 
that known as right-censoring will be explained here.
A subject is right-censored when it is known only that an event has not occurred by a 
certain point in time, say, from the time origin, G say. The observation is censored at
, and has a right-censored survival time of ) • The analysis of censored data is
only straightforward if it can be assumed that the true unknown survival time, t  >  i s  
independent of the reason why the individual was censored at time G •
A parametric model is fully described by a set of parameters for which probability 
distributions can be specified. One example used in survival analysis is the Weibull 
model. The hazard function for this distribution is given by 
h [ t )  =
with À > 0  and y  > 0 .  The corresponding survivor function is given by 
S ( t )  = exp(- X V ) . (Eq 5.1_3)
The scale parameter is X  and the shape parameter is y  . The simplest form of the 
Weibull distribution is the exponential distribution, which has shape parameter equal to 
1. Parametric models were not fitted to the Breast Cancer Audit data, but the 
exponential distribution was modelled in a theoretical exercise based on simulated 
datasets, described in Chapter 6.
In contrast, a non-parametric model makes no assumptions about the distribution of T . 
An example of this approach, the Kaplan-Meier teclmique, is discussed in the next 
section. The third method is the semi-parametric approach. Part of the model is 
specified by parameters which can be obtained from modelling the data. The Cox’s 
proportional hazards model is an example of a semi-parametric model and is described 
in Section 5.1.2.
5.1.1 KAPLAN-MEIER THEORY AND THE LOG-RANK TEST
I N T R O D U C T I O N
The Kaplan-Meier method is a non-parametric technique for estimating the siuvivor 
function, S { t ) , at time t . Rather than model the suiwival data, it obtains the survivor 
function for intervals between consecutive end-points (i.e. deaths in the present context) 
from the ratio of the number o f subjects still at risk (i.e. alive here) at the end of an 
interval to the number of subjects at risk at the start of that interval.
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%The Kaplan-Meier estimate o f the survivor function is a step function. Collett (1994) 
provides a full derivation of this, a brief summary of which is outlined below.
B R IE F  D E R I  VA T IO N
The observed survival times for the n  individuals in the sample aie assumed to be 
t„ . These may include censored observations and ties at the same time 
points. Thus, there are only r  death times among the n  individuals, with r  < n .  The 
J th  ordered death time is denoted here by .
nj rij
where d j  is the number of deaths that occurs at j and r ij is the number of people still at 
risk just before
As no deaths are assumed to occur in the interval from to just before , then p j  is
equivalent to the probability of surviving from to .
With the time intervals spanning from one death time to the next death time, the 
probability of surviving past is equivalent to surviving through all of the intervals
before and surviving through the interval from to , where k  =  \ ,  2, ..., r  .
Therefore, the overall Kaplan-Meier estimate of S { t )  is given by
S { t )  =
V-l "j
for < t  <  , k  =  \ ,  2, ..., r , S { t )  =  \ î o r t <  .
The probability that an individual survives past ty^ given that they were at risk just
•4before t y^ can be estimated by
d :  r i j - d :p, = \ ' " '
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The standai'd error for the Kaplan-Meier estimate of the survivor function for any value 
of t  in the interval from to is
f  ^ , 1 2
^g(0}=[^(0] È  / ' , (Eq5.1.1_l)
['■' ”j["j
and is known as Greenwood’s formula (Collett, 1994).
POINT ESTIMATES WITH CONFIDENCE INTERVALS
An approximate confidence interval for the estimate S { t )  can be obtained using its 
calculated standard error. This is derived under the assumption that S ( t )  comes from a 
normal distribution with mean S { t )  and standard deviation given by Eq 5 .1 .11 . 
Survival curves can be generated for subgroups of individuals in each of the levels of a 
factor; such as, different age groups. The results of the Kaplan-Meier analyses of the 
Breast Cancer Audit data are given in Section 5.2.1.
TESTING FOR EQUALITY OF THE SURVIVAL CURVES
Several tests of equality of the survival curves can be canied out. The log-rank and 
Wilcoxon tests are discussed here for a factor with only two levels, but both can be used
for factors with more levels. r
|,
The null hypothesis for both of these tests for two levels of a factor is ;S
H q : (/) = ^ '2  { t )  for all f > 0 .  i
I.■I
The log-rank test is powerful when the assumption of proportional hazards is valid I'h
(Gregory et al, 1997). If this seems questionable, it may be better to use the Wilcoxon 
test (Collett, 1994). To decide which of these tests to perform, it is good practice to 
examine whether or not the hazards for the levels are proportional. The survivor "Ifunctions for the different levels do not cross when the hazard functions are proportional 
(Collett, 1994). Thus, examination of the estimated survival curves for the two (or 
more) levels gives an informal indication as to whether the proportional hazards 
assumption holds or not for the set of data being considered.
Î:;ï
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Having identified factors where there is evidence to reject the test of equality among the 
sui'vival curves for the levels of the factors, multivariate sur vival analysis is then often 
employed to investigate whether or not the differences remain once other factors have 
been taken in account.
5.1.2 THEORY OF COX’S PROPORTIONAL HAZARDS REGRESSION 
MODELS
IN T R O D U C T I O N
The aim of modelling the survival data is to describe the dependence of the outcome on 
one or more of the covariates. Models with proportional hazards are often used in 
survival analyses. The assumption of proportionality implies that the ratio of the 
hazards between different levels of a factor, or different values of a continuous variable, 
are constant over time. The Cox model is one example of a proportional hazards model.
T H E  M O D E L
A  Cox’s proportional hazards regression model is usually given in the general form 
h { t ; x )  = exp(^^ .
Hq ( t )  is known as the baseline hazard and is assumed to be unknown and is not itself 
necessarily of interest. It represents the hazard function for an individual with all of the 
explanatory covariates taking the value zero. As no form is assumed for /Zo(^), this part
of the model is non-parametric. A parametric component of h { t ; ^  arises thi’ough 
exp( /^?  ^xjand hence the model is referred to as semi-parametric.
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BRIEF DERIVATION OF THE REGRESSION PARAMETERS
Cox (1972) showed how the regression parameters could be estimated without the 
necessity of calculating using a method called partial likelihood. Collett (1994)
provides details of this, a brief summary of which is given here.
Again, it is assumed that there are n  individuals with svu'vival times , C, •••» -
There are r  < n  death times, with the yth ordered death time given by . Let the
individuals at risk, i.e. those alive and uncensored, just before be denoted by
j and be called the risk set at that time. Then, the probability that the 
dh individual dies at time , conditional on being a time of death, is equal to
exp
E  exp(^''x,)
l&R
where represents the covariates for the individual who dies at time and are
the explanatory variables for individual I . Using independence, the partial likelihood 
function is given by
#  = n  y
A  ^ l )
leR>k))
The method of maximum likelihood can be used to find the estimates for p  by
maximising the partial likelihood function. Thus, the estimates for the parameters for 
the covariates have been derived without knowing anything about the baseline hazai'd 
function, h ^ i t ) ,
THE SURVIVOR FUNCTION
Having estimated the regression parameters, the baseline hazard function and 
corresponding survivor function (Kalbfleisch & Prentice, 1980) can then be obtained to
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provide an estimate of the survival curve for all times. The estimated survivor function 
is given by
= (E q 5 .1 .2 J)
with covariate pattern x . for the zth individual and ( t )  is the estimated baseline 
survivor function, obtained from Eqs 5 . 1 2  in Section 5.1.
The formula for the standard error for ( t )  can be obtained from Kalbfleisch & 
Prentice (1980). These estimates for survival and their standai'd errors are available in 
statistical packages such as SPSS and SAS.
MODEL SELECTION
In arriving at a final Cox model, vaiiable selection methods used in multiple regression 
are commonly employed. Both forward selection and backward elimination can be 
performed, along with other stepwise teclmiques (Aimitage & Beixy, 1994). The 
forward selection stepwise method was used to obtain the model in the analysis of the 
Breast Cancer Audit data and this was checked using backward elimination.
The results of fitting a Cox model to the Breast Cancer Audit data are presented in the 
paper by Twelves et al (1998a) and are extended in Section 5.2.2.
5.2 SURVIVAL ANALYSIS OF THE BREAST CANCER AUDIT DATA
INTRODUCTION
A survival analysis was performed on data from the Breast Cancer Audit. Only the 
subgroup of women who had no evidence of métastasés at presentation and who 
underwent surgeiy were included in the analysis (Section 3.1). The aim was to 
investigate any variations in survival after surgery for women diagnosed with breast 
cancer in Scotland in 1987.
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CENSORING AND END-POINT IN THE BREAST CANCER A UDIT DATA 
The time origin was taken to be the time of diagnosis and the end-point was death from 
any cause. Cause-specific survival was not analysed because cause of death information 
from death certificates has been shown to be umeliable (Maudsley & Williams, 1993). 
Deaths up to the end of 1993 were linked to the original audit data using probability 
matching (Kendrick & Clarke, 1993) with death data from the General Registers Office. 
Thus, subjects without a recorded death from the matching were assumed to be alive at 
31/12/1993 and were censored at this point.
THE DATA
Table 5.1 presents the variables chosen for inclusion in the survival analysis. The levels 
for these factors have already been given in Section 3.2.
CLINICAL FACTORS
Agg_Clinical stage
Pathological node status
Pathological tumour size
Oestrogen receptor (ER) status
SERVICE FACTORS
Health Board of first treatment
Deprivation
Surgical case load
Seen by an oncologist
TREATMENT FACTORS
Type of surgery
Adjuvant radiotherapy
Adjuvant chemotherapy
Adjuvant endocrine therapy
Adjuvant chemotherapy or endocrine therapy 
Table 5.1: List o f variables in the three categories.
ANALYSIS STRATEGY
Initially univariate log-rank tests were performed on all of the factors listed above to 
identify which were important. Kaplan-Meier survival estimates at five years were also 
obtained for the levels of each factor.
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Subsequently, two Cox regression models were fitted. The first model included the 
significant clinical factors plus any significant service factors. The second model 
included the significant clinical factors, but this time incorporated any significant 
treatment factors. The treatment and service factors were not included in a single model 
because the study was retrospective and so the nature of treatment may have been 
determined, in part, by service factors and would therefore be confounded. For 
example, women were unlikely to receive chemotherapy if they did not see an 
oncologist.
U S IN G  S P S S  F O R  S U R V IV A L  A N A L Y S E S
SPSS was used to perform both the Kaplan-Meier and the Cox survival analyses. An 
estimated ‘average’ survivor function for any of the death times can be obtained from 
the Cox model by using the means as the values of the covariates. This is 
straightforward for continuous variables. However, for categorical variables, the 
‘average’ is obtained by using the relative frequencies of the numbers of cases in each of 
the levels as weights. These are then multiplied by the corresponding parameter 
estimates for each level and an ‘average’ survival obtained from this.
For example, for factor A with tliree levels, the ‘average’ risk, exp^^^ xj from Eq
5.1.21 in Section 5.1.2, would be given by
exp^^ Xj = exp| ^ ^ P  + p  + p  , (Eq 5.2_1)
where represent the numbers of cases in levels 1, 2 and 3 of factor A
and the total number of cases in factor A respectively. P , P  and p  represent the
parameter estimates for levels 1, 2 and 3 of factor A, with P  -  Oin the particular set-up 
of indicator variables. The ‘average’ suivival estimate would then be obtained using Eq
5.1.21 from Section 5.1.2. This would give an indication of how the hazards 
calculated from the parameter estimates affect the percentage o f patients sui'viving to a 
particular time point, in general.
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It is also possible to derive model based survival estimates for particular risk factor 
profiles; that is, obtaining the risk for certain levels of the factors. For example, age 
group 50-64, clinical stage II, ER positive, node negative, tumour size < 2cm. The 
survival estimate at five years for individuals with these characteristics could then be 
reported.
5.2.1 RESULTS OF UNIVARIATE ANALYSES
Separate Kaplan-Meier analyses were performed on a subgroup of the factors in the 
Breast Cancer Audit data. A full table of results showing the 5-year % survival figures 
can be found in Table 1 o f the paper by Twelves et al (1998a). The overall Kaplan- 
Meier estimate of 5-year survival was 70.9% with a 95% confidence interval (68.6%, 
73.1%). The P values for log-rank tests for equality of the survival curves are given 
below in Table 5.2.
Factor P value
C L I N I C A L  F A C T O R S
Age <0.0001
Clinical stage <0.0001
Pathological node status <0.0001
Pathological tumour size <0.0001
ER status <0.0001
S E R V I C E  F A C T O R S
HB of first treatment 0.02
Deprivation 0.03
Surgical case load 0.03
Seen by an oncologist 0.25
T R E A  T M E N T  F A  C T O R S
Type of surgery 0.01
Adjuvant radiotherapy 0.49
Adjuvant chemotherapy 0.02
Adjuvant endocrine therapy 0.74
Adjuvant chemotherapy or endocrine therapy 0.28
T a b l e  5 .2 :  P  v a lu e s  f o r  th e  o v e r a l l  lo g - r a n k  t e s t s  o f  e q u a l i t y  o f  th e  
s u r v i v a l  c u r v e s  in  u n i v a r ia te  a n a l y s e s .
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As can be seen, there were significant differences between levels for each o f the clinical 
factors. Figures 5.1 and 5.2 give the Kaplan-Meier estimated survival curves for the 
factors pathological node status and pathological tumour size to illustrate the 
differences. The remaining Kaplan-Meier curves for the clinical variables are given in 
Section 5.3.2. There was also evidence of variation in survival among the levels of all 
o f the service factors, except referral to an oncologist, and of the treatment factors type 
o f surgery and use o f adjuvant chemotherapy.
Survival functions for pathological node status Survival functions for pathological tumour size
Nodo posiüvo
.2
.1
1 2 3 2 3 5 7
Timo m years
F i g u r e  5 . 1 :  K a p la n - M e i e r  s u r v i v a l  
c u r v e s  f o r  p a t h o l o g i c a l  n o d e  s ta tu s .
F ig u r e  5 .2 :  K a p l a n - M e i e r  s u r v i v a l  
c u r v e s  f o r  p a t h o l o g i c a l  tu m o u r  s i z e .
Having identified the statistically significant factors in the univariate analyses, 
multivariate Cox’s proportional hazards regression modelling was then used to 
investigate whether these factors remained statistically significant once other factors had 
been allowed for. The results of this analysis are described in the next section.
5.2.2 COX’S PROPORTIONAL HAZARDS ANALYSIS: THE ‘CLINICAL 
FULL’ MODEL
IN T R O D U C T I O N  A N D  M E T H O D S
The results of fitting two Cox’s proportional hazards (PH) regression models are 
reported. The first Cox model involved testing all of the clinical and service factors
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(Model 1), whereas the second model had all o f the clinical and treatment factors 
available for selection (Model 2).
The forward selection stepwise technique (Armitage & Beny, 1994) was used to 
identify the ‘best’ model on the basis of the variables offered to it. Unfortunately, it was 
not possible to enter all of the service factors together in Model 1 without losing some 
cases; i.e. those with either surgical case load or referral to an oncologist unknown. 
These factors were therefore included separately into a model with the clinical factors 
and Health Boai’d.
Variables were added to the model if they were significant at the 5% level and were 
removed if, with the addition of other variables, they became non-significant at the 10% 
level. The P values for the Wald statistics for the estimates in the model, conditional on 
the other variables being present, are given for the significant variables, whereas the 
score statistics for entering are given for those that were non-significant.
The P values given here for the non-significant factors are slightly different to those 
quoted by Twelves et al (1998a). In that paper, the P values shown for the Wald 
statistics were for f o r c e d  entry, one at a time, for the non-significant factors with o n l y  
the significant clinical factors included in the model. The reason for the difference is 
that a referee requested that the adjusted suivival estimates be given for the non­
significant factors to allow comparison with the Kaplan-Meier estimates. Health Board 
was not included in this procedure of forcing in variables as some of the service factors |
were correlated with this factor. However, it was included in the analysis reported 
below for Model 1, where the service factors were available for entry with the clinical 
factors and Health Board.
Hauck & Miike (1991) suggest a method for presentation of results when using the 
stepwise selection technique. Their technique illustrates the order o f entry of the 
variables by highlighting which vaiiable enters at each step. The P values shown in 
their suggested table format are for entry for those variables not included in the model 
and for removal for these from the model. They also identify variables whose 
significance changes greatly between steps n - ~ \  and 12 as a result of another variable 
entering at step n  indicating a high degree of correlation between the variables. Thus,
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these variables probably will not both enter the model, even though both may affect the 
dependent variable independently. Gordon et al (1992) make use of tliis mode of 
presentation in their paper with minor modifications. Elements of this and the original 
approach are used in this thesis.
Only point estimates for survival are given in this thesis for Cox regression models 
because an apparent problem was discovered during this research with the estimated 
standard error obtained for the survival estimate from Cox regression using Version 9.0 
of the SPSS statistics package. Some examples of this problem are given in Appendix 
5, along with the results o f fitting a simpler model using binary variables only. This was 
used to compare the standard en’ors obtained from SPSS and SAS. The estimates are 
different (substantially in some situations) from the two packages. All of the other 
estimates and standard errors relating to survival analyses appear to be correct in SPSS, 
and it is only in the standard error on the survival estimate that there are differences 
between the two statistics packages.
Unfortunately, there was not enough time to repeat all of the Cox regression analyses 
given in this thesis using SAS due to the difficulties in dealing with categorical 
covariates in SAS. On the basis of the findings discussed in Appendix 5, it was decided 
not to include standard errors until the apparent discrepancies had been sorted out. 
However, this issue is currently unresolved and remains a subject under discussion with 
SPSS Inc.
RESULTS FOR MODEL 1
All of the clinical factors were required in the model as expected, along with the service 
factor Health Board (HB) of treatment. The P values given in Table 5.3 are for Wald 
statistics for presence in the model for that factor with all o f the other significant 
variables in the model.
The other service factors; deprivation, surgical case load and referral to an oncologist 
were not significant in models with the factors given in Table 5.3, and were therefore 
not included in Model 1. The P values for the variables that were not entered into the
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model were 0.36 for deprivation, 0.88 for surgical case load and 0.34 for referral to an 
oncologist.
Significant Factors F Value
Age Group 0.0017
Clinical Stage 0.0008
ER Status <0.0001
Node Status <0.0001
Tumour Size <0.0001
Node Status by Tumour Size 0.0059
HB of Treatment 0.0160
T a b l e  5 .3 :  P  v a lu e s  f o r  W a l d  s t a t i s t i c s  f o r  th e  
s i g n i f i c a n t  f a c t o r s  in  M o d e l  1.
To present the hazard ratios and the 5-year % survival estimates for the interaction 
between node status and tumour size, a factor consisting of the nine possible 
combinations of the two factors was created. The numbers and percentages for the 
levels of this new variable are given in Table 5.4.
Combination Number %
Node not known. Tumour size < 2cm 185 11.4
Node not known. Tumour size > 2cm 138 8.5
Node not known. Tumour size not known 112 6.9
Node positive. Tumour size < 2cm 171 10.6
Node positive, Tmnour size > 2cm 312 19.3
Node positive, Tumom* size not known 100 6.2
Node negative. Tumour size < 2cm 269 16.6
Node negative, Tumour size > 2cm 212 13.1
Node negative, Tumour size not known 120 7.4
Total 1619 100.0
T a b l e  5 . 4 :  N u m b e r s  a n d  p e r c e n t a g e s  in  e a c h  o f  th e  c o m b i n a t i o n s  o f  th e  
in t e r a c t io n  b e tw e e n  n o d e  s t a tu s  a n d  tu m o u r  s i z e .
Table 5.5 shows the order of entiy of the variables along, with the P values for removal 
for those variables already in the model and for entry for the non-significant variables.
As can be seen from this table, all of the clinical factors were highly significant and the 
order of entry of these factors is not important. The significance of deprivation altered 
upon the addition of ER status into the model at Step 2.
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Stepl Step 2 Step 3 Step 4 Step 5 Step 6 Step?
A 0.0001 <0.0001 0.0001 e 0.0002 a 0.0012 a 0.0014 a 0.0035
C <0.0001 <0.0001 0.0005 0.0026 e 0.0022 a 0.0009 a 0.0007
E <0.0001 e <0.0001 a <0.0001 a <0.0001 a <0.0001 a <0.0001 a <0.0001
N e <0.0001 a <0.0001 a <0.0001 a <0.0001 a <0.0001 a <0.0001 a <0.0001
T <0.0001 <0.0001 e <0.0001 a <0.0001 a 0,0004 a <0.0001 a <0.0001
N*T 0.0093 0.0177 0.0097 0.0098 0.0040 e 0.0045 a 0.0059
H 0.0154 0.0251 0.0051 0.0134 0.0113 0.0141 e 0.0157
D 0.0410 0.1278 0.1860 0.1819 0.2485 0.2808 0.3628
T a b l e  5 .5 :  P r e s e n t a t i o n  o f  r e s u l t s  f r o m  p e r f o r m i n g  th e  s t e p w i s e  s e l e c t i o n  o n  th e  
v a r i a b l e s  th a t  w e r e  in i t i a l l y  o f f e r e d  to  M o d e l  1. N o te  th a t  ‘e  ' i n d i c a te s  w h ic h  v a r i a b l e  
e n t e r e d  th e  m o d e l  a t  th a t  s t a g e  a n d  th a t  ‘a  ’ in d i c a te s  th a t  th e  v a r i a b l e  h a s  a l r e a d y  b e e n  
e n t e r e d  in  th e  m o d e l .  T h e  P  v a lu e s  r e p r e s e n t  e n t r y  f o r  th e  o n e s  n o t  a l r e a d y  in  th e  m o d e l  
a n d  r e m o v a l  f o r  th o s e  f a c t o r s  in  th e  m o d e l .  A g e  g r o u p  i s  g i v e n  b y  A , c l i n i c a l  s t a g e  (C ),  
E R  s t a t u s  (E ), n o d e  s t a t u s  (N ), tu m o u r  s i z e  (T ), th e i r  in te r a c t io n  (N '^T), H e a l th  B o a r d  
(H ) a n d  d e p r i v a t i o n  (D ).
The overall adjusted 5-year suiTival estimate was 74.3%. This represents the suivival at 
five years for an ‘average’ subject. It uses the weighted risks for each o f the levels in 
each of the factors. Thus, the ‘average’ subject does not represent any individual 
subgroup. Table 5.6 below gives the hazard ratios with 95% confidence intervals (Cl) 
along with the adjusted 5-year % survival for the significant factors in Model 1. No CIs 
are given for the survival estimates due to the apparent problem with the estimates of 
their standard errors from SPSS (Appendix 5).
The adjusted survival estimates were obtained by specifying in SPSS that the survival 
estimates for each of the levels of the separate factors be given, whilst averaging over 
the other factors. These figures are the estimates for all women in one level of one 
particular factor, conditional on having weighted risks for other factors. The weighted 
risks of the other factors are assumed to be the same for all levels o f that particular 
factor. For example, the estimate of adjusted survival at five years for age group 50-64 
represents the survival for women in this age group, assumed to have ‘average’ 
characteristics for all of the other factors. The estimate does not represent the true risk 
for the women aged 50-64 in the cohort, all of whom will have meaningful levels of the 
other prognostic factors.
The purpose of reporting these figures is because the adjusted survival estimates simply 
re-express the hazard ratios on a scale that is easier to intei-pret; namely, percentage 
surviving at five years.
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Variable H azard Ratio 
(95% Cl)
Adjusted 5-yr 
%  Survival
Age
< 50  years 1 76.4
5 0 -6 4 1.04 (0.84, 1,29) 75.5
6 5 - 7 9 1.18 (0.95,1.47) 72.8
> 80  years 2.01 (1.39,2.90) 58.2
Clinical Stage
Stage I 1 80.9
II 1.41 (1.07, 1.85) 74.2
III 1.98 (1.42,2.78) 65.6
Not known 1.54(1.13,2.09) 72.2
E R  Status
Positive 1 80.7
Negative 2.11 (1.69, 2,63) 63.6
Not known 1.45 (1.15,1.82) 73.3
Node Status by Tum our Size
N nk, T < 2cm 2.28 (1.50,3.48) 77.1
N n k , T > 2 3.53 (2.32, 5,38) 66.9
N nk, T nk 3.00(1.93,4.67) 71.1
N +ve, T < 2cm 3.91 (2.62, 5.84) 64.1
N 4-ve, T > 2 4.37(3.01,6.35) 60.8
N +ve, T nk 4.46 (2.89, 6.88) 60.2
N -ve, T < 2cm 1 89.2
N -ve, T > 2 2.72(1.82, 4.07) 73.4
N -ve, T nk 1.45 (0.86,2.44) 84.8
H ealth Board
A 1.52(1.10, 2.10) 66.9
B 1.46 (0.72, 2.93) 68.1
C 1.49(1.06,2.10) 67.5
F 1.55 (1.05,2.29) 66.3
G 1 76.8
H 0.97 (0.61, 1.54) 77.4
I 0.64 (0.31, 1.34) 84.5
L 1.20 (0.86,1,66) 72.9
N 0.95 (0.69,1.31) 77.8
S 0.88 (0.65, 1.19) 79.3
T 1.33 (0.94,1.87) 70.4
V 1.41 (0.90, 2.20) 68.9
Y 1.11 (0.71,1.76) 74.5
T a b l e  5 .6 :  H a z a r d  r a t i o s  a n d  a d j u s t e d  5 - y r  %  s u r v i v a l  e s t im a te s ,  
w i t h  9 5 %  C I s  f o r  th e  h a z a r d  r a t io s .  N o te  th a t  N  a n d  T  s t a n d  f o r  n o d e  
s t a t u s  a n d  tu m o u r  s i z e  r e s p e c t i v e l y .  A ls o ,  n k  s t a n d s  f o r  n o t  k n o w n ,  
-Vve f o r  p o s i t i v e  a n d  - v e  f o r  n e g a t i v e .
91
The significance of the node status by tumour size interaction highlights the importance 
o f both of these factors in terms of the survival prospects of women with breast cancer. 
Women who were node negative with small tumours had a 89% adjusted 5-year survival 
estimate whereas women with large tumours and node negative disease only had a 73% 
chance of survival at five years. This indicates that if a woman had a favourable node 
status, she still had reasonable (though not as good) chances of survival when her 
tumour was large. However, women with node positive disease with small tumours 
only had a marginal advantage over women with large tumours and node positive 
disease (64% compared with 61% respectively). Thus, the effect of tumour size was 
less for women who were node positive compared with those with node negative 
disease.
The finding that Health Board of treatment was significant in the model is important. 
The magnitude of the apparent differences among the Health Boards were clinically 
significant when compared with the magnitude differences in the survival estimates 
between use and no use of treatments such as tamoxifen and chemotherapy drugs seen 
in clinical trials (Section 2.3.2).
I
U N IV A R IA T E  V E R S U S  M U L T IV A R IA T E  R E S U L T S  F O R  M O D E L  1
It does not make sense to directly compare the survival estimates obtained from the Cox
model with those from Kaplan-Meier analysis because of the difference in the
interpretations of the survival estimates. A Kaplan-Meier figure represents the actual a
survival for particular group of women with a particular level of a factor. The Cox
regression estimate represents the risk for a particular level of a factor ‘averaged’ over
the other factors.
As expected, all o f the clinical factors were significant in both the univariate and 
multivariate analyses. The factors deprivation and surgical case load were significant in 
the univariate log-rank tests but not in the multivariate Cox’s PH model, once the 
clinical factors had been adjusted for. It appeared that least deprived women had a 
better prognosis from the univariate analysis, but deprivation was not significant in the 
Cox model with clinical factors in it. Table 5.5 suggested that deprivation and ER status 
were correlated because the significance of deprivation changed from 0.04 to 0.13 when
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ER status was added to the model. The test statistic for the test for association 
between deprivation and ER status was significant with P value <0.001. Table 5.7 
displays this association and reveals that there were more women who were ER negative 
and resident in an area of greatest deprivation then would be expected had these 
variables been independent.
The association remained when the women with ER status unknown were excluded 
from the analysis (P=0.004); that is, there was still an excess of women with ER 
negative disease resident in areas of high deprivation. Thus, the poorer observed 5-year 
survival for being most deprived may be due in part to this greater proportion of women 
who were ER negative. This is discussed further in Section 5.2.3.
Least Deprived Interm ediate M ost Deprived
ER Obs 165 354 80
Positive Exp 149.5 363.3 86.2
Res 1.8 -1.0 -0.9
ER Obs 90 218 83
Negative Exp 97.6 237.2 56.3
Res -1.0 -2.3 4.4
ER Obs 149 410 70
Not known Exp 157.0 381.5 90.5
Res -0.9 3.0 -3.0
T a b l e  5 .7: O b s e r v e d  (O b s )  a n d  E x p e c t e d  (E x p )  n u m b e r s  o f  c a s e s  u n d e r  th e  a s s u m p t i o n  
o f  n o  a s s o c ia t i o n  b e tw e e n  th e  v a r i a b l e s  E R  s t a tu s  a n d  d e p r i v a t i o n .  N o te :  R e s  s t a n d s  f o r  
th e  a d j u s t e d  s t a n d a r d i s e d  r e s i d u a l  f o r  th e  c e l l  a n d  c a n  b e  t e s t e d  a s  a  N o r m a l  ( 0 ,1 )  
d e v ia t e .  T h u s , c e l l s  w i t h  m a g n i tu d e  in  e x c e s s  o f  a b o u t  +2 o r  - 2  c a n  b e  r e g a r d e d  a s  
b e in g  s ig n i f ic a n t .
Referral to an oncologist was not significant in either the univariate or multivariate 
analyses. This is not a surprising result as it is likely that whether or not a women saw 
an oncologist, as well as a surgeon, would depend on the nature of her disease. Some 
women will have had a good prognosis and will have had breast conservation followed 
by radiotherapy (thus seeing an oncologist). Others will have had a poor prognosis 
being node positive, but would be seen by an oncologist for the administration of 
chemotherapy.
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R E S U L T S  F O R  M O D E L  2
The second Cox model fitted was restricted to clinical and treatment factors. It was 
found that none of the treatment factors were significant. The P values for the score 
statistics for non-entry of these factors were 0.90, 0.60, 0,98, 0.42 and 0.25 for type of 
surgeiy, use of adjuvant radiotherapy (RT), use o f chemotherapy (CT), use o f adjuvant 
endocrine therapy and use any adjuvant systemic therapy respectively. The fact that all 
of these treatment factors were non-significant is not completely surprising with this 
being a retrospective study and not a randomised trial. The treatment would have been 
determined by the severity of the disease and thus would probably be strongly 
confounded by the presence of the clinical factors in the model.
Significant differences were observed between the survival curves in the Kaplan-Meier 
analyses for both use o f CT and type of surgery (Figures 5.3 and 5.4).
Survival functions for use of chemotherapy
.8
.7
No chemotherapy
1 ' 
f: Chemotherapy
.1
Survival functions for type of surgery
1.0
.9
.8
.7
1 ' 
I:
.3
.2
0.0 0 1 2 3 4 S 6 7 a
F ig u r e  5 . 3 :  K a p l a n - M e i e r  s u r v i v a l  
c u r v e s  f o r  u s e  o f  c h e m o th e r a p y .
F ig u r e  5 .4 :  K a p l a n - M e i e r  s u r v i v a l  
c u r v e s  f o r  ty p e  o f  s u r g e r y .
Thus, the poorer Kaplan-Meier survival chances aie for women who had a mastectomy 
or received CT. These treatments tend to be given to women with poorer prognosis 
tumours, i.e. women with a large tumour size or with node positive disease. Therefore, 
the women who needed to receive these treatments will have been expected to have the 
worse observed survival chances. This is accounted for in the full multivariate model, 
in which the treatment effects are no longer significant, once the clinical factors have 
been modelled.
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THE ‘CLINICAL FULL ’ MODEL
Model 1 was taken to be the ‘best’ model for these Breast Cancer Audit data and was 
the one used to obtain results presented in Twelves et al (1998a). The same model was 
obtained when the method of backward elimination was used (Armitage & Berry, 1994), 
when only the main effects and two-way interactions among the clinical factors were 
offered to the model. The only interaction that approached significance at the 5% level 
was that of clinical stage by node status, with P value 0.062.
Thus, the ‘Clinical Full’ model includes the factors: age, clinical stage, ER status, node 
status, tumour size, their two-way interaction and HB of treatment. Further discussion 
about the interpretation o f these findings and comparison with the results of other 
studies are given in the next section and investigation into the use o f the additional 
categories method for dealing with the missing values in the covariates is presented in 
Section 5.4.2.
5.2.3 DISCUSSION OF THE AUDIT RESULTS AND COMPARISON W ITH  
O TH ER RELEVANT STUDIES
INTRODUCTION
The findings of the analysis of the Breast Cancer Audit data are now compared with the 
published literature and discussed in the different groups: clinical factors, service 
factors, deprivation, treatment factors and patient characteristics.
CLINICAL FACTORS
All o f the expected clinical factors were significant in the 'Clinical Full' model. It was 
found that there was a monotonically increasing hazard ratio of death h  om any cause 
with increasing age group. The 33 women aged under 35 years at diagnosis were 
combined with the 35-49 age group prior to the survival analysis, giving <50 years as 
the reference category. Therefore, it was not possible to examine whether the under 35
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year olds had a worse prognosis, as suggested by Miller et al (1994) and Richards et al 
(1996).
Clinical stage was also a significant factor in the results from the Audit data, with an 
increasing risk of death with increasing stage. Similarly, ER status was significant in 
the model, with ER negative tumours having a worse outcome than ER positive 
tumour s. Both node status and tumour size were significant in the Breast Cancer Audit 
data analysis, along with the interaction between them. This is similar to the finding of 
Carter et al (1989). The general effects of all of these factors on survival fr om breast 
cancer were discussed in Section 2.3.2.
SERVICE FACTORS
Basnett et al (1992) showed that survival was better for women treated in a hospital in a 
teaching district (T) than for women treated in a non-teaching (NT) district. The odds 
ratio of death for NT vs T, adjusted for age and clinical stage, was 1.74 (95% Cl: 1.34, 
2.27). They suggested that variations in use of different forms of adjuvant treatments in 
the NT and T districts may be the reason for the different survival figures observed. 
Similarly, Sainsbuiy et al (1995b) found variations in survival chances probably due to 
differences in use of adjuvant treatment in different regions in Yorkshire. Although not 
identical, use of Health Board of treatment in the analysis of the Audit data showed that 
none of the three Health Boards which had significantly higher hazard ratios (A, C and 
F) than Greater Glasgow Health Board (G) contained a Cancer Centre or a teaching 
hospital and appeared to have lower odds of use of adjuvant treatment (see Table 3 in 
Twelves et al, 1998a). However, use of any adjuvant systemic therapy was not 
statistically significant in the survival model, possibly because the Audit was not a 
randomised trial, with the clinical factors probably determining the treatment given. A 
fuller discussion is given in Twelves et al (1998a).
Instead of examining the facilities of the hospital delivering the care, Sainsbury et al 
(1995a) investigated the effect o f the case load of the surgeon on survival. They found 
that surgeons treating more than 30 women a year had a risk ratio of death of 0.85 (95% 
Cl: 0.77, 0.93) when compai'ed to surgeons seeing less than 10 women with breast 
cancer per year. They also examined the rates of the usage of chemotherapy and
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endocrine therapy and found that high case load surgeons were more likely to prescribe 
adjuvant treatment than low case load surgeons, suggesting a possible reason for the 
observed improved survival rates for the high case load surgeons. The administration of 
chemotherapy suggests involvement of an oncologist implying, perhaps, that it was the
Rather than using case load as a measure of expertise of the sui geon, Gillis & Hole 
(1996) coded each surgeon responsible for women with breast cancer in the West of 
Scotland in 1980-88 as being specialist surgeons or not. The surgeons were coded by 
“local perception”. Gillis & Hole (1996) point out that each of the specialist surgeons
I
multidisciplinary approach to care which improved survival.
“demonstrated the following indicators of specialist interest... setting up a dedicated 
breast clinic; a defined association with pathologists and oncologists; organising and 
facilitating clinical trials; and maintaining a separate record of all patients with breast 
cancer in their care.” The hazard ratio for specialist (spec) vs non-specialist (non-spec) 
was 0.84 (95% Cl: 0.75, 0.94), after adjustment for age, tumour size, deprivation and 
any nodal involvement.
In the analysis of the Breast Cancer Audit data, the variable described by Sainsbury et al 
(1995a) for surgeon case load was used, except that it was modified to include surgeons 
identified prior to analysis as working in breast clinic teams in the groups treating 30 or 
more women per year. This factor was found to be significant when a log-rank test was 
performed on the factor univariately (Section 5.2.1), but was not significant in the
multivariate Cox model (Section 5.2.2). This makes sense because Section 4.1 showed
"i;that surgeon case load was significantly associated with each of the factors: age, clinical 
stage, ER status and node status in tests of association for the pairs of variables.
Initial examination o f the breakdovm of these pairs of variables in Appendix 4 shows 
that the surgeons with a higher case load had a better case-mix and saw patients with 
already improved prognoses.
However, these surgeons provided better staging of the disease for the women treated in !
their care as there was a lower proportion than expected in the unknovm categories in S
the clinical factors for the high case load surgeons. When the unknowns in the clinical 
factors were removed from the analysis, none of the pairs of associations for the clinical 
factors with surgeon case load remained significant.
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Thus, only the association between surgeon case load and age group was significant
:::
when unknowns were excluded. Therefore, the observed better survival chances for ?
.women seen by the high case load surgeons were partly due to these surgeons seeing a 
younger group of women (mainly <65 years) and partly because they staged the disease 
more extensively, thus providing the opportunity for the most appropriate treatment to 
be given.
■' i- 
’Twelves et al (1998a) make the point that taking the results from Gillis & Hole (1996) *
and Sainsbury et al (1995a) with the findings from the Audit leads to the conclusion that 
the ‘surgeon effect’ probably translates into an effect of improved overall care, with 
treatment administered in a multidisciplinary team.
D E P R IV A T IO N  O R  S O C IA L  C L A S S
Gillis & Hole (1996) showed that there were differences in the crude survival figur es by 
deprivation, although the absolute figures varied by whether or not the women were 
treated by a specialist sui’geon or not. Affluent women had 72% and 64% survival at 
five years for spec and non-spec respectively, compared to deprived women having 5- 
year suiwival figures of 65% and 54% for spec and non-spec respectively.
Sainsbury et al (1995a) also reported a higher hazard ratio for the most deprived 
category vs the rest (1.16; 95% Cl: 1.10, 1.22), having adjusted for other factors in a 
Cox model. Sclirijvers et al (1995) detailed a similar relationship for relative survival 
rates. Gordon et al (1992) used different area-based measures of socioeconomic status, 
such as percentage with higher education, mean family income, percentage in poverty. 
They also reported a higher risk of death with lower socioeconomic status. Carnon et al 
(1994) discussed a gradient in survival by deprivation category in approximately 7,500 
women in the West of Scotland. They examined the association between deprivation 
categoiy and the prognostic factors: tumour size, percentage of nodes positive, grade 
and ER status in about 1,300 women and found none of them to be significant. 
However, they did not examine survival in this subgroup of women where pathological 
infoiination was available.
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Rather than use the area-based measures of deprivation category, Karjalainen & Pukkala 
(1990) and Haybittle et al (1997) used social class, based on occupation, as a measure of 
material affluence (OPCS, 1975). Kaijalainen & Pukkala (1990) found that the risk of 
death for being in a high social class (lo^v deprivation) was 0.78 (95% Cl: 0.68, 0.90) 
times that of being in the lowest social class. However, Haybittle et al (1997) did not 
find significant differences between the social classes with manual (Him, IV, V) vs non- 
manual (I, II, Illn) having a relative risk of 1.07 (95% Cl: 0.97, 1.19). The P value for 
the log-rank test between these groups was 0.12.
In the analysis of the Breast Cancer Audit data, deprivation was significant in the 
univariate analysis, but not in the multivariate Cox model. This suggests that the 
observed survival differences for the deprivation categories could partly be explained to 
the different proportions of ER status in the deprivation categories, with a larger number 
of ER negative women in the most deprived group (see last section). ER negative 
tumours have been shown to have a worse prognosis than ER positive tumours, both in 
the Audit and by other studies (Newman et al, 1997; Shek & Godolphin, 1988; Hawkins 
et al, 1996), thus perhaps explaining why women living in deprived areas had a poorer 
observed survival.
One possible explanation why women living in deprived areas have more ER negative 
tumours could be because a larger proportion o f women resident in deprived areas also 
have low or average body mass index (BMI); that is not in the obese categoiy. This 
hypothesis follows from Giuffrida et al (1992), who showed an excess of ER negative 
tumours in women with low or average BMI. However, the weight and deprivation 
relationship in the Breast Cancer Audit could not be examined as weight details were 
not collected.
Overall, although there is some evidence to support the observation that deprivation 
affects survival, it has still not been proved definitely.
TREATMENT FACTORS
Univariately, having a mastectomy or receiving chemotherapy indicated significantly 
worse survival in the analysis o f the Breast Cancer Audit data. These factors were not
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significant in the multivariate model, however. This was as expected with the Audit 
being not being a randomised trial but a retrospective study of how women had their 
breast cancer managed in 1987. Thus, the treatment would probably have been driven 
by the prognostic clinical factors, with most of the women receiving chemotherapy 
having poor prognosis node positive disease, for example. The influence of treatment 
factors on survival have already been discussed in Section 2.3.2.
PATIENT CHARACTERISTICS
Haybittle et al (1997) found that survival was affected by the weight o f women who 
were postmenopausal, with a highly significant risk ratio for women >60 kg vs <60 kg 
being 1.20 (95%CI : 1.08, 1.33). No relationship was observed for pre- or 
perimenopausal women of weight on survival. However, Ewertz et al (1991) found a 
different pattern with relative risks of 1.48 (1.03, 2.12) for <50 kg; 0.88 for 60-69; 0.99 
for 70-79; and 1.02 (0.90, 1.55) for >80 kg with 50-59 taken as the reference category. 
Gordon et al (1992) found no relationship of survival with body mass index (BMI), 
which has weight as one of its constituents. However, Nevyman et al (1997) did find 
that BMI was related to survival, but only for women who were node negative. The 
hazard ratios relative to women with BMI <22.8 with no nodal involvement were 2.1 
(1.1, 4.2) and 2.5 (1.2, 5.2) for no nodal involvement and BMI 22.8-28.9 and BMI >28.9 
respectively. Neither weight nor BMI were available for analysis in the Audit. The 
relationship of these factors with survival remains unclear.
Overall, it would appear- that the results from the analysis of the Breast Cancer Audit 
data discussed here and in Twelves et al (1998a) are similar- to the findings of others and 
suppoif the need for a multidisciplinary approach to the care of women with breast 
cancer.
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5.2.4 EXPLORATION OF OTHER TWO-WAY INTERACTIONS
INTRODUCTION
When the original survival analysis was performed (Twelves et al, 1998a), the available 
computing facilities were not sufficiently powerful to allow for interactions with the 
factor for Health Boai’d to be examined (because this factor has 13 levels). Each of the 
two-way interactions between the pairs o f the clinical factors was examined for 
significance. None achieved the 5% significance level, except for the interaction 
between node status and tumour size. This factor makes clinical sense as discussed in 
Section 5.2.2.
However, the computing facilities are now available to allow the interactions between 
Health Board and the clinical factors to be examined. The results are presented below.
RESULTS
The interaction between node status and tumour size is already part of the 'Clinical Full' 
model. Two further interactions were significant (P=0.02 for clinical stage by Health 
Board; P=0.03 for node status by Health Board). However, the model including the 
interaction between node status and Health Board did not converge properly before the 
Information matrix became singular and therefore the result presented for that 
interaction relate to the model that had been fitted in the iteration before this happened 
and may or may not be acceptable. Thus, this possible interaction must be treated very 
cautiously.
The model including the interaction between clinical stage and Health Board did 
converge and so further investigation was necessary. Initially, the numbers in each 
Health Board for each clinical stage were examined. These numbers are shown in Table 
5.8 below.
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Clinical Stage
Health Board I II III Unknown Total
A 17 53 11 45 126
B 6 8 2 6 22
C 21 44 14 28 107
F 31 48 9 3 91
G 73 180 29 61 343
H 17 31 7 17 72
I 3 8 8 6 25
L 16 66 22 31 135
N 31 73 38 44 186
S 34 162 33 6 235
T 25 79 3 41 148
V 11 31 5 21 68
Y 17 30 6 8 61
Total 302 813 187 317 1619
T a b l e  5 .8 :  S im p le  b r e a k d o w n  o f  n u m b e r s  o f  c a s e s  in  e a c h  c l i n i c a l  s t a g e  
f o r  e a c h  H e a l th  B o a r d .
As can be seen, some of the clinical stage by Health Board combinations have very 
small numbers in them. These give concern about the stability of the model containing 
this interaction and, therefore, about the reliability of the estimates obtained for the 
hazard ratios for these combinations. In fact, when the standai'd errors were examined 
for some of the parameter estimates, it was clear that the model was unstable.
To investigate the two interactions fuither, some of the Health Boards were grouped 
together and new interactions fitted. The Health Board variable in groups kept the five 
Health Boards containing Cancer Centres separate (i.e. G, H, N, S and T) and combined 
the remaining Health Boards into one group to represent ‘the re s f . This grouped Health 
Board variable with six levels was then fitted both as the main effect for Health Board 
and in interactions with the clinical variables.
Table 5.9 shows the significance for inclusion of these new interactions with the slightly 
modified 'Clinical Full' model and also the pairs of clinical variables in the original 
'Clinical Full' model.
'"a
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Interactions P Value
P a i r s  o f  C l i n ic a l  F a c to r s
A*C 0.815
A*E 0.720
A*N 0.804
A*T 0.749
C*E 0.166
C*N 0.062
C*T 0.859
E*N 0.709
E*T 0.326
H e a l th  B o a r d  w i th  C l i n ic a l  F a c to r s
A*HG 0.320
C*HG 0.085
E*HG 0.163
N*HG 0.647
T*HG 0.405
T a b l e  5 .9 :  S ig n i f ic a n c e  f o r  in c lu s io n  o f  th e  in te r a c t io n s  w i th  
H e a l th  B o a r d  in  g r o u p s  in  th e  s l i g h t l y  m o d i f i e d  'C l in ic a l  F u l l '  
m o d e l  a n d  th e  p a i r s  o f  c l i n ic a l  f a c t o r s  in  th e  'C l in ic a l  F u l l ’ m o d e l .
A g e  g r o u p  i s  g i v e n  b y  A , c l i n i c a l  s t a g e  (C ), E R  s t a tu s  (E ), tu m o u r  
s i z e  (T ), n o d e  s t a tu s  (N ) a n d  H e a l th  B o a r d  in  (H G ) g r o u p s  r e s p e c t i v e l y .
None of the interactions of the clinical factors with Health Boards in groups were 
significant.
DISCUSSION
The model including the interaction between node status and all of the Health Boards 
separately did not converge properly. Although the interaction between clinical stage 
and all o f the Health Boards separately appeared to converge, the estimates of some of 
the standard errors implied that the model was unstable. When the Health Boards were 
grouped, the interaction of this variable with clinical stage was not significant (P=0.09). 
However, the group comprising the Test’ of the Health Boards consisted of a mixture of 
veiy different Health Boards, which may have cancelled out any differences between 
these Health Boards in terms of the treatment of women with different clinical stage. It 
does not make sense to group any of the clinical stages together. The conclusion, 
therefore, was that when the Health Board was grouped, none of the interactions were 
significant. Overall it, therefore, cannot definitely be concluded that any further 
interactions were necessary in the 'Clinical Full' model, and therefore none were added.
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5.3 MODEL CHECKING FOR ADEQUACY OF FIT AND VALIDITY OF 
PROPORTIONAL HAZARDS ASSUMPTION
INTRODUCTION
This section now investigates the adequacy of the fit of the 'Clinical Full' model and the 
validity of maldng the assumption o f proportional hazards in that model.
The adequacy of the model is looked at using Cox-Snell residuals and is discussed more 
fully in the next section.
The proportionality of the hazards assumption is studied in Section 5.3.2 using two 
techniques. Firstly, informally through a plot of log{- log)S(/)} versus log{r} and, 
secondly, by including a time-dependent covariate in the Cox regression model.
5.3.1 EXAMINING THE ADEQUACY OF THE FIT OF THE MODEL
INTRODUCTION
The ‘Clinical Full’ model defined in Section 5.2.2 is the model with the variables: age 
group, clinical stage, ER status, pathological node status, pathological tumour size, their 
two-way interaction and also Health Board of treatment. All of these vaiiables were 
fitted as categorical factors. How well this model fits is assessed informally by 
examining the Cox-Snell residuals for all of the cases and then separately for each of the 
factors by plotting the different levels of the factors.
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THEORY- DERIVING THE COX-SNELL RESIDUALS
Let the survival times for the n  individuals be and suppose there are
r  death times among the n  individuals, with r  < n  . The estimated hazard function from 
the Cox model for the zth individual with covariatex., / = 1, 2, « , is given by
The Cox-Snell residuals are defined, for the zth individual, as
= ^ , ( t j ,  by integrating Eq 5.3.11
= -log^ ,.(r,), (Eq 5.3.1^2)
where H ^ {t^ ) is the estimated cumulative baseline hazard, evaluated at the observed 
survival time for the zth individual.
The following mathematical result is needed to derive the Cox-Snell residuals.
R e s u l t  I :  If Tis the random variable associated with the survival time of an 
individual with corresponding survivor function of S ( t ) , then the random 
variable Y  =  -  log S { t )  will have an exponential distribution with unit mean, 
irrespective of the form of S { t ) .
If the fitted model is appropriate, then
That is, the fitted value of the survivor function is close to the true value of the survivor 
function for the zth individual at time r , . Therefore, from Result 1, -  log ,5, (r, ) should 
be consistent with being a sample fr om a unit exponential distribution. The values 
-  log ,5, are the Cox-Snell residuals, r„. (see Eq 5.3.1_2).
These residuals are unlike those obtained for linear regression as they do not relate the 
observed value to the expected value. Instead, they are useful for studying how well the 
residuals fit an exponential distribution with mean one. They are not symmetrically 
distributed, camiot be negative and are positively skewed.
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T H E O R Y  - A S S E S S IN G  T H E  F IT  O F  T H E  M O D E L  5
From the survivor function for a Weibull distribution, given in Eq 5.1_3 in Section 5.1, 
for the exponential distribution,
log{-log5'(r)} = Alogr.
Hence, for data from an exponential distribution with parameter A = 1, a plot of
log{- log*5(r)| against log{r} should be approximately a straight line with intercept at
zero and a slope of one (Collett, 1994). Note that log{- log»5(/^)| is the same as the
:estimated log cumulative hazard from the known relationship between the hazard and f*
survivor function, given in Eq. 5.1_2 in Section 5.1.
Thus, by analogy, if a plot of log{- log s(r^^ )} against logjr^,} gives a straight line with
'lbslope one and zero intercept, then this implies that the Cox-Snell residuals can be 
assumed to come from a unit exponential distribution. This, in turn, implies that the 
fitted model is a good one (from Result 1).
M E T H O D S
The Cox-Snell residuals were obtained by fitting a Cox regression model to the data and 
saving the cumulative hazard for each individual to give the Cox-Snell residuals, . 
These values were then taken as the ‘survival times’ in a Kaplan-Meier analysis and the 
values of s(r^^ ) obtained from this. A plot of lo g j-  log5(z;, ) | , by transforming the
s(r^^ ) obtained from Kaplan-Meier, against logjr^,.}, with the obtained from the Cox
regression, was examined to see whether the scatter plot of the observations lay roughly 
on a line with slope one and intercept zero.
It was also possible to look at the log cumulative hazard plots of the Cox-Snell residuals 
for different levels of each of the factors. If the fitted model is a good one, the points on 
the plot should be homogenous across the different levels of each factor. If, however, 
the points for the different levels are widely dispersed, then there would be a suggestion 
that this factor has not been fully taken into account in the model. The points on the 
curves only represent the Cox-Snell residuals for the event times.
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RESULTS FOR THE ‘CLINICAL FULL ' MODEL
A l l  C a s e s :  The plot of the log cumulative hazards of the Cox-Snell residuals against the 
log of the Cox-Snell residuals for all o f the cases (Figure 5.5) shows that the ‘Clinical 
Full’ model appeared to fit quite well, with only very slight departure from the line with
unit slope and intercept zero at small values of logjr^  ^| .
Cox-Snell residuals for all c a se s
1
g
log (C ox-S n ell re sid s)
F ig u r e  5 .5 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  C o x - S n e l l  r e s i d u a l s  f o r  a l l  
c a s e s .
I n d i v i d u a l  F a c t o r s :  However, looking at each of the plots for the separate factors: age 
group, clinical stage and ER status (Figures 5.6 to 5.8) suggests some departures from 
the line thi'ough zero with slope one. Some of the points for the different levels in the 
factors separated out, rather than overlapping each other. Most of the separation, 
however, occurred for the early event times and appeared to stabilise for the majority of 
the residuals.
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Cox-Snell residuals for age group
2
o a g e  group
< so yrs
log (C ox-S n ell re sid s)
F ig u r e  5 .6 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  C o x - S n e l l  r e s i d u a l s  f o r  a g e  
g r o u p .
Cox-Snell residuals for clinical sta g e
2
0
-2
Clinical s ta g e  
unknown
■3
log (C ox-S n e ll resid s)
F ig u r e  5 .7 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  C o x - S n e l l  r e s i d u a l s  f o r  c l i n i c a l  
s ta g e .
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Cox-Snell residuals for ER status
2
0
1 " 
I  ^
?
g  -s
ERSTATUS
o Not Known
'■ Negative
-8 A Positive
log (C ox-S n ell re sid s)
F ig u r e  5 .8 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  C o x - S n e l l  r e s i d u a l s  f o r  E R  
s ta tu s .
Due to the fact that an interaction term for node status and tumoui' size was included in 
the model, it seemed sensible to examine the plot for the combined levels rather than for 
the factors alone. However, this plot was too busy to make any sense of and, therefore, 
is not given.
The slight deviations noted from these plots perhaps suggests that there was some lack 
of fit of the model.
5.3.2 ASSESSING THE ASSUMPTION OF PROPORTIONAL HAZARDS IN 
THE COX MODEL
INTRODUCTION
This section concentrates on checking the crucial assumption of proportional hazards. 
This was assessed initially using two informal graphical methods. These plots were 
obtained from Kaplan-Meier analyses on the individual factors that were ultimately 
significant in the Cox model. The second method is a formal examination of the 
proportional hazards assumption using the technique of time-dependent modelling. 
Before the results are presented, some theoiy needs to be given.
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Kaplan-Meier survival curves: When the hazards are proportional, 
h^{t) khiXt) 
for a factor at two levels, say, a and b, so 
HSt)  = k'H,(t)
or - logS„(?) = k' { -  l o g S j ( 0 }  ■
Thus,
sM = [sM' .
Therefore, the survivor function of one level is always greater than or equal to the 
survivor function of the other level for all times. This argument can be extended to 
factors with more than two levels.
It is therefore worth examining the Kaplan-Meier survival curves for each of the factors 
to check whether the estimated cur ves for the different levels cross or not. If they do 
cross repeatedly, the assumption o f proportional hazar ds may be in question.
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Î
THEORY-KAPLAN-MEIER SURVIVAL CURVES AND LOG CUMULATIVE HAZARD
PLOTS Î
Log cumulative hazard plots: The survivor function for a Cox model (Section 5.1.2) is
s w = h o
Therefore,
log{-logS'(/)} = log{-log5'o(0)
Thus, log{- logkS'(f)} is a function o f time plus a constant.
Therefore, plots of lo g (- log5'(?)} versus a function of time should be par allel across 
different levels of variables of x . This suggests estimating S{t) within subgroups and 
plotting log{~ logiS(/‘)} against t , say, for each subgroup, to look for departures from 
parallelism, indicating non-proportionality. Now log{-log*S'(/‘)} = log H{t) , which is 
the log cumulative hazard function, indicating the name of the plot.
:|
Alternatively, this could also suggest that there is no difference between the levels of the 
factor. The assumption of proportionality may also be doubtful if  the curves diverge 
considerably.
Both of these informal plots are obtained using the Kaplan-Meier method. In contrast, 
the next subsection relates to the theory of some formal modelling, where the Cox 
model is fitted to examine the assumption of proportional hazards.
T H E O R Y - T IM E -D E P E N D E N T  M O D E L L IN G  T O  A S S E S S  T H E  P R O P O R T IO N A L IT Y  O F  
H A Z A R D S  A S S U M P T IO N
The assumption of proportional hazards means that the ratios of the instantaneous risks 
of death for the individuals in each of the levels of a factor are assumed to be constant 
over time. The teclmique of fitting time-dependent covariates can be used to assess this 
assumption.
The idea is to fit the chosen Cox model with an additional term for the interaction 
between some function of time and one of the covariates. The significance of the 
parameter for the interaction in the extended model is then examined. This is 
straightforward for continuous and binary variables, but is more problematic for 
categorical factors at more than two levels.
Suppose, for simplicity, that all of the covariates are binary with X j = 0 for level 1 and
= 1 for level 2 of the covariates X j ,  7  = 1, ..., 7?, where x = (xj, Xj, ..., ) . Let the
validity of the proportional hazards assumption be checked for covariate x ^ . An 
additional term is created to represent the multiplicative interaction o f this covariate 
with a function of time. So let
where g ( t )  is any function of time, although it is usual to assume a monotonie form for
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The hazard for the i th  individual is given by
4 '  ( 4  =  e x p [ ^  X, +  4 ,’h-i^ p+i) ^ o* W  •
Now = 0 for level 1 ofx^ and = g { t )  for level 2 of Xj. Therefore, the hazard 
ratio for being in level 2 versus level 1 for covariate Xj is given by
exp(7i' + A,g(f))-
Thus, the hazard ratio depends on time t  and, therefore, is no longer constant for all 
time, meaning that the hazards are no longer proportional.
The null hypothesis that = 0  i s  examined using the Wald statistic for this paiameter 
when the interaction of the function of time multiplied by covariate Xj is added into the 
model. The Wald statistic is compared to the X i distribution for significance.
M E T H O D S
Since the ‘Clinical Fulf model consisted entirely of factors at more than two levels, it 
was necessary to create dummy variables for every level for every factor. No unique 
method exists to circumvent this problem and, therefore, this way was chosen so that 
each contrast compared each level with the rest of the levels, for each factor, thus 
providing one degree of freedom tests for each o f the interactions.
Thus, for example, for age group, foui' dummy variables were created as follows:
a g e l tS O  =  1 if  age <50  yrs
0 otherwise; 
a g e 5 0 6 4  = 1 if age 50-64 yrs
0 otherwise; 
a g e 6 5 7 9  = 1 if age 65-79 yrs
0 otherwise; 
a g e g e S O  = 1 if age > 80 yrs
0 otherwise.
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The dummy variables were named so as to indicate which level was being compared 
against the rest of the levels for each contrast in each factor. Dummy variables were 
created in a similar fashion for the other factors. Thus, for example, s t a g e l x  t  gives the 
interaction of clinical stage I vs the rest (of the clinical stages) with time. For the 
interaction between node status and tumour size, nine dummy variables were set up to 
represent the nine different possible combinations for these two factors, each with three 
levels. Full details are given in the Results section.
The dummy variables were entered separately, one at a time, with the 'Clinical Full' 
model. Thus, for each factor, a series of Cox models were fitted, each assessing an 
assumption of proportional hazards. In this manner, it was possible to check whether 
there was any time-dependency in a particular level versus the rest of that pailicular 
factor, after allowing for the effects of the other explanatory variables being in the 
model. For each model, the other factors were assumed to be independent of time.
For example, for age group, four different Cox models were fitted. The first was the 
'Clinical Full' model plus the interaction a g e l tS O  x t. That is, the interaction of the 
single contrast age less than 50 years versus the rest with time was added into the 
'Clinical Full' model, where age group was already included with three degrees of 
freedom, with the other thi*ee levels compared to age less than 50. The next three Cox 
models fitted were the 'Clinical Full' model along with a g e 5 0 6 4  x t ,  a g e 6 5 7 9  x t  and 
a g e g e S O  x t  (the ‘ge’ standing for greater than or equal to). The results of the modelling 
are given below, along with the informal plots, for each of the factors separately. The 
chosen function of time here was simply g ( t )  =  t .
R E S U L T S  
A g e  G r o u p :
Firstly, the Kaplan-Meier survival curves and the log cumulative hazards plots for age 
group are presented (Figures 5.9 and 5.10 respectively). The Kaplan-Meier curves do 
not cross, except for the cui'ves for the <50 and 50-64 groups. These two groups appear 
to be nearly identical as they cross several times.
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KM survival functions for age group
1.0
< 50 
50-64
65-79
13EO
>= 80
0.0
0 1 3 4 5 62 97 8
Time in years
F ig u r e  5 .9 :  K a p la n - M e i e r  s u r v i v a l  c u r v e s  f o r  a g e  g r o u p .
Log cumuiative hazard vs time
for age group
1
0
•1
-2
-3 age group
>=80yfs
cn -5
50-64 yrs•6
-7 < 60 yrs
0 1  2 3 4 5 6 7 8
Time in years
F ig u r e  5 .1 0 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  a g e  g r o u p .
Looking at the log cumulative hazards plot shows that the scatter plots for each of the 
levels are nearly parallel. Perhaps, there is a slight suggestion that the curves come 
together. However, this could just be due to the fact that there were not many 
observations early on and that too much weight is being given to the data occurring in 
the first two years. In fact, there were only 58 deaths in total during the first yeai'.
The dummy variables created to examine the proportional hazai'ds assumption for age 
group were given in the Methods section above. Table 5.10 below gives the results for 
fitting the four interactions of the dummy variables with time.
114
Param eter
estimate
Standard
erro r
P value for 
W ald statistic
a g e l t 5 0  X t -0.0400 0.0547 0.4649
a g e 5 0 6 4  x t 0.0165 0.0504 0.7437
a g e 6 5 7 9  x t 0.0098 0.0510 0.8479
a g e g e S O  x t 0.0274 0.0927 0.7676
T a b l e  5 .1 0 :  R e s u l t s  o f  t im e - d e p e n d e n t  m o d e l l i n g  f o r  a g e  g r o u p .
E a c h  o f  th e  c o n t r a s t s  r e p r e s e n t  o n e  l e v e l  o f  th e  f a c t o r  v.s th e  
c o m p l e m e n t a r y  l e v e l s  in  th e  in te r a c t io n  w i t h  tim e . N o te  th a t  
I t a n d  g e  s t a n d  f o r  l e s s  th a n  a n d  g r e a t e r  th a n  o r  e q u a l  to  
r e s p e c t i v e l y .
None of these interactions were significant at the 5% level and, therefore, there was no 
reason to reject the assumption of proportional hazards for age group.
C l i n i c a l  S t a g e :
Examination of the Kaplan-Meier survival cui'ves for clinical stage (Figure 5.11) shows 
that the curves do not really cross except, perhaps, the unknown group and stage II, 
showing that the group of unknowns are very similar to the group with stage II disease. 
Alternatively, the unknowns could be a mixture of all tlnee clinical stages and the 
mixture just happened to be similar to the stage II group. Figure 5.12 gives the 
corresponding log cumulative hazards plot for clinical stage.
KM survival functions for clinical stage
EO
unknown
Time in years
F ig u r e  5 .1 1 :  K a p la n - M e i e r  s u r v i v a l  c u r v e s  f o r  c l i n ic a l  s ta g e .
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Log cumulative hazard vs time 
for clinical stage
1
0
■1
-2
-3 clinical stage 
" unknown
stage
0 1 2 3 4 5 6 7 8
Time in years
F ig u r e  5 .1 2 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  c l i n ic a l  s ta g e .
Again, the curves seem to be reasonably parallel after the first two years.
None of the interactions were significant when the formal modelling for clinical stage 
with time was performed (range of P values for contrasts from 0.46 to 0.99). Thus, 
there is no evidence to assume that the hazards were not proportional for clinical stage.
ER Status:
The Kaplan-Meier survival curves for ER status is given in Figure 5.13. It does not 
show any serious crossing, except the ER negative curve drops down dramatically at 
about six months. In fact, out of 22 events that occuiTed before six months, 16 were in 
the ER status unknown group. This was compared with two in the ER positive group 
and four in the ER negative group. Discussion of this seemingly strange pattern is given 
below and in the next section.
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KM survival functions for ER status
positive
unknown
negative
EO
0.0
0 1 32 4 5 6 7 8 9
Time In years
F ig u r e  5 .1 3 :  K a p la n - M e i e r  s u r v i v a l  c u r v e s  f o r  E R  s ta tu s .
The log cumulative hazards plot for ER status (Figure 5.14) reflects the pattern observed 
in Figure 5.13.
Log cumulative hazard vs time
for ER status
1
0
■1
-2
-3
ER statusi :
-6
°  Not Known
Negative
-7  ^ Positive
3 4 5
Time in years
F i g u r e  5 .1 4 :  L o g  c u m u la t i v e  h a z a r d s  p l o t  f o r  E R  s ta tu s .
The main problem occurs prior to the first year of survival. The curves are not parallel 
and the sudden drop in survival observed in the Kaplan-Meier plot (Figure 5.13) for the 
ER negative group is mirrored by the rapid increase in the log cumulative hazard for this 
group after the six months mark (Figure 5.14). After the first year of survival, ho'wever, 
the curves are nearly parallel, although there is a slight suggestion that they converge on 
each other. The occurrence of this pattern is due to the fact that until three months the
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hazard ratio for being ER negative vs ER positive is one, as no events happened for 
either group. There was an event at tliree and at five months in the ER positive group. 
Four events occurred between five and six months in the ER negative group. After this 
point, the hazard increases for both groups. This increase is more rapid for ER status 
negative than positive. Eventually, however, the hazard ratio for being ER negative vs 
ER positive begins to attenuate as the gradient of the estimated survival curve for ER 
negative, seen in Figure 5.13, becomes less steep.
The results of fitting the interactions of the dummy variables for this factor with time are 
given below in Table 5.11.
Param eter
estimate
Standard
erro r
P value for 
W ald statistic
e r p o s  X  t 0.1904 0.0547 0.0005
e r n e g  x t -0.1153 0.0530 0.0298
e r u k  X  t -0.0559 0.0488 0.2518
T a b l e  5 .1 1 :  R e s u l t s  o f  t i m e - d e p e n d e n t  m o d e l l i n g  f o r  E R  s ta tu s .
E a c h  o f  th e  c o n t r a s t s  r e p r e s e n t  o n e  l e v e l  o f  th e  f a c t o r  th e
c o m p l e m e n t a r y  l e v e l s  in  th e  in t e r a c t io n  w i th  t im e . N o te  th a t  
p o s ,  n e g  a n d  u k  s t a n d  f o r  p o s i t i v e ,  n e g a t i v e  a n d  u n k n o w n  
r e s p e c t i v e l y .
Both of the interactions of time with ER status positive vs rest and ER status negative vs 
rest were significant. Thus, there appeared to be a changing risk ratio of death over time 
for ER status.
The signs of the parameter estimates for the two interactions were positive for ER 
positive vs rest with time and negative for ER negative vs rest with time. Thus, the risk 
ratio for being ER negative decreased with time, although Figure 5.13 shows that 
women having ER negative tumours had a poorer prognosis than those with ER positive 
tumours. One interpretation of these results could be that being ER negative carried an 
important additional risk in the short term, but the magnitude of the risk decreased over 
time. These findings ai'e discussed further in Section 5.3.3.
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Node Status with Tumour Size:
Neither the Kaplan-Meier survival cui ves nor the log cumulative hazar ds plots are given 
here because the plots showing the nine combinations for this interaction were too busy 
to interpret meaningfully.
When the formal time-dependent modelling was performed for this factor, none of the 
interactions were significant and, therefore, the proportional hazards assumption could 
not he rejected for the node status by tumour size interaction with time.
Health Board:
Again, due to the large number of levels (13) for Health Board, neither the Kaplan- 
Meier survival curves nor the log cumulative hazards plots are given here. The time- 
dependent modelling for this factor revealed that two of the interactions were significant 
at the 5% level. These were the Islands Health Board (I) vs the rest (P===0.034) and Forth 
Valley HB (V) vs the rest (P=0.018). If these two interactions were not just due to 
chance, then this meant that the ratios of the risks of death for these two levels with the 
others were changing over time.
The hazard ratio for the Islands Health Board vs Greater Glasgow Health Board (G) in 
the 'Clinical Full' model was less than one, implying a decreased risk. However, 
because the parameter estimate for the interaction with time was positive, then women 
treated in the Islands HB appealed to have an increasing risk with time. In contrast, 
women treated in Forth Valley (V) appeared to have a decreasing risk compared to the 
rest over time. This Health Board had an increased risk of death compaied to Greater 
Glasgow HB in the 'Clinical Full' model.
It is hard to interpret exactly what is happening when there are so many levels involved. 
This problem is heightened by the fact that in the 'Clinical Full' model the contrasts for 
the full Health Board factor, with twelve degrees of freedom, were all compared with 
Greater Glasgow, whereas in the interactions with time the thirteen individual contrasts 
of each level for time dependence were each compared to the rest of the twelve levels 
together. Possible interpretations for these two significant interactions are given in the 
next section.
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5.3.3 CONCLUSIONS FROM THE MODEL CHECKING
INTERPRETATIONS OF THE RESULTS
A d e q u a c y  o f  t h e  m o d e l :  The previous two sections presented the results from 
examining the adequacy of the fit of the Cox model and of the validity of the 
proportional hazards assumption. From Section 5.3.1, the global plot of the Cox-Snell 
residuals for all cases seemed to fit adequately (Figure 5.5). However, when the 
subgroups were examined, the plots for the individual factors (Figures 5.6 to 5.8) 
showed that there was some suggestion that the model did not entirely fit adequately and 
that the factors had not fully been taken into account in the Cox model. However, 
when other interactions (the interaction of node status by tumour size is already present 
in the 'Clinical Full' model) were searched for in Section 5.2.4, it was found that none of 
the interactions were significant when added to the modified 'Clinical Full' model, when 
the Health Board variable was grouped.
P r o p o r t i o n a l  h a z a r d s  a s s u m p t i o n :  The finding that there were significant interactions 
with time for two of the three levels of ER status and two of the 13 levels of Health 
Boar d is perhaps of greater concern.
(i) E R  status: Examination of Figures 5.13 and 5.14 in Section 5.3.2 showed that the 
ER status unknown group had the worst prognosis early on (up to about six months) and 
then the group became the intermediate prognostic group once deaths in the ER negative 
group became more abundant. It was found that 16 out of 22 women who had died 
before six months did not have the ER status of their tumours determined. This number 
appeared to be too great to simply be due to chance. Possible reasons to explain why 
this pattern was observed have been explored, following discussions with clinical 
colleagues.
One interpretation could be that some women had such poor prognoses that they did not 
have their ER status ascertained. This seemed an unlikely explanation, however, since 
the cohort for these analyses included only those women who were deemed fit enough 
for surgery and in whom no documentation o f evidence of metastatic disease at 
presentation was found.
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Another suggestion was that the 16 women with ER status not recorded and who died 
within the first six months were treated at rural hospitals, which may have low annual 
breast cancer case loads and no definitive protocols for staging the tumour. However, 
when the list o f hospitals performing the surgeiy on these 16 cases was collated, this 
argument could not be supported (data not given).
A further possibility examined was that these women died suddenly of a cause of death 
not related to breast cancer; for example, a lieait attack. However, ten of the cases had 
breast cancer as the primary cause of death; two cases had another cancer (lung and 
stomach, which probably were actually métastasés from the breast cancer) and only four 
cases had deaths due to heart or pulmonary problems. Therefore, this suggestion was 
also not supported.
Thus, leading to the remaining possible clinical reason that all of the women dying 
before six months did in fact have métastasés despite that there was no mention of them 
in the documentation. In many cases, métastasés are not routinely searched for unless 
they are suspected at presentation or there is extensive lymph nodal involvement. 
Section 4.2.3 showed that ER status was more likely to be missing if node status was 
missing than if  node status were known. However, examination of staging of node 
status and tumour size was similar in the women dying early, with and without ER 
status recorded. Thus, there is no obvious reason why having métastasés not detected at 
presentation should be more prevalent in women with ER status unknovm, than in those 
women where it was known.
None of these clinical reasons explained the observation and so it seems, therefore, that 
it was due to chance that 16 of the 22 deaths in the first six months were for women 
with unknown ER status.
It is plausible that the effect o f the ER status covariate changes over time and the 
proportional hazards assumption does not hold. That is, ER status has an effect on 
outcome immediately after diagnosis and treatment, but this effect is not maintained 
over a long time. Miller et al (1994) support this. Collett et al (1998) foiuid that the 
effect of ER status on a prognostic index they were deriving was strong in the first five 
years, but then weaker after that. They also highlighted a lessening importance of ER
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status on survival with time. However, many other studies have included ER status in 
Cox regression models (Gordon et al, 1992; Hawkins et al, 1996; Newman et al, 1997; 
Shek & Godolphin, 1988) without reporting any non-proportionality.
In terms of interpreting the results from fitting the 'Clinical Full' model, it is likely that 
the hazard ratios for ER status were not overly biased in terms of the order of the 
hazards and that the model probably gave a reasonable estimate of the average hazard 
ratios. It is possible, however, that it may over-estimate the long term predictions for 
the importance of ER status on survival from breast cancer.
(ii) Health Board: This is the other factor where significant interactions of two of the 
levels of the factor with time were found. One interpretation o f the fact that the Islands 
(I) Health Board had a significant interaction with time with a positive parameter 
estimate but with the Health Board in the 'Clinical Full' model having a negative 
parameter estimate could be that this perhaps implies that these women had sub-optimal 
follow-up treatment. Maybe the women chose not to travel to either Glasgow or 
Inverness to receive radiotherapy subsequent to any breast conserving surgery on the 
Islands.
In the circumstance of the Forth Valley (V) Health Board interaction with time, 
however, the signs of the parameters probably indicate that the initial treatment was 
poorer than that received by women treated in Greater Glasgow (G) Health Board, but 
this increased mortality risk decreased over time.
These significant interactions could possibly reflect changing patterns of care over time 
in the Health Boards, which may have happened at different times in the different 
Health Boards, causing the effects on survival over time to change in these Health 
Boards.
However, the interactions with the two Health Boards could also be due to chance.
After all, 33 tests in total were conducted and presented in the last section so that it 
would be expected that at least one would be significant at the 5% significance level 
merely by chance.
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W E A K N E S S E S
Although the usefulness o f the 'Clinical Full' model has been questioned by the findings 
from the model checking, several weaknesses of the methods employed should be borne 
in mind when interpreting the findings.
Cox-Snell residuals: Firstly, Collett (1994) points out that the use of the Cox-Snell 
residuals may not be appropriate if small samples are involved. This is because the 
distributional results relating to a unit exponential distribution may not be valid. 
However, this is probably not a necessary caveat in this particular situation, except 
perhaps for some of the Health Board levels.
The main problem with using the Cox-Snell residuals plots, however, is the informal 
nature of them. The interpretation of these plots is entirely subjective and it can be 
difficult to judge whether the observations lie within the margin of error expected due to 
fitting estimated values.
Kaplan-Meier and log cumulative hazards plots: Similarly, using the plots of the 
Kaplan-Meier survival curves and the log cumulative hazards plots to assess the 
proportional hazards assumption presents the same problem of subjectivity. It is not too 
difficult to spot survival curves that cross, although it is necessaiy to remember that the 
crossing may just be due to fitting estimated values. It is slightly more awkward to 
decide whether the estimated log cumulative hazard lines are par allel for most of the 
time. Although, in theoiy, the Kaplan-Meier curves would not be expected to cross and 
the curves on the log cumulative hazards plot to be parallel, in practice there would be 
some deviance from the expected positions because only the estimated values were 
being plotted.
Formal time-dependent modelling: Using formal time-dependent modelling has the 
benefit in that it can be assessed by formal tests derived using statistical inference. There 
are no problems with this method for the simple situations when the covariates are 
either continuous or binary. However, it is not entirely clear how to perform the 
modelling, or interpret the results, when the covariates are categorical factors with more 
than two levels, as there is no unique method in this situation. The use of the dummy 
variables seemed to be an acceptable method for partially assessing the proportional
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hazards assumption for each of the factors. This method should be powerful if one of 
the groups were different from the rest.
D IS C U S S IO N
The validity of predictions made from the 'Clinical Full' model may have to be treated 
cautiously, although all of the weaknesses described above should be taken into account 
before the soundness o f the model is ruled out completely. The 'Clinical Full' model 
probably provides acceptable average hazard ratios for the factors in the short term, but 
may be more questionable in the longer term.
One disadvantage of fitting a Cox model is that it does not allow the effect of a 
covariate on survival to diminish over time. Instead of fitting a Cox model, non­
proportional hazards models could have been fitted to the data. Unfortunately, due to 
time constraints, this was not pursued here. However, Gore et al (1984) fit various non­
proportional models to a series of nearly 4,000 women with breast cancer referred to one 
hospital between 1954 and 1964. They found that the hazaid functions converged over 
time. Schemper (1992) examines, theoretically, violations of the proportional hazards 
assumption in a Cox model.
5.4 SURVIVAL ANALYSIS INTERPRETATIONS WITH RESPECT TO 
MISSING VALUES
Whether the missing values in the four* main clinical variables were related to the Health 
Board of treatment is discussed in the next section. Approaches to handling the missing 
values are examined in Section 5.4.2 to investigate whether the method influenced the 
results and interpretations from the survival analyses. Possible explanations why the 
variables age and clinical stage had different results in the models based on all cases and 
complete cases only are discussed in Sections 5.4.3 and 5.4.4.
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5.4.1 MISSING VALUES IN THE HEALTH BOARD OF TREATMENT
I N T R O D U C T I O N
Here, univariate associations between Health Board of treatment and having missing 
values in the clinical factors are examined.
R E S U L T S
The percentages of cases with complete data in each of four clinical factors are tabulated 
for the thirteen Health Boards (Table 5.12). The P values for the tests of association 
for missingness of data for the clinical factors across Health Boards were all very highly 
significant (P <0.0001 for all tests). Therefore, whether or not the information was 
missing for each of the clinical variables depended on which Health Board the woman 
had her surgery in.
Health
Board
% complete 
inC
% complete 
inN
% complete 
inT
% complete 
in E
% complete 
in all 4
Number 
of cases
A 64.3 67.5 75.4 83.3 34.9 126
B 72.7 90.9 81.8 9.1 0.0 22
C 73.8 78.5 79.4 62.6 31.8 107
F 96.7 69.2 81.3 69.2 45.1 91
G 82.2 76.4 80.5 77.0 47.5 343
H 76.4 79.2 87.5 4.2 2.8 72
I 76.0 64.0 88.0 4.0 4.0 25
L 77.0 67.4 77.8 43.0 23.7 135
N 76.3 82.3 79.0 72.0 40.3 186
S 97.4 84.7 85.5 88.5 64.7 235
T 72.3 66.9 64.2 35.1 15.5 148
V 69.1 52.9 73.5 1.5 1.5 68
Y 86.9 31.1 91.8 52.5 16.4 61
Overall 80.4 73.1 79.5 61.1 35.7 1619
T a b l e  5 .1 2 :  P e r c e n t a g e s  c o m p l e t e  in  e a c h  o f  th e  f o u r  c l i n ic a l  p r o g n o s t i c  f a c t o r s  
s e p a r a t e l y  a n d  in  a l l  f o u r  o f  th e m  to g e t h e r  b y  H e a l th  B o a r d .  N o te  th a t  C , N , T  a n d  E  
s t a n d  f o r  c l i n i c a l  s ta g e ,  n o d e  s ta tu s ,  tu m o u r  s i z e  a n d  E R  s t a tu s  r e s p e c t i v e l y .
To tiy to simplify the findings, a variable was created to represent those Health Boards 
which contain the five Cancer Centres (HBs: G, H, N, S and T) as one level (CC) versus 
those Health Boards which do not have a Cancer Centre (No CC). The results for the 
grouped Health Boards are given below in Table 5.13.
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IS
% complete % complete %complete % complete % complete Number i:inC inN inT inE in all 4 of cases y:
No CC 76.7 65.2 79.5 51.8 25.7 635
CC 82.8 78.3 79.5 67.2 42.2 984 ,Overall 80.4 73.1 79.5 61.1 35.7 1619 l'ïa;.
T a b l e  5 .1 3 :  P e r c e n t a g e s  c o m p l e t e  in  e a c h  o f  th e  f o u r  c l i n ic a l  p r o g n o s t i c  f a c t o r s  
s e p a r a t e l y  a n d  in  a l l  f o u r  o f  th e m  to g e t h e r  b y  w h e th e r  o r  n o t  th e r e  w a s  a  C a n c e r  C e n tr e  
(C C ) .  N o te  th a t  C , N , T  a n d  E  s t a n d  f o r  c l i n ic a l  s ta g e ,  n o d e  s ta tu s ,  tu m o u r  s i z e  a n d  E R  
s t a t u s  r e s p e c t i v e ly .
This table shows that the four main prognostic factors were available more frequently in 
the larger Health Boards, containing the Cancer Centres, than the smaller non-Cancer 
Centre Health Boards. Table 5.14 gives the corresponding P values for the tests of 
association for Cancer Centre Health Board group against having missing values in the 
clinical factors.
P Value
CC y/n with C kw or nk 0.002
CC y/n with N kw or nk <0.001
CC y/n with T kw or nk 0.980
CC y/n with E kw or nk <0.001
CC y/n with all four vars kw or nk <0.001
T a b l e  5 .1 4 :  P  v a lu e s  f o r  W s ts  o f  a s s o c ia t i o n  f o r  
C a n c e r  C e n tr e  H e a l th  B o a r d  ( C C )  w i th  th e  
f o u r  c l i n i c a l  p r o g n o s t i c  f a c t o r s  a s  e i t h e r  k n o w n  (k w )  
o r  m i s s i n g  (n k). N o te  th a t  C, N , T  a n d  E  s t a n d  f o r  
c l i n i c a l  s ta g e ,  n o d e  s ta tu s ,  tu m o u r  s i z e  a n d  E R  s t a tu s  
r e s p e c t i v e l y  a n d  ‘v a r s  ’f o r  v a r ia b l e s .
Thus, it appears that whilst there were differences among the ascertainment of 
pathological tumour size for all o f the Health Boards, on average, there were no 
differences between the Cancer Centre Health Boards and the non-CC Health Boards.
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5.4.2 MODELS FOR COMPLETE AND ALL CASES DATASETS
INTRODUCTION
One of the main aims of this thesis was to examine the influence o f missingness o f data 
on the results of the Cox regression analysis reported by Twelves et al (1998a), 
performed on the 1619 surgical cases. The model fitted in that paper is referred to here 
as the ‘Clinical Full’ or all cases model (ACM). The results of this were summarised in 
Section 5.2.2 and will be further discussed here.
When a model hased on the complete cases only was fitted excluding the Health Boar d 
variable, the standard errors obtained for the factors in the model were of similar 
magnitude to those obtained when the model was fitted on all cases.
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The technique used by Twelves et al (1998a) for handling the missing data was to add 
extra categories for the unknown values in each factor. The assumption that the missing 
data were missing at random (MAR) was implicitly made when the model was fitted, 
although this camiot be tested directly, as discussed in Section 4.3. However, 
comparisons of this method with the complete cases method and also fitting the two 
partially-complete cases models, suggested in Section 4.4, are examined to investigate 
whether the results are consistent or disparate for the different models.
COMPLETE CASES ANALYSIS
Initially, a Cox model was fitted on the 578 cases for which there was known 
information for the four main clinical variables: clinical stage, node status, tumour size 
and ER status. However, examination of the results showed that the model produced |
parameter estimates which were unstable. f
Table 5.15 below provides a breakdown of the numbers of cases in each of the Health 
Boards in the all cases model and those left when only the cases with complete 
information were retained. The percentage remaining for each Health Board is also 
given.
Health
Board
Number in all 
cases model
Number (%) with 
complete information
A 126 44 (34.9)
B 22 0 (0)
C 107 34 (31.8)
F 91 41 (45.1)
G 343 163 (47.5)
H 72 2 (2.8)
I 25 1 (4.0)
L 135 32 (23.7)
N 186 75 (40.3)
S 235 152 (64.7)
T 148 23 (15.5)
Y 68 1 (1.5)
Y 61 10 (16.4)
Total 1619 578 (35.7)
T a b l e  5 .1 5 :  N u m b e r  o f  c a s e s  in  e a c h  H e a l th  b o a r d  w h e n  a l l  c a s e s  
a n d  w h e n  o n l y  th o s e  w i t h  c o m p l e t e  in f o r m a t io n  w e r e  in c lu d e d .
Since the Health Board factor had not been expected to be significant a priori in the all 
cases analysis, it was important to try to ascertain whether it was present in that model 
only because of the presence of incomplete information in some of the other variables or 
because real differences existed among the sui vival chances of women treated in 
different Health Boards.
To try to address this, the four Health Boards (Borders (B), Highland (H), the Islands (I) 
and Forth Valley (V)) with only zero, two, one and one case respectively left with 
complete information were excluded and another Cox model obtained.
The variables present in the ACM were age, clinical stage, ER status, node status, 
tumour size, the interaction between these two variables, and Health Board of treatment. 
When the model was derived for the complete cases only, using the technique of 
forward stepwise selection, the variables age and clinical stage were not significant (P 
values for non entry were 0.30 and 0.14 respectively).
To allow comparison of the hazard ratios for these two factors between the two models, 
the factors were forced into the complete cases analysis. It was assumed that the 
addition of these non-significant factors into the model would not affect the results for
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the other factors noticeably. This complete cases analysis, with the reduced Health 
Board factor, was based on only 574 cases and is henceforth referred to as the complete 
cases model (CCM). The P values for ER status, node status, tumoui’ size, their 
interaction and Health Board of treatment were all very highly significant (<0.001) in 
the CCM.
RESULTS - COMPARISON OF THE ALL CASES AND COMPLETE CASES MODELS
Unfortunately, it was not possible to test formally whether the results were different 
using a statistical test because the two sets of estimates were not independent, since the 
women included in the complete cases model also belonged to the all cases model.
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II
(i) Hazard Ratios
Table 5.16 below gives the hazard ratios with 95% CIs for the two models. The 
estimates for the unknown levels in the all cases model are not presented here as the 
objective was to compare the findings with the complete cases model. For the same '■ireason, no estimates were given for the ACM for the four Health Boards which were 
excluded from the complete cases analysis. The results for the unknown levels for the 
ACM have already been detailed in Table 5.6 of Section 5.2.2.
All Cases Model Complete Cases Model
Variable Hazard
Ratio
95% Cl for 
Hazard Ratio
Hazard
Ratio
95% Cl for 
Hazard Ratio
Age
<50 1 1 »
50-64 1.04 0.84, 1.29 0.95 0.67, 1.33
65-79 1.18 0.95, 1.47 1 . 0 1 0.68, 1.48
>80 2 . 0 1 1.39, 2.90 3.25 0.75, 14.09
Clinical Stage
I 1 * 1 *
II 1.41 1.42, 2.78 1.64 0.98, 2.73
III 1.98 1.13, 2.09 1 . 6 6 0.89, 3.09
ER Status
Positive 1 * 1 »
Negative 2 . 1 1 1.69, 2.63 3.04 2.23,4.16
Node Status by 
Tumour Size
N+ T<2 3.91 2.62, 5.84 4.73 2.72, 8.21
N + T > 2 4.37 3.01,6.35 4.87 2.87, 8.27
N -T<2 1 * 1 *
N -T > 2 2.72 1.82,4.07 2.64 1.52, 4.59
Health Board
A 1.52 1.10,2.10 1 . 2 0 0.67, 2.16
C 1.49 1.06, 2.10 2.74 1.56, 4.82
F 1.55 1.05,2.29 2.70 1.57,4.65
G 1 * 1 *
L 1 . 2 0 0 .8 6 , 1 . 6 6 0.97 0.51, 1.84
N 0.95 0.69, 1.31 1.16 0.70, 1.91
S 0 . 8 8 0.65, 1.19 0.87 0.58, 1.31
T 1.33 0.94, 1.87 1.87 0.90, 3.89
Y 1 . 1 1 0.71, 1.76 0.18 0.02, 1.29
JL U t l V t L /  J. W .  JL L /t /  ^ t  ^  ^  / U  ^  K K L /  K A i l \ ^ l ^ 0 C > 0 .  I f l L i l  1  V
aM(7 T s t a n d  f o r  n o d e  s t a t u s  a n d  tu m o u r  s i z e  r e s p e c t i v e ly .
It is possible to obtain an idea about differences between the models by simple 
examination of Table 5.16 and Figure 5.15 below. The first observation to note is that 
some of the confidence intervals on the hazard ratios are very wide. Thus, qualitatively 
the findings appear to be quite similar, with almost the same patterns observable for the 
ordering of risk among the levels of the prognostic factors.
Quantitatively, there is a suggestion that there ai'e more extreme hazard ratios in the 
complete cases analysis. For example, for the clinical factors, except for clinical stage,
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the poorer prognostic levels (ER negative, node positive and large tumour size) 
appeared to be more severe for the complete cases model. For example, for ER status, 
there was an increased hazard ratio o f 3.04 (95% Cl 2.23, 4.16) for the CCM compared 
to 2.11 (1.69, 2.63) for the ACM for ER negative relative to the baseline ER positive, 
although it is unknown whether the two were statistically different.
I
For the Health Board factor, Ayrshire & Arran Health Board (A) did not have a 
statistically significant hazard ratio compared with Greater Glasgow Flealth Board (G) 
in the complete cases model (Figure 5.15).
Comparison of hazard ratios from the all cases and complete cases models
Note that _a represents the results 
from the all cases model. The _c 
represents the results from the 
complete cases model.
A_a A_c G_a C_c F_a F„c L_a L_c N_a N_c S_a S_c T_a T_c Y_a Y_c
Health Boards for all and complete cases
F ig u r e  5 .1 5 :  H a z a r d  r a t i o s  w i th  9 5 %  C I s  f o r  th e  a l l  c a s e s  a n d  c o m p l e t e  c a s e s  m o d e l s  
f o r  th e  n in e  H e a l th  B o a r d s .
!
Î
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Examination of the ranks of the hazard ratios (Table 5.17), on the basis of the point
■Hestimates for the nine Health Boards shows some variation, but the ranks can be split 
into two distinct groups, ranks 1-4 and 5-9.
Rank ACM CCM
High hazard
Low hazard
1 F C
2 A F
3 C T
4 T A
5 L N
6 Y G
7 G L
8 N S
9 S Y
T a b l e  5 .1 7 :  T h e  r a n k s  o f  th e  H e a l th  B o a r d s  
in  th e  A C M  a n d  C C M  o n  th e  b a s i s  o f  th e  
h a z a r d  r a t i o s  c o m p a r e d  y\nth  H e a l th  B o a r d  G .
This does not demonstrate that only F, A and C had a statistically significantly higher 
risk than G in the all cases model, and in the complete cases model, only F and C were 
statistically different from G,
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It is possible that including the four Health Boards which were dropped from the CCM 
(HBs: B, H, I and V) in the ACM altered the findings for the other variables. Therefore, 
another model with unknown values included in the prognostic factors was fitted. This 
model excluded the women in these four Health Boards, leaving 1432 cases. Table 
A6.1 in Appendix 6  gives the hazard ratios with 95% CIs for this model. Although 
there were some minor differences between the results for the two models with 
unknown values included (based on 1619 and 1432 cases respectively), none were very 
striking when compared with Table 5.16 in this section and Tahle 5.6 in Section 5.2.2.
It appears, therefore, that including the four Health Boards in the ACM did not greatly
influence the results for the ACM, in terms of making comparisons with the CCM.
Whilst the hazard ratio has the benefit o f depending only on the parameter estimates 
calculated for the model, it can sometimes also be informative for clinicians to see the . :
effect of differences in hazards on overall survival, say at a particular point in time, or 
on survival for each of the different levels of a factor. Therefore, the 5-year survival 
estimates are now considered.
(ii) 5~year % Survival Estimates
Before the results from the Cox models are presented, univariate Kaplan-Meier analyses 
are discussed. These were performed on the 574 women in the complete cases model 
and are compared with the results based on all cases discussed in Section 5.2.1 and by 
Twelves et al (1998a), Table A6.2 of Appendix 6  gives the Kaplan-Meier 5-year % 
survival estimates with 95% CIs hased on all cases and only on the complete cases, 
although only the results for the known levels are given for the all cases Kaplan-Meier 
analyses. Table 5.18 below gives the P values for the univariate log-rank tests of 
equality of the sur vival curves for the different levels of the different factors from both 
the all cases and the complete cases analyses.
The overall Kaplan-Meier survival based on the complete cases was 72.7% (95% Cl: 
69.0%, 76.3%) compared with 70.9% (6 8 .6 %, 73.1%) for all cases. Thus, there is a 
suggestion that the subgroup with complete prognostic information had a slightly better 
survival, but this was probably not significant. Again, it is not possible to formally test 
whether they are different as the two groups are not independent.
Factor P value 
based on 
all eases
P value based 
on complete 
cases
C L I N I C A L  F A C T O R S
Age <0 . 0 0 0 1 0.74
Clinical stage <0 . 0 0 0 1 0 . 0 0 0 1
Pathological node status <0 . 0 0 0 1 <0 . 0 0 0 1
Pathological tumour size <0 . 0 0 0 1 <0 . 0 0 0 1
ER status <0 . 0 0 0 1 <0 . 0 0 0 1
S E R V I C E  F A C T O R S
HB of first treatment 0 . 0 2 0.14
Deprivation 0.03 0 . 0 2
Surgical case load 0.03 0.13
Seen by an oncologist 0.25 0.18
T R E A  T M E N T  F A C T O R S
Type of sur gery 0 . 0 1 0 . 0 1
Adjuvant radiotherapy 0.49 0.27
Adjuvant chemotherapy 0 . 0 2 0.0008
Adjuvant endocrine therapy 0.74 0.003
Adjuvant chemotherapy or endocrine therapy 0.28 0.16
T a b l e  5 .1 8 :  P  v a lu e s  f o r  th e  o v e r a l l  l o g - r a n k  t e s t s  o f  e q u a l i t y  o f  th e  s u r v i v a l  c u r v e s  
in  u n i v a r ia t e  a n a l y s e s .
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Examination of Table 5.18 reveals that there are differences in the sets of factors which 
were significant in the two cohorts, one of which is that Health Board was not 
significant univariately when hased on the complete cases (P=0.14). However, it was 
significant in the multivariate Cox model based on complete cases when other factors 
had been adjusted for (P=0.0001). There was no evidence of differences among the 
survival curves for surgeon case load in the complete cases Kaplan-Meier analysis. This 
could be due to surgical case load for all cases having different survival prospects 
because the Team/3 0+ group staged their cases more thoroughly and, therefore, had less 
unknown information. Thus, the women under their care may have received more 
appropriate treatment.
It is interesting that there were statistical differences in survival for all of the treatment 
factors, except use of any adjuvant treatment, in the univariate log-ranks tests o f equality 
of the complete cases. The differences observed in the complete cases situation 
univariately may be due to women with complete staging information receiving optimal 
treatment. This may mean that some women were not given treatment because their 
disease had been staged, who may have been given it had their staging information been 
unknown. However, when the treatment factors were added to a Cox model with the 
clinical factors, but not Health Board, based on 574 cases, none were significant with P 
values ranging from 0.06 for any adjuvant systemic therapy to 0.90 for type of surgery.
In the publication, Twelves et al (1998a), 5-year % survival estimates obtained from the 
Cox model were presented for each of the factors, by ‘averaging’ over the other factors.
These included an ‘average profile’ by Health Board (Section 5.2.2). These estimates 
were made up of weighted averages of each of the levels of eaeh of the other factors 
(Section 5.2). It would be possible to present similar figures for the nine Health Boards 
included in the CCM. However, there would be problems of inteipretation due to 
differences in the frequency distributions for the factors for the two models (see Table 
5.19 below). Thus, the ‘average profile’ by Health Board (HB) for the two models 
would not be comparing ‘like’ with ‘like’, because the weighting of the risks in the other 
factors would be different in the two models (Eq 5.2_1 in Section 5.2). This could lead 
to mis-interpretations of any differences observed between the results for the two 
models.
.':3
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All Cases Model Complete Cases Model
Variable Number of
Cases
% % when 
nks 
excluded
Number of
Cases
%
Age
< 50  years 476 29 180 31
5 0 -6 4 591 37 $ 245 43
6 5 -7 9 480 30 * 145 25
> 80 years 72 4 * 4 7
Clinical Stage
Stage I 302 19 23 1 0 2 18
II 813 50 62 391 6 8
III 187 1 2 14 81 14
Not known 317 2 0 * *
ER Status
Positive 599 37 61 352 61
Negative 391 24 39 222 39
Not known 629 39 » * *
Node Status by 
Tumour Size
N nk, T < 2cm 185 1 1 * » *
N n k ,T > 2 138 9 * $
N nk, T nlc 1 1 2 7 * *
N +, T < 2cm 171 1 1 18 1 0 1 18
N + ,T > 2 312 19 32 183 32
N + ,T n k 1 0 0 6 * * $
N -, T < 2cm 269 17 28 157 27
N - , T > 2 2 1 2 13 2 2 133 23
N - , T n k 1 2 0 7 * * *
T a b l e  5 .1 9 :  O b s e r v e d f r e q u e n c y  d i s t r i b u t i o n s  f o r  th e  tw o  a n a l y s e s .  N o te  th a t  N  a n d  T  
s t a n d  f o r  n o d e  s t a tu s  a n d  tu m o u r  s i z e  r e s p e c t i v e ly .  A ls o ,  n k  s t a n d s  f o r  n o t  k n o w n .
One potential way to avoid comparing ‘average profiles’ by HB was to obtain survival 
estimates for particular levels of particular factors. To reduce the number of 
combinations (96 possible for the Imown values) to a more manageable set, the eight 
different combinations of ER status, node status and tumour size by Health Board were 
presented for age group 50-64 and clinical stage II (the largest levels in both factors) for 
the two models. Therefore, all of the weights for the risks (Eq 5.2 1 in Section 5.2) 
were now 1 in each of the eight groups for each of the 13 Health Boards separately.
When the 5-year % survival estimates for the two models are compared, it is necessary 
to be aware that any observed difference between the two models for a particular
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combination and a particular Health Board (known here as Health Boaid, prognostic 
groups) could be due to different parameter estimates for the Health Boar d from the two 
models; different values of the linear combinations of the other parameters from the two 
models; or simply due to the two models having different baseline survival estimates at 
that time point (or a combination of all three possibilities).
The results for the ACM and CCM are given in Tables 5.20a and 5.20b respectively. 
The eight prognostic groups given in these tables have heen sorted into order of 
prognosis, hased on the all cases model, from best to worst outcomes. The t  and i  in 
the body of Table 5.20b highlight which Health Board, prognostic group combinations 
had estimates of 5-year % survival in the CCM which were at least 10% in absolute 
magnitude greater than or smaller than respectively those of the ACM. The standard 
errors for the survival estimates for the Health Boards for the eight prognostic groups 
are not given due to the apparent problem with them using SPSS (Appendix 5).
Several comments can be made about Tables 5.20a and 5.20b. Note that all changes of 
percentage survival estimates stated below relate to absolute changes in percentages 
rather than percentage changes between the two models.
(1) The effect o f the node status by tumour size interaction on survival can be observed 
clearly for both models. For example, comparing group E+, N-, T<2 with E+, N~, T>2 
shows roughly a difference of 10% for most Health Boards; whereas E+, N+, T<2 vs 
E+, N+, T>2 has a difference of only about 3%. Thus, the large tumour size (poor 
prognosis) had more of an effect when node status was negative (good prognosis) than 
when node status was positive (poor prognosis).
Similarly, looking at group E+, N-, T<2 compared to E+, N+, T<2 demonstrates a 
difference of about 25% for most Health Boards. The corresponding difference for 
E+, N-, T>2 vs E+, N+, T>2 Is about 12%. Therefore, being node positive (poor 
prognosis) had a larger effect when tumour size was small (good prognosis) than when 
it was large (poor prognosis).
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All Cases Model: 5-year % survival for age group 50-64 and clinical stage II
Health
Board
E+, N-, 
T<2
E-, N-, 
T<2
E+,N -,
T>2
E+, N+, 
T<2
E+, N+, 
T>2 T>2
E-, N+, 
T<2
E-, N+, 
T>2
A 89.9 79.9 74.9 6 6 . 0 62.8 54.3 41.6 37.5
C 90.1 80.3 75.3 6 6 . 6 63.4 55.0 42.4 38.3
F 89.7 79.5 74.8 65.4 62.1 53.6 40.8 36.7
G 93.2 86.3 82.7 76.1 73.6 66.9 56.1 52.4
L 92.0 83.8 79.6 72.1 69.3 61.8 50.1 46.1
N 93.6 86.9 83.5 77.1 74.8 68.3 57.8 54.2
S 94.0 87.8 84.6 78.6 76,4 70.3 60.2 56.7
T 91.1 82.2 77.7 69.6 6 6 . 6 58.7 46.5 42.5
Y 92.5 84,8 80.9 73.7 71.1 63.9 52.6 48.7
T a b l e  5 .2 0 a :  F o r  th e  a l l  c a s e s  m o d e l :  5 - y e a r  % s u r v i v a l  e s t im a te s  b y  H e a l th  B o a r d  f o r  
th e  e i g h t  g r o u p s  o f  th e  c l i n ic a l  f a c t o r s .  N o te  th a t  E , N  a n d  T  s t a n d  f o r  E R  s ta tu s ,  n o d e  
s t a t u s  a n d  tu m o u r  s i z e  r e s p e c t i v e l y .  A ls o ,  n o te  th a t  th e  H e a l th  B o a r d s :  B o r d e r s ,  
H i g h la n d ,  I s la n d s  a n d  F o r th  V a l l e y  a r e  n o t  p r e s e n t e d  h e r e  a s  th e y  w e r e  n o t  in c l u d e d  in  
th e  c o m p l e t e  c a s e s  m o d e l ,  a l th o u g h  th e y  w e r e  in c l u d e d  in  f i t t i n g  th e  a l l  c a s e s  m o d e l .
Complete Cases Model: 5-year % survival for age group 50-64 and clinical stage II
Health E+, N-, E-, N-, E+, N-, E+, N+, E+, N+, E-, N-, E -,N +, E-, N+,
Board T<2 T<2 T>2 T<2 T>2 T>2 T<2 T>2
A 93.7 82.1 84.2 73.6 t  72.9 59.3 39.3 382
C 8 6 . 2 4 63.7 67.6 4 49.6 4 48.6 4 30.4 4 11.9 4 1 1 . 2
F 86.4 4 64.2 6 8 . 0 4 50.1 4 49.1 4 30.9 4 1 2 . 2 4 11.5
G 94.8 84.9 86.7 77.5 76.9 64.8 4 46.0 45.0
L 94.9 85.3 87.1 78.0 77.5 65.6 47.0 46.0
N 93.9 82.7 84.8 74.4 73.7 60.5 4 40.6 4 39.6
S 95.4 86.7 88.4 80.2 79.6 68.7 51.0 50.0
T 90.4 73.5 76.6 62.0 61.1 4 44.4 4 23.3 4 22.4
Y 99.0 t  97.1 t  97.5 t  95.6 t  95.4 t  92.6 t  87.1 t  86.7
T a b l e  5 .2 0 b :  F o r  th e  c o m p l e t e  c a s e s  m o d e l :  5 - y e a r  %  s u r v i v a l  e s t im a te s  b y  H e a l th  
B o a r d  f o r  th e  e i g h t  g r o u p s  o f  th e  c l i n ic a l  f a c t o r s .  N o te  th a t  E , N  a n d  T  s t a n d  f o r  E R  
s ta tu s ,  n o d e  s t a t u s  a n d  tu m o u r  s i z e  r e s p e c t i v e ly .  A ls o ,  n o te  th a t  th e  H e a l th  B o a r d s :  
B o r d e r s ,  H ig h la n d ,  I s la n d s  a n d  F o r th  V a l l e y  a r e  n o t  p r e s e n t e d  a s  th e y  w e r e  n o t  
i n c l u d e d  in  th i s  m o d e l .  T h e  t  a n d  i  r e p r e s e n t  a n  in c r e a s e  a n d  d e c r e a s e ,  r e s p e c t i v e l y ,  o f  
a b s o l u t e  m a g n i tu d e  g r e a t e r  th a n  1 0 %  w h e n  c o m p a r e d  w i th  th e  c o r r e s p o n d i n g  c e l l s  o f  
T a b l e  5 .2 0 a .
(2) For the best prognostic group (E+, N-, T<2) there were very few differences 
between the two models. Both models predicted high 5-year survival estimates for all 
Health Boards, with range 89.7% to 94.0% for the all cases model and 86.2% to 99.0% 
for the complete cases model. This was the only prognostic group where the estimate
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for Dumfries & Galloway (Y) Health Board was not at least 10% greater in absolute 
magnitude for the CCM than it was for the ACM (as it was not feasible since the 5-year 
% survival estimate for Y for the ACM was 92.5%).
For the intermediate prognostic groups (E+, N+, T<2 and E+, N+, T>2), there were 
several substantial differences between the results obtained for the ACM and for the 
CCM. In Health Boards C and F (Argyll & Clyde and Fife), both groups had a much 
lower 5-year survival estimate for the complete cases model, with estimates that were 
nearly 15% lower, than those for these Health Boards in the all cases model. However, 
the estimate for Health Board Y was increased by about 20% for both prognostic groups 
when the CCM was compared to the ACM. Also, for E+, N+, T>2, Ayrshire & Arran 
(A) Health Board had a 10% higher survival estimate in the CCM than it had in the 
ACM.
In the poorest prognostic group (E-, N+, T>2), five out of the nine Health Boards had 
absolute differences of more than 10% between the two models. Health Board Y was 
again at least 10% higher for the CCM than the ACM (in fact, the estimates were 86.7% 
and 48.7% respectively). The other four changes were decreases of more than 10% in 
the Health Boards C, F, N (Grampian) and T (Tayside). These drops were all about 
20% in size when the CCM was compared to the ACM.
(3) The estimates for the CCM appeared to be more extreme than the ACM estimates. 
For those Health Boards with either the better or the poorer survival figures in the all 
cases model, the complete cases model seemed to emphasise them. This finding is 
similar to the previous discussion that was given after the hazard ratios for the two 
models were compared in Table 5.16.
P A R T IA L -C O M P L E T E  C A S E S  A N A L Y S IS
Suppose rather than limiting the cases to those where there was complete information in 
all four variables, the restriction was changed to (i) only heing complete for node status 
and tumour size and (ii) being complete in the three pathological factors; namely: ER 
status, node status and tumour size.
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;The numbers remaining in each Health Board in these two situations are given below in 
Table 5.21.
The percentages relate to the numbers of cases remaining for each Health Board from all 
of the 1619 surgical cases. The differences between the percentages kept in each Health 
Board in the two columns were remarkable. The most notable was that when only node 
status and tumour size needed to be known, Borders Health Boai’d (B) actually kept the 
greatest percentage of cases, with Highland Health Board (H) keeping the third highest 
percentage. This was in stark contrast to the percentages remaining in these Health 
Boards (0 and 2.5% respectively) when ER status also had be known in order to be kept 
in the analysis.
'f«
Health Board
N and T complete E, N and T complete
Number Percentage Number Percentage
A 65 51.6 57 45.2
B 16 72.7 0 0.0
C 66 61.7 45 42.1
F 55 60.4 42 46.2
G 225 65.6 188 54.8
H 51 70.8 2 2.8
1 14 56.0 1 4.0
L 70 51.9 36 26.7
N 123 66.1 95 51.1
S 167 71.1 156 66.4
T 64 43.2 26 17.6
V 31 45.6 1 1.5
Y 17 27.9 10 16.4
Total 964 59.5 659 40.7
T a b l e  5 .2 1 :  N u m b e r  o f  c a s e s  a n d  p e r c e n t a g e s  in  e a c h  H e a l th  b o a r d  w h e n  
o n l y  n o d e  s t a tu s  a n d  tu m o u r  s i z e ,  a n d  w h e n  a l l  th r e e  p a t h o l o g i c a l  f a c t o r s ,  w e r e  
c o m p l e t e .  N o te  th a t  E , N  a n d  T  s t a n d  f o r  E R  s ta tu s ,  n o d e  s t a tu s  a n d  tu m o u r  s i z e  
r e s p e c t i v e l y .
Due to these differences, the four Health Boards which had to be dropped from the 
complete cases analysis (HBs: B, H, I and V) were kept in the first extra analysis but had 
to be dropped in the second extra analysis (thus losing four cases). Cox models were 
fitted to the 964 and 655 cases respectively.
For model (i), age was not statistically significant and for model (ii), neither age nor 
clinical stage were significant. These non-significant factors were forced in for
I
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consistency (as for the CCM) and comparisons were made with the all cases and 
complete cases models. When the results from these analyses were examined, it was 
found that the hazard ratios for models (i) and (ii) were only slightly different from 
those fiom the ACM and CCM (see Table A6.3 in Appendix 6 ).
5.4.3 RELATIONSHIP OF AGE WITH MISSING VALUES IN OTHER 
COVARIATES
INTRODUCTION
In the last section, it was observed that age was a significant factor in the all cases 
model (ACM), but not in the complete cases model (CCM). This section tries to 
identify possible reasons for this difference. One obvious explanation could be a lack of 
power in the CCM to detect a relationship between age and survival, as the same level 
of significance (5%) was used as the cut-off in hoth situations. Another possible reason 
could be that age was related to missingness o f data in the other variables. This is 
investigated here.
RESULTS
Firstly, when the ACM was fitted, the Wald statistic for age was significant, both 
univariately and multivaiiately. However, it was not significant in either the 
multivariate CCM (P=0.30), or when the factor was fitted imivariately (P=0.69) based 
on only the complete cases. The fact that there appeared to be no differences among the 
survival curves for the four levels of age univariately for the complete cases, but there 
were differences when all cases were included in a univariate analysis, supports the idea 
that there was some sort of association between age group, missing values in the other 
variables and outcome. Table A6.2 in Appendix 6  gives the Kaplan-Meier estimates at 
five years based on all cases and complete cases only.
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To assess this in a simple manner, various tabulations were examined. Firstly, the 
simple distributions of age group for the complete and incomplete cases (the cases with 
at least one of the four variables missing) are given in Table 5.22 below.
Complete lucomplete All
Age Group N um ber (% ) Num ber (% ) Num ber (% )
<50 years 184 (31.8) 292 (28.0) 476 (29.4)
5 0 - 6 4 245 (42.4) 346 (33.2) 591 (36.5)
6 5 - 7 9 145 (25.1) 335 (32.2) 480 (29.6)
>80 years 4 (0.7) 6 8  (6.5) 72 (4.4)
Total 578 (100.0) 1041 (100.0) 1619
T a b l e  5 .2 2 :  D i s t r i b u t io n s  o f  a g e  g r o u p  f o r  th e  c o m p l e te ,  th e  in c o m p l e t e  
a n d  a l l  c a s e s .
To demonstrate the difference between the two distributions more clearly, the levels of 
age group were merged into two groups representing under 65 and aged 65 and over 
(Table 5.23).
Age Group
Complete lucomplete All
Num ber (% ) N um ber (% ) Num ber (% )
<65 years 429 (74.2) 638 (61.3) 1067 (65.9)
>65 years 149 (25.8) 403 (38.7) 552 (34.1)
Total 578 (100.0) 1041 (100.0) 1619
T a b l e  5 .2 3 :  D i s t r i b u t i o n s  o f  c a s e s  a g e d  u n d e r  6 5  a n d  6 5 + f o r  th e  c o m p l e te ,  
th e  in c o m p l e t e  a n d  a l l  c a s e s .
There were big differences in the percentages in the two age groups between the 
complete cases, the women with incomplete cases and all cases (comprising the two 
groups o f women). For example, only 25.8% of the 578 complete cases were aged 65 or 
over, compared with 38.7% of the 1041 cases with some incomplete information.
The next simple tabulation presented examines whether there was any relationship 
between the number of variables with missing information (out of the four clinical 
variables with missing information discussed in detail in Section 4.2) and age in two 
groups, along with the crude indicator of percentage dead at 31/12/1993. The number of 
variables with missing data were grouped into none (containing 578 women), one or two 
variables with missing data (896 cases) and three or all four variables with missing 
information (145 cases). Table 5.24 below gives the breakdown of observed numbers in
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these three groups by under or over 65 years with the expected number under a null 
hypothesis of independence in each cell along with the observed percentage dead by 
31/12/1993.
Complete 1 or 2 vars missing 3 or 4 vars missing
Obs (Exp) Obs (Exp) Obs (Exp)
Age < 65 years 429 (380.9) 
Dead=32.9%
556 (590.5) 
Dead=32.9%
82 (95.6) 
Dead-3 4.1%
Age >65 years 149 (197.1) 
Dead=36.2%
340 (305.5) 
Dead=45.3%
63 (49.4) 
Dead-44.4%
Total 578
Dead-33.7%
896
Dead=37.6%
145
Dead=38.6%
T a b l e  5 .2 4 :  O b s e r v e d  ( O b s )  a n d  e x p e c t e d  (E x p )  n u m b e r s  o f  c a s e s  a n d  th e  c r u d e  
p e r c e n t a g e s  d e a d  in  th e  d i f f e r e n t  a g e  g r o u p s  f o r  th e  g r o u p s  o f  n u m b e r s  o f  v a r i a b l e s  
( v a r s )  m i s s i n g  ( o u t  o f  th e  f o u r  c l i n i c a l  v a r i a b l e s  w i th  m i s s i n g  in f o r m a t io n ) .
There appeared to be no effect in the <65 group on percentage dead for differing 
amounts of missing data in the other clinical variables. There was a difference, 
however, in the women aged 65 and over group. The crude percentages dead were 
36.2% for complete cases compared with approximately 45% of cases with some 
missing information. Therefore, there was a different relationship between having 
missing data and outcome by age.
CONCLUSIONS
Data were more likely to be missing for the women aged >65 and having any missing 
information for these older women was associated with poorer outcome. Thus, when 
the unknowns were included in the survival analysis, age affected the outcome, but it 
did not when the cohort was limited to those with complete information only. Whilst 
there will still be lack of power in the CCM to detect age, it is probable that the effect of 
age on survival in the ACM was partly due to a relationship between age and the 
presence of missing values in other covariâtes.
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5.4.4 RELATIONSHIP OF CLINICAL STAGE WITH MISSING VALUES
INTRODUCTION
In Section 5.4.2, both age and clinical stage were found to be significant in the all cases 
model (ACM), but non-significant in the complete cases model (CCM). An exposition 
for the differing findings for clinical stage is given here.
One possible reason why clinical stage was not significant in the CCM could be lack of 
power. Another suggested cause could be an association of clinical stage with missing 
data in the other clinical variables and the influence on outcome.
RESULTS
Univariately, clinical stage was significant (P-0.0001) in the complete cases analysis, 
but became non-significant in the presence of other variables, with P value 0.14 in the 
multivariate CCM. This differs from the finding for modelling age in the complete 
cases situation, discussed in the last section. The P value of the Wald statistic for the 
presence of clinical stage with other factors in the ACM was <0.001.
For the complete cases, the fact that clinical stage was significant univariately, but not 
when other variables were included in the model, suggests that there must have been 
confounding in the multivariate CCM. To examine this and try to identify which 
variables were associated with it, a modified forward selection analysis was performed. 
(A simple stepwise selection was of no use because clinical stage never entered the 
model in the complete cases analysis.) The forward selection method was stopped as 
soon as clinical stage became non-significant upon the addition of a variable.
The analysis was based on the 574 cases with at least 10 cases remaining in each of the 
Health Boards (full details given in Section 5.4.2). The entering variable was selected 
on the basis of the Wald statistic for being in the model in the presence of other 
variables with the smallest P value for forced entry with clinical stage, and any other 
variables in the model. Assessment of the significance of clinical stage was also made 
on the basis of the P value for the Wald statistic. Table 5.25 below reports the findings
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of this forward selection. Step 1 gives only the P value for the Wald statistic for clinical 
stage as none of the other variables were offered to the model. The P values in Step 2 
are those for the Wald statistic for forced entry with clinical stage, with each of the 
variables fitted separately in models with clinical stage. The P value given for clinical 
stage is that which was obtained in the model for the variable which was chosen for 
entiy at Step 2. Similarly in Step 3, P values are for forced entiy with clinical stage and 
the variable selected in Step 2 for all variables.
'4
Step 1 Step 2 Step 3
c e 0.0003 a 0.0015 aO.ll lO
A $ 0.5357 0.8360
E * e <0.0001 a <0.0001
N * <0.0001 e <0.0001
T * 0.0004 0.0075
H * 0.0230 0.0013
T a b l e  5 .2 5 :  P r e s e n t a t i o n  o f  r e s u l t s  f r o m  p e r f o r m i n g  a  f o r w a r d  s e l e c t i o n  o n  th e  
v a r i a b l e s  w i th  c l i n ic a l  s ta g e .  N o te  th a t  ‘e  ’ in d i c a te s  w h ic h  v a r i a b l e  e n t e r e d  th e  m o d e l  |
a t  th a t  s t e p  a n d  th a t  ‘a  ' in d i c a te s  th a t  th e  v a r i a b l e  h a s  a l r e a d y  b e e n  e n t e r e d  in  th e  
m o d e l .  T h e  P  v a lu e  f o r  th e  v a r i a b l e s  a l r e a d y  in  th e  m o d e l  a r e  th o s e  w h ic h  a r e  o b t a i n e d  
f r o m  th e  m o d e l  f o r  th e  n e w  e n te r in g  v a r ia b l e .  T h e  P  v a lu e s  r e p r e s e n t  f o r c e d  e n t r y  f o r  
a l l  o f  th e  v a r i a b l e s .  C l i n ic a l  s t a g e  is  g i v e n  b y  C , a g e  (A ), E R  s t a tu s  (E ), n o d e  s t a t u s  (N ), 
tu m o u r  s i z e  (T ) a n d  H e a l th  B o a r d  (H ) r e s p e c t i v e ly .
3-Thus at Step 2, ER status was fitted with clinical stage. The significance of clinical 
stage did not alter upon addition of this variable. However, when either node status or 
tumour size were forced in with just clinical stage, the significance of clinical stage was 
greatly affected (data not given in Table 5.25). The P values for clinical stage with node 
status and tumour size were 0.033 and 0.039 respectively. This suggested that these two 
variables were associated with clinical stage. This was observed in Section 4.1 (and 
Appendix 4), where it was shovm that these variables were not independent.
%At Step 3, node status was fitted into a model including clinical stage and ER status.
Clinical stage became non-significant (P-0.11), suggesting that the addition o f node 
status in the presence of ER status caused clinical stage to lose its significance at the 5% 
level in the CCM.
The percentages of women who were dead by 31/12/1993 in the two age groups are 
given split by extent of missing data (Table 5.26).
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Complete 1 var missing 2 or 3 vars missing
O b ^ x p ) Obs (Exp) Obs (Exp)
Stage I 102 (123)
D ead-18.6%
116 ( 1 1 1 ) 
Dead-22.4%
84 (6 8 ) 
Dead-27.4%
Stage II 394 (331) 
Dead-3 5.0%
274 (298) 
Dead-3 3.2%
145 (184) 
Dead-42.8%
Stage III 82 (76) 
Dead=46.3%
75 (69) 
Dead—61.3%
30 (42) 
Dead=60.0%
Unknown 81 (129) 
Dead-3 8 .3%
129 (116) 
Dead-43.4%
107 (72) 
Dead-3 7.4%
Total 659
Dead-3 4.3%
594
Dead-3 6 .9%
366
D ead-39.1%
T a b l e  5 .2 6 :  O b s e r v e d  (O b s )  a n d  e x p e c t e d  (E x p )  n u m b e r s  o f  c a s e s  a n d  th e  c r u d e  
p e r c e n t a g e s  d e a d  in  th e  d i f f e r e n t  c l i n i c a l  s t a g e  g r o u p s  f o r  th e  g r o u p s  o f  n u m b e r s  o f  
v a r i a b l e s  ( v a r s )  m i s s i n g  ( o u t  o f  th e  o th e r  th r e e  c l i n ic a l  v a r i a b l e s  w i th  m i s s i n g  
in f o r m a t io n ) .
Thus, for women with stage I disease, there was a progressive increase in death risk as 
the amount of missing information in the other three variables increased. For stage II 
disease, it appeared that having two or three of the other three variables unknown was a 
lot worse in terms of outcome than having either none or only one other variable with 
missing data. Stage III disease appeared to have much higher risk of death if any of the 
other variables were missing. No definite pattern was observed for women with 
uiiknown clinical stage.
DISCUSSION
In the complete cases, clinical stage became non-significant in the model started with 
only that factor in it, once ER status and node status had also been entered into the 
model. This makes some clinical sense because one element of clinical stage is c l i n i c a l  
node status. It is expected, therefore, that clinical node status would agree reasonably 
with pathological node status (the node status available for analysis here). Thus, clinical 
stage would probably be expected to be partly redundant when pathological node status 
was determined and included in the analysis.
'S'
f-
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;A table of pathological node status vs clinical node status was examined for the
f  2 1 2 ]complete cases (Table 5.27) and revealed that 36.7% ——  of the cases were notV578/
classified in the same way. However, it was not important to calculate the sensitivity,
specificity or positive predictive values here because the majority o f cases had the same
code. ■
. . . i
Positive
Clinical
Negative Total
Positive 136 151 287
Negative 61 230 291
Total 197 381 578
T a b l e  5 .2 7 :  N u m b e r s  o f  c a s e s  in  th e  g r o u p s  w i th  c l i n ic a l  a n d  p a t h o l o g i c a l  
n o d e  s ta tu s ,  e i t h e r  p o s i t i v e  o r  n e g a t i v e  f o r  th e  c o m p l e t e  c a s e s .
One possible reason that clinical stage was not in the complete cases model could be 
that there was enough of an overlap between the known pathological node status and the 
Imown clinical node status element of clinical stage to make clinical stage unnecessary. 
Similarly, another element of clinical stage is clinical tumour size, which would be 
expected to be similar to the pathological tumour size recorded, thus explaining why the 
introduction of known pathological tumour size in the model with known clinical stage 
appeared to affect the significance of clinical stage (as discussed in the paragraph after 
Table 5.25).
In contrast, in the all cases model, clinical stage was necessary in the multivariate Cox
model even with these other variables in it. It, therefore, appeared that the introduction 
of the extra categories for the unknowns and inclusion of the cases with missing values 
in other variables, as well as clinical stage, allowed the variable for clinical stage to 
enter the model. Thus, clinical stage also appeared to be linked to the amount of 
missing data and outcome. However, it could also be due to the fact that the clinical 
stage variable is not the same in the two models, as the factor has an extra degree of 
freedom in the ACM.
The fact that clinical stage was significant on its own in the complete cases situation but 
it was not necessary in the presence of other variables with known factor levels (in a
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5.4.5 GENERAL DISCUSSION
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particular ER status and node status), perhaps suggests that clinical stage was in the all 
cases model because when it had known clinical stage values, it is acting as a surrogate 
for the missing information in the other prognostic factors. For example, there were 435 
cases with unknown pathological node status and only 317 cases with missing clinical 
stage in the ACM. In Section 4.2.2, it was shown that clinical stage and pathological 
node status were independent in the log-linear model fitted relating missing values in
'1ï|the clinical variables. Thus, it would be expected that some cases with pathological ;
node status missing would have clinical stage known, thus providing an indication of
the extent of disease for these cases. This reason could explain the presence of clinical
::;estage in the ACM and the absence of it in the CCM, where the information about the
other prognostic factors is obviously known. ;
■I
This argument is supported by the fact that in the partial complete cases analysis, also 
described in Section 5.4.2, when only node status and tumour size had to be known, but 
ER status could be missing, clinical stage was necessary in the model (model (i)).
However, once the analysis was limited to only those cases where all three pathological 
factors were complete, clinical stage was again no longer significant in the Cox model 
(model (ii)).
.
i
However, the reason for the absence of clinical stage in the CCM could just be due to
the lack of power to detect it. This surmise is based on the fact that the P value for this |
■'Vfactor was only marginally non-significant at 0.14 for non-entry.
The results given in Sections 5.2.1 and 5.2.2 and by Twelves et al (1998a) support the 
findings of other relevant studies of breast cancer survival (Section 5.2.3), especially in 
relation to the need for management of this disease to be given in the setting of the 
multidisciplinary team approach.
When the ‘Clinical Full’ model was examined to assess the adequacy of the fit o f the 
model (Section 5.3.1) and the assumption of proportional hazards checked (Section 
5.3.2), it was found that there was a suggestion of non-proportionality for two of the 
levels of ER status. However, it was noted in Section 5.3.3 that there is no unique 
approach to assessing proportional hazards using time-dependent modelling for non­
binary categorical factors.
In Section 5.4.2, the results from fitting the all cases and complete cases model were 
compared. One of the main problems with this approach is that it was not possible to 
test statistically whether any of the apparent differences were real on the basis of any 
known tests. All of the observations noted above about differences among the four 
analyses were informal.
It appears that the missing values, added as extra categories, caused some lar ge absolute 
differences in the point estimates. These might lead to different interpretations of the 
importance of Health Board of treatment on survival, and indeed whether there were any 
true differences. However, it was consistently shown, by examining the different Health 
Board, prognostic groups (Tables 5.20a and 5.20b, Section 5.4.2), that women treated in 
some of the Health Boards had poorer outcomes than women treated in other Health 
Boards.
It is not clear whether using the complete cases technique for dealing with the missing 
values would have heen more appropriate for the analysis o f the Breast Cancer Audit 
data, although losing 64% of the cases appears to be wasting a great deal of information 
on other variables. Also, whether the data were missing at random cannot be tested and 
so it is unknown whether this was a valid implicit assumption to have made. The extent 
o f any biases in the estimates for both the ACM and the CCM cannot be obtained.
On the basis of these two models, very different conclusions could be drawn in terms of 
differences in absolute magnitudes of survival for different Health Boards. These would 3
perhaps then have different implications in terms of political and organisational 
structures of provision of services for breast cancer management in Scotland in the 
future.
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CHAPTER 6 INVESTIGATIONS OF BIAS IN MODELS WITH
:SADDITIONAL CATEGORIES FOR MISSING VALUES
3
6.1 INTRODUCTION TO THE ABSTRACT PROBLEMS AND SOME 
GENERAL THEORY
It is not clear whether, in general, the assumption of proportional hazards for contexts 
involving these extra levels is consistent with the same assumption for designs with 
complete data (i.e. without these additional levels). This is the focus of this chapter. To 
avoid the complexities of the Cox regression model, exponential regression modelling is 
performed for the majority of the analyses.
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INTRODUCTION
One method of handling missing values for categorical factors in proportional hazards 
models is by creating additional categories to represent the unknown levels. In Section
5.2.2, the results of fitting a Cox regression model to the Breast Cancer Audit data using 
this method were reported. The assumption of proportional hazards for the chosen 
model was investigated in Section 5.3.2.
THE ABSTRACT PROBLEMS 
The exponential regression model is a very simple model with the proportional hazards I
property. To make the situation as uncomplicated as possible, the exponential 
regression model is assumed to have either one or two factors which have only two 
levels to represent the known values and an additional level to represent the missing 
values in each of the factors. Although the outcome is known for the missing values, 
the true levels of the factors are unknown. That is, the observations would have been
classified as level 1 or 2 for the factors, had this information been available. As a 
further simplification, the problem of censored data is ignored and the context where all 
subjects are followed until their event time is considered.
Two different situations are examined. Firstly, in Section 6.2, the theoretical situation 
is explored where the observations falling in the third levels consist of random mixtures 
of two (or more) exponential distributions across the known levels. In Section 6.3, 
however, simulation models investigate the effects on bias of making the naive 
assumption that the observations falling in the third levels also have exponential 
distributions.
The aim of the initial theoretical exercise is to investigate whether or not the assumption 
of proportionality holds when the missing values are included as extra levels in a model 
which has proportional hazards for the levels for the known values.
GENERAL DISTRIBUTIONAL THEORY
The probability density function (pdf) for an exponential regression model is given by 
f { y )  =  exp(^^x)exp[- y exp(^^x) (Eq 6 .1 _ 1 )
and, letting the term exp^/?^xj be replaced by %, it can easily be shown that the hazard 
function is given by
h { y )  = 3L = exp(^^’ x ) , (Eq 6 .1_2) 
which is constant for all values of y .
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6.2 EXPONENTIAL REGRESSION MODEL WITH FACTOR(S) EXTENDED 
FROM TWO LEVELS TO THREE LEVELS BY ASSUMPTION THAT THIRD 
LEVEL IS RANDOM MIXTURE OF FIRST TWO LEVELS
6.2.1 THE ONE FACTOR SITUATION
f  (y) = exp(a, ) exp[- y  e x p ( a , . )
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In Section 6.2.1, a factor at two levels is examined, with outcomes assumed to satisfy an 
exponential regression model. A third level for missing values in this factor is created 
on the basis that the observations arise from a random mixture of the first two levels. |
The aim is to derive the hazard function for this third level. It is then of interest to 
assess whether this hazard function is proportional to the hazard functions for the 
observations in the first and second levels. The effects of changing the mixing 
parameter for weighting the pdfs of the two levels, and of changing the ratio of the 
hazards between the first two levels, are examined graphically.
The theory for two factors, both originally at two levels, is then examined in Section
.6.2.2. The missing values are incorporated into the two factors as additional levels o f : Î
the factors and are assumed to be random mixtures of the first two levels for both
factors.
DERIVATION OF THE HAZARD FUNCTION
4 .
An exponential regression model for a single foctor with two levels has pdf for the 
zth level, from Eq 6 .1 1  in Section 6.1, given by
for z = 1 , 2 .
Suppose the factor is then extended to tliree levels to incorporate missing values, where 
the observations in this third level are assumed to be a random mixture of data from the
.*1
original two levels. This third level has a pdf, (y ) , which is a mixture of two 
exponential density functions, and is
/s  W  = z/l (y) + (l -  z)/2 W  ■
The hazard functions for the first two levels are
K { y )  ~  Gxp((%J = Aj and = exp(«2 ) = 2^ . (Eqs 6.2.1_1)
The hazard function for the third level can then be shown to be equal to 
^ ^  f i j y )  ^  zAi exp(- A ^ y )  + ( l - z %  e x p (-À ^ y )
S j { y )  1 - z  1 - exp(- I j j ) ]  -  (l -  z)[l -  exp(- À ^ y ) ]
. (Eq 6.2.1_2)
zA] exp(- À ^ y )  + (l -  z ) À 2 exp(- À ^ y )  
zexp(- À ^ y )  + ( 1  ~ z)exp(- X ^ y )
Thus, with the exception o f the trivial cases z = 0 or 1, this is not proportional to either 
/zj (y) or (y ), as it is not constant for all values of y . This lack of proportionality can 
be illustrated graphically.
GRAPHICAL REPRESENTATION
An arbitrary value was chosen for the hazard function of the first group; namely 
^i(t ) = 3lj = 0.25.
To choose a sensible range for time, values were selected to represent time from zero to 
the 95^ percentile for the exponential distribution of the first level. The range for y
was taken to be [o, . Therefore,
P rob(r < ) = 1 -  exp(- 0 .2 5 y ^ ^  ) = 0.95,
which implies that
T m a x  “  ^  ft! 1 2  .
Twenty-five equally-spaced points for y  between 0 and 12 (i.e., at 0, 0.5, 1, ..., 11, 
11.5, 12) were used.
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For simplicity, the hazard ratio for level 3 vs level 1 was considered. This is obtained 
from Eqs 6 .2 .11  and 6.2.1_2 and is
_ K { y )  _  g e x p (-Pi^y) + y ( 1  - z )e x p (- yX^y)  
h ^ { y )  zexp(-A iy) + (l-z)exp(~ ;?4jy)
with Aj fixed at 0.25, replaced by yX^, and z  e[0, l] and y g [0, o o ]  being varying 
quantities.
The values selected to represent the mixing weight (z) of the two pdfs were 0.2, 0.4, 0.7 
and 0.9. Values 0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1, 1.5, 2, 2.5, 4, 5 and 10 were chosen for y  
the value of the hazard ratio for level 2 vs level 1. The logarithm of was then 
plotted for each of the combinations of z and y  . T o  illustrate the wide variation 
caused by changing the values of z and y  , six of the 48 possible curves were picked 
out and are shown in Figure 6.1 below.
R E S U L T S
Log (hazard ratios) of level 3 vs level 1 
for various combinations of
z and gamma2.50 T
2.00  - -
1.50 -
z=0,2, gamma=41,00 '■
o' 0.50 - z-0.9, gamma=4
2=0.7, gamma=1.5 (="=:"T ~ 1  "0.00 c~
2=0.7, gamma=0.5-0.50 -
2=0.9, gamma=0.1
- 1.00 -■
-1.50 -
2=0 .2, gamma=0.1- 2.00  - -
-2.50
Time (y)
F ig u r e  6 . 1 :  C h a r t  s h o w in g  th e  l o g  o f  th e  h a z a r d  r a t i o  f o r  l e v e l  3  v.s l e v e l  1 f o r  s i x  
d i f f e r e n t  c o m b i n a t i o n s  o f  z  a n d  y
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When the scale factor, y  , is equal to one, the hazard ratio is constant at 1, and is 
represented by the horizontal line thi’ough zero. When y  is greater than 1, both level 2 
and level 3 have an increased risk relative to level 1, as the curves for y >1 remain above 
zero on the log scale in Figure 6 .1. Similarly, the curves with y  <1 remain below zero 
indicating that y  < \  leads to a reduced risk for both levels 2 and 3 compared to level 1.
Figure 6.1 has illustrated graphically the fact that when a third level was assumed to be a 
random mixture of the first two levels which do fit an exponential regression model, the 
hazard for this third level was not proportional to the hazards for these first two levels 
and that the non-proportionality could be quite considerable.
6.2.2 THE TW O FACTORS SITUATION
T H E  P R O B L E M
The design is now extended to include two factors. Again, the aim is to derive the 
hazard functions for the missing categories and to check whether or not these hazard 
functions are proportional to the hazard functions for the known levels.
D E S I G N  W IT H O U T  M IS S IN G  V A L U E S
Suppose there are two factors at two levels with observations arising from a main effects 
exponential regression model, with y  as the dependent variable. Let rij^ i denote the
number of observations in cell (^,Z), where k  and I represent the levels of factors FI 
and F2 respectively. Figure 6.2 is a diagrammatical representation of the basic design, 
where there are no missing values.
154
F2
1 2
FI
Ml, M,2
2^1 2^2
F ig u r e  6 .2 :  D ia g r a m  to  r e p r e s e n t  th e  d e s i g n  
w i t h o u t  m i s s i n g  v a lu e s  in  th e  tM>o f a c t o r s .
The pdf for the n^i observations falling in cell (A:,/)is given by 
/* /b )  = ^ e x p ( - / l „ y ) ,  (Eq6.2.2_l)
for A: = 1, 2 and / = 1, 2 ,  where
A; = exp[/^i + a j ^ + f \  (Eq 6.2.2_2)
and the constraints = 0  and = 0  are imposed.
The parameters are main effects related to factor FI and the parameters are main
effects related to factor F2.
The hazards for these four cells are constant and, therefore, proportional. The hazard 
function for cells (l,2 ) , (2 ,l) and (2 ,2 ) can be written, respectively, as
1^2 =exp(/?2)2,ii
^ 2 1  “  y  2 ^ \\
^ 2 2  = , (Eqs 6.2.2_3)
where is the hazard function for cell (l,l) .
D A T A  W IT H  M IS S IN G  V A L U E S
Now suppose that the cases with missing values for FI and/or F2 are to be included. Let 
the mixing parameter for factor FI be p  for level 1 and (l -  j?) for level 2. Similarly, let
the mixing parameter for factor F2 be q  for level 1 and (l -  for level 2. It is assumed
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that the mixing operates independently in the rows and columns. Figure 6.3 shows the 
structui'e of the model with missing values.
F2
2
l - q
FI
1
P
2
1-p
M l ! M ] 2 M i 3
^ 2 1 M 2 2 ^ 2 3
M 3 I M 3 2 M 3 3
F ig u r e  6 .3 :  D ia g r a m  to  r e p r e s e n t  th e  d e s i g n  f o r  th e  
tw o  f a c t o r s  w h e n  m i s s i n g  v a lu e s  a r e  in c lu d e d .
The pdfs for the observations falling in the four cells ( l ,l) , (l,2 ), (2,l) and (2,2) are 
given by Eqs 6.2.2 1 and 6 .2.2 2 as before. Using the mixing parameters, jc and q , 
from above, the pdfs for the observations in the missing categories can be written as 
mixtures of two (or four) exponential density functions, as follows. The pdf for the 
?î,3 observations in cell (l,3) is given by
/i3 b ) = «AI b )+ ( i-? ) /i2  b )  •
The pdfs for cells (2,3), (3,l) and (3,2) can be written down in a similar maimer, using 
the appropriate combination of the mixing parameters.
The pdf for cell (3,3) is assumed to be
/33 b ) =p<ifÀy)+H i -  i)fn  b ) + H i -  p)fii b ) + ( i - H ( i  -  ? ) / 2 2  b )
Concentrating on the pdf for cell (l,3 ), the hazard function for the observations falling 
in this cell can be calculated using
/u b )  9^1 Gxp(- + (l -  g)^ 2 exp(-
h n { y ) Sn{y) ?exp(-;i„q + (l-9)exp(-A,2:)2)
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Then, by substitution using Eqs 6.2.2_3, the hazard function for cell (l,3) can be 
rewritten as
h  ( \ Gxp(- A it)  + (i -  exp (- r A ^ y )  
q Q x p { - \ ^ y )  + ( l - ^ ) e x p ( -  r i A i y )
D IS C U S S IO N
The third level in the one factor exponential regression model did not satisfy the 
proportional hazards assumption and similar findings were observed in the two factors 
situation. It therefore seems reasonable to assume that the argument would carry 
tlii'ough to the more complex Cox’s proportional hazards model. The implications of 
this non-proportionality o f the hazards are explored in the remainder of this chapter.
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Similarly, the hazard functions for the cells (2,3), (3,l) and (3,2) can be derived. 
The hazard function for cell (3,3) can be shown to be equal to
where
A = pq\ ^ exp( - + p{\  - exp(- r,2,,;p) + q{\ - exp(- r 2^ iy )
+(i -  p\\ - q)yj2\i exp(- nri\,y)
and
B = pq  exp(- + p(l -  g)exp(- + g (l-f)e x p (-
+ (l -  p)(l -  9)exp(- n n Â iH
None of the hazard functions for the missing cells are constant for all values of y . 
Therefore, they cannot be proportional to any of the hazards defined for the known 
values failing in cells (l,l) to (2,2), given by Bq 6.2.2_2. Therefore, an additive 
exponential regression model would not fit satisfactorily for the additional levels created 
for the missing values in the factors FI and F2 since the hazard functions for 
observations falling in the five cells are not proportional to the hazard functions for the 
observations with known levels for both FI and F2.
6.3 EXPONENTIAL REGRESSION MODEL WITH FACTOR(S) EXTENDED 
FROM TWO LEVELS TO THREE LEVELS BY NAIVE ASSUMPTION THAT 
THIRD LEVEL IS ALSO EXPONENTIAL
Having just shown that the assumption of proportionality of hazards for missing data 
categories can be inconsistent with the true proportional hazards assumption for the 
complete data context, the aim now is to investigate whether or not this invalidation of 
the assumption matters in practice. Exponential distributions are used to generate the 
complete cases data in such a manner that these cases satisfy a main effects additive 
exponential regression model. Here, the observations falling in the extra levels for the 
missing values are also naively assumed to have exponential distributions, although 
these observations were in reality generated from mixtures of two or four exponential 
distributions. Simulations were carried out to investigate whether it is a problem, in 
terms of parameter estimate bias, that an incorrect model is fitted and the assumption of 
proportional hazards violated.
6.3.1 SIMPLE THEORY FOR THE ONE FACTOR SITUATION
IN T R O D U C T I O N
Here, an exponential regression model on one factor is considered. Missing values are 
incorporated by creating an additional level which are obtained to be a random mixtuie 
of observations from the first two levels. The effect of taking the outcomes for the 
missing data category to naively be assumed to have an exponential distribution is 
investigated. The main interest is whether or not the inclusion of the extra level affects 
the parameter estimates for the first two levels.
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S O M E  S IM P L E  T H E O R Y
Suppose that the observations in the zth level of the factor are , with z = 1, 2, 3 and 
6  = A: = 1 , zzj for observations in level 1 ; 6  -  / = 1, « 2  ^ r  observations in level
2; and b  =  m = \ ,  for observations in level 3 respectively. The pdf is given by
/ { P w  ) = exp(a,. ) exp[- exp(«,. )].
5•i.
■ :i
If exp(«. )  =  then the joint pdf for the tliree levels is given by
f ( i u  ^  ’
by the independence of the thi ee samples. This can be re-written as
"1n^ exp(-Vii)
k = \
f[-^exp(-2jy2/)
/= !
since observations within samples are also independent.
'■3
n ^ G X p (- / l ,} ';„ )
m =\
Clearly, in this simple case, the maximum likelihood estimates for Tj and 2^, and hence 
«J and « 2 , independent of the outcomes ( 2 3  and respectively) for the missing data 
category. They are exactly the same as they would have been had the missing data 
category been ignored.
I
Thus in the one factor situation, the fact that the hazard function for level 3 was not 
proportional to the hazard functions for levels 1 and 2 (Section 6.2.1) does not influence 
the parameter estimates obtained for levels 1 and 2  when an exponential regression 
model is fitted to these data, when it is naively assumed to fit the third level also.
s.
‘1
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6.3.2 INTRODUCTION AND STRATEGY FOR DEVELOPING THE 
THEORETICAL DATASETS IN THE TWO FACTORS SITUATION
IN T R O D U C T I O N
The remainder of this chapter concentrates on the two factors situation. The main aim is 
to investigate whether the non-proportionality of the hazard functions, shown in Section
6 .2 .2 , affects the estimates of the parameters in the model describing the observations 
falling in the known levels when exponential regression models are fitted with two 
factors for various designs. It is assumed that both factors have two levels of known 
values and an additional level created for missing values. The missing value outcomes 
are again assumed to be a random mixtures of outcomes for the two known levels. The 
exponential regression model fitted to the data is taken to be additive so that there is no 
interaction term present.
Figui’e 6.4 shows the design with two factors at three levels. The observations with 
unknown levels fall into one of the five cells (l,3), (2,3), (3 ,l), (3,2) and (3,3).
F2
1 2 3
1 « 11 « 1 2 « 1 3
FI 2 « 2 1 « 2 2 « 2 3
3 « 3 1 « 3 2 « 3 3
F ig u r e  6 .4 :  D ia g r a m  r e p r e s e n t i n g  th e  d e s i g n  f o r  
tw o  f a c t o r s ,  b o th  a t  th r e e  le v e ls .
When fitting models to the data, all of the observations falling into the nine cells are 
assumed to be exponential and so the assumed pdfs for all nine cells can be denoted by
f{ykim ^, ) -  sxp(— ) > (Eq 6 .3 .21)
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I
where
= exp[Mi (Eq 6.3.2_2)
with A: = 1, 2, 3 and / = 1, 2, 3 and the constraints = 0  and ^  = 0 are imposed. 
These 2^ , are the hazard functions from the assumed model for the nine cells.
S T R A T E G Y  F O R  D A T A  G E N E R A T IO N
F o r  T h e  C o m p l e t e  C a s e s  D e s i g n s :  Figure 6.5 shows the four cells representing the 
known factor levels. These four cells will be referred to as the known cells and the 
context will be referred to as the complete cases design.
The aim here is to derive two sets of normal equations to try to obtain the parameter 
estimates for the known levels. Firstly, when only the observations with known factor
levels (i.e. cells (l,l) ,(l,2 ) , (2 ,l) and (2 ,2 ) ) and, secondly, when all o f the observations 
(i.e. known plus missing) are included in the design. Exponential regression models are 
fitted to observations in these contexts and the results are compared.
When the normal equations ar e obtained, using standard maximum likelihood 
techniques, for both the situations with and without the missing data categories, the 
equations cannot be solved analytically (see Appendices 7 and 8  for complete and all 
cases designs respectively). Therefore, simulation methods are used to study the 
properties of parameter estimates in the presence of missing information in the factors.
To perform these exercises, artificial datasets needed to be generated such that ï
observations for the four cells with known factor levels arose from an exponential 
regression model with additive contributions from both factors but with no interaction.
The missing values categories were created to have observations from random mixtures 
of the four laiown exponential distributions. The potential bias arising when the third 
levels are incorrectly taken to satisfy the exponential regression model is examined. All 
calculations, including random number generation, were earned out in SAS.
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F2
1 2 3
1 nil ni2
FI 2 nil n22
3
F ig u r e  6 .5 :  T h e  k n o w n  c e l l s .
The observations are generated from four exponential distributions such that 
represents the number of observations falling in cell (A:,/), where A: = 1, 2 and / = 1, 2 
and Eqs 6 .3 .21  and 6.3.2_2 are satisfied. The %  parameters are main effects related to 
factor FI and th e p a ra m e te rs  are main effects related to factor F2.
The respective hazard functions for the four cells are given by
-  exp(/i^) for cell ( l ,l ) ,
= exp(//ii +  P 2 )  for cell (l,2 ) ,
^2 1  = exp(/z„ + « 2  ) for cell (2 ,l)
and
^ 2 2  = exp(/Zji + (%2 + A  ) for cell (2,2) . (Eqs 6 .3.2 3)
For all of the analyses described in the remainder of the chapter, the true values chosen 
for the parameters were:
Ml “  ,
<%2 -  0.5 
and p 2 =  0.3.
The value for was chosen arbitrarily. The values for and were chosen such
that the hazard ratio for level 2 versus level 1 of FI was exp(a2 ) « 1-6 and the hazard
ratio for level 2 versus level 1 of F2 was exp(y^) % 1.3. These are similar in size to 
hazard ratios observed in the analysis of the Breast Cancer Audit data.
Thus, observations in cell (l,l) were generated from an Ex(exp(l.25)) distribution and so 
the mean of observations in the cell would be e x p (-1.25). Similarly, the exponential
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distributions for the observations in cells (l,2 ) ,  (2 ,l) and (2 ,2 ) were £v(exp(l.5 5 ) ) , 
Ex(exp(l.75)) and Æ'x(exp(2.05)) respectively.
The SAS procedure L i f e r e g  was used to perform all of the exponential regression 
modelling. The purpose of fitting the models to the complete cases only was to test the 
SAS program. As all of the four known cells were observations from exponential 
distributions, then when the exponential regression model was fitted, the parameter
estimates //u , â ju n d  ought to have been very close to the true values set up for
// j j ,  CK^and p2.'
For T h e  All C a s e s  D e s i g n s :  Figure 6 . 6  represents the five cells corresponding to the 
missing factor level information. These are known as the missing cells.
F2
1 2 3
1 ni3
FI 2 Ü23
3 U31 U32 U33
F ig u r e  6 . 6 : T h e  m i s s i n g  c e l l s .
Each observation falling in a missing cell was generated from one of the four possible 
exponential distributions. A mechanism was needed to decide from which distribution 
the observation should be generated. The mixing paiameters for each of the five cells 
were chosen here such that the proportions of observations generated from the different 
exponential distributions in the missing cells were the same as the relative frequencies
of the known cells. For example, the observations in cell (l,3) consist of 
observations from a mixture of two exponential distributions with the true mixture pdf 
for the observations given by
_ n,/,13 "11 +Z7 ■/ll +12 "12« 1 1  + « 1 2 /l12
= r / i ,  + ( l - r ) / i 2
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« 1 2  + « 2 2  «12  + «2 2
-  « /l2  + ( l “ «)/22
For ceil (3,3), the observations are generated from a mixture of four exponential 
distributions such that
f  ^ ______ î!li_________f  + _______^ ________f  ^ ............... y
«11 + « 1 2  + «21  + « 2 2  «11 + « 1 2  + «21  * ^ « 2 2  «11 + « 1 2  + « 2 1  + « 22
+ ----------— ------------f22
«11 + « 1 2  +  «21 + « 2 2
Full details are given in Appendix 9. Note that these mixing parameters are different 
from those used in Section 6.2.2. Clearly this is just one particular structure that could 
have been chosen for generating observations in the five missing cells. This process of 
using the relative frequencies was selected because it meant that the distributions of 
responses in the missing categories ai’e weighted with respect to the observed numbers 
of subjects in the individual complete data categories.
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Similarly, for cell (3,2), the observations were created from a mixture of two 
exponential distributions such that the true mixture pdf is
THE ASSUMED MODEL 
All observations are assumed to satisfy the exponential regression model, which is 
known to be incorrect for the missing values. This is known because the observations 
falling in the missing cells have been generated to be random mixtures from the two 
known levels. In Section 6.2.2, it was shown that including third levels which have 
observations which are random mixtures of the exponential distribution for the first two 
levels produces hazard functions for the third levels which are not proportional to those 
for the first two levels. The primary aim is to investigate whether the parameter
estimates andy^, obtained when the missing values are also included in the dataset,
are different from the true values of the parameters. /
. ..
If the fitted model were true, then the log hazards for the cells would be those given by 
Figure 6.7. The values of //jj, and are unimportant here as it is really the values of 
and p 2 that are of interest.
FI
1
F2
2 3
1 Ml Ml + A Mil + A
2 Ml + ^ 2 Ml + ^ 2  +/% Mil + ^ 2  + A
3 Ml +«3 Mil +<^ 3 + A Mil + (^ 3 + A
F ig u r e  6 .7 :  L o g  h a z a r d s  f o r  th e  n in e  c e l l s  w h e n  th e  m o d e l  i s  tr u e .
Here the estimated hazard ratio for being in level 2 of FI versus level 1 of FI is given by 
exp((%2 ) and similarly for being in level 2 of F2 versus level 1 of F2, the estimated
hazard ratio is exp(y4 ) • Thus, if  the parameter estimates obtained for the complete and
all cases designs are different, then the hazard ratios will also be different, possibly 
leading to different interpretations and conclusions.
6.3.3 RESULTS FOR THE COMPLETE CASES DESIGNS BASED ON 
SIMULATED DATA
INTRODUCTION TO THE NINE GROUPS
Nine groups of designs for the complete data cells were created in three types according 
to the different numbers in the laiown levels. The most obvious type was the one with 
equal numbers in the laiown cells. The next two groups formed the second type, where 
the proportions of observations in level 1 out of the total for factor F2 were created to be 
the same for both levels of factor FI. The remaining six groups fell into the third type, 
where there was no definite pattern among the numbers in the known cells. Some of 
these six groups were chosen to have some extreme variations in the numbers in the four 
known cells.
'
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Table 6.1 gives the numbers n^i falling in cell(A:,/) for the complete cases (see Figure 
6.5 in Section 6.3.2). Note that all of the numbers are in units of a 1000. Large sample 
sizes were used to obtain biases in an asymptotic situation.
Type and Numbers in known cells
Group nil n i2 nzi n 22
I - A All 20
II --B 2 0 40 50 1 0 0
II --C 25 35 50 70
III -  D 1 0 1 0 0 50 40
III -  E 15 75 2 0 90
III -  F 40 5 35 1 2 0
III -  G 2 90 1 0 0 8
III -  H 2 0 40 1 0 0 40
III - 1 30 40 60 2 0
T a b l e  6 .1 :  N u m b e r s  in  th e  k n o w n  c e l l s  f o r  th e  n in e  g r o u p s .
THE COMPLETE CASES DESIGNS
Exponential regression models were then fitted to these nine groups for the complete 
cases. The biases for the three parameters and were calculated by
(Ai -M u ), (<^2 ~ ^ 2 ) (Â -  A ) denoted by ^ (A i), ^(« 2 ) ^(Â )
respectively. The standard errors, derived from the model fits, for the parameter 
estimates are given by .yg(Ai), s e { p ^  respectively and the results given in
Table 6.2.
G roup K A i) ^ A i  ) K 4 ) s e { a 2 I 4 Â ) ^ a )
A 0.0040 0.0061 0.0030 0.0071 -0.0036 0.0071
B -0.0025 0.0051 0 . 0 0 1 2 0.0048 0.0066 0.0046
C -0.0041 0.0050 0.0029 0.0050 0.0080 0.0048
D -0.0074 0.0060 0.0065 0.0052 0.0067 0.0057
E 0.0003 0.0059 0.0094 0.0045 -0.0013 0.0059
F 0.0025 0.0048 -0.0014 0.0065 0.0034 0.0056
G -0.0013 0.0106 0 . 0 0 2 1 0.0104 -0.0004 0.0103
H -0.0014 0.0052 0.0033 0.0052 0.0049 0.0049
I 0 . 0 0 0 2 0.0049 -0.0009 0.0055 0.0019 0.0056
T a b l e  6 .2 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  c o m p l e t e  c a s e s  d e s i g n s  f o r  
th e  n in e  g r o u p s .
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All o f the estimated biases were compatible with true values of zero bias, except for
b ( a 2 ) for Group E. This was more than 2 standard errors from zero. However, it is not
surprising to find one result significant at the 5% level, given that 27 tests have been 
conducted.
Thus, it appears that the complete cases designs gave the expected results, confirming 
that the SAS program generated the observations coiTectly and the estimation process 
worked successfully.
The estimated standard errors for Group G for all parameter estimates were much larger 
than those for the rest of the gi’oups, probably because of the relatively smaller sample 
sizes in two of the four cells.
167
T H E  A L L  C A S E S  D E S IG N S
For these nine groups with different numbers in the four known cells, a total of 79 
different designs were then created with differing numbers in the missing cells. The
numbers in these cells were chosen to investigate how the biases in A  and A  changed 
depending on the overall percentage missing and the distribution of the missing 
observations in the five cells. Exponential regression models were then fitted to the 79 
designs in the nine groups.
However, before the results of these 79 designs could be examined in detail, it was 
necessary to consider the validity of the model based standard errors. This was because 
the exponential regression model was known to be incorrect, as the hazards were not 
proportional (Section 6.2.2), when the missing values were included in this manner and, 
therefore, the standard errors obtained from an incorrect model would probably also be 
incorrect. The question, therefore, is by how much are the standard errors incorrect?
To tackle this problem, simulations were used to generate 20 replicates for 19 of the 79 
designs. For six of these 19 designs, further iterations were performed to obtain larger 
numbers of replicates. The sample standard deviations in the parameter estimates
.1
I
obtained from these simulations are compared to the model derived standard errors for 
the 19 designs and the results are given in the next section.
6.3.4 SIMULATION STRATEGY AND RESULTS EXAMINING THE 
INACCURACIES OF THE MODEL BASED ESTIMATED STANDARD 
ERRORS FOR THE ALL CASES DESIGNS
IN T R O D U C T I O N
To investigate the validity of the estimated standard errors obtained from these designs, 
simulations were performed to obtain replicates. The numbers (in units of a 1000) in 
the nine cells for the 19 designs involved in this analysis are given in Table 6.3.
I
Known cells Missing ce11s
Design nil n i2 n 2 i H22 ni3 1123 n3i n32 n33
A2 2 0 2 0 2 0 2 0 5 1 0 15 25 35
B4 2 0 40 50 1 0 0 5 1 0 15 25 35
Cl 25 35 50 70 35 25 5 2 50
D5 1 0 1 0 0 50 40 5 5 5 5 5
D6 1 0 1 0 0 50 40 2 5 1 0 5 2
D7 1 0 1 0 0 50 40 5 2 5 2 5
D9 1 0 1 0 0 50 40 5 2 2 2 5
DIO 1 0 1 0 0 50 40 2 2 2 2 2
El 15 75 2 0 90 150 150 150 150 150
E8 15 75 2 0 90 2 0 2 0 2 0 2 0 2 0
F5 40 5 35 1 2 0 1 0 1 0 1 0 1 0 1 0
FIG 40 5 35 1 2 0 1 0 1 0 5 2 5
F12 40 5 35 1 2 0 5 2 2 1 0 5
G2 2 90 1 0 0 8 1 0 0 50 2 2 2
H9 2 0 40 1 0 0 40 1 0 1 0 1 0 1 0 1 0
H14 2 0 40 1 0 0 40 1 0 1 0 5 5 2
H21 2 0 40 1 0 0 40 2 2 1 0 2 2
12 30 40 60 2 0 5 5 5 5 5
18 30 40 60 2 0 2 2 2 2 2
s
.'ï-
'VÏ
:
T a b l e  6 .3 :  N u m b e r s  in  th e  n in e  c e l l s  f o r  th e  d e s i g n s  w h e r e  r e p l i c a t e s  w e r e  s im u la te d . I
For each of these 19 designs, the 20 replicates were generated to identify any substantial 
deviations between the model based standard errors and the sampling standard
■I
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deviations for a particular design. However, since 20 is not a large number of iterations, 
further replications were obtained for six of the designs. Tliis was to try to identify 
more subtle differences. The number of additional iterations was limited by computer 
space, due to the size of the seeds file used to generate the observations and the 
sequences of random uniform numbers, and by the time taken to run the simulations. 
The larger numbers of replicates used are given in Table 6.4.
Design Number of replicates
A2 285
D5 100
D7 100
G2 100
H21 100
12 165
T a b l e  6 .4 :  T h e  l a r g e r  n u m b e r s  o f  r e p l i c a t e s  
g e n e r a t e d  f o r  s i x  o f  th e  d e s ig n s .
From Cox & Oakes (1984) and Ford et al (1995), the variance-covariance matrix for the 
exponential regression model can be computed solely from the design matrix and does 
not depend on the parameter estimates. Therefore, the model based standard errors
obtained for A  and A  will be independent of the simulated data given a particular 
design.
The aim here was to compare whether this known asymptotic standard error, based on 
the assumption that the exponential regression model fitted the data, was similar to the 
sampling variability of the par ameter estimates, due to the bias introduced by the fact 
that the exponential regression model was inappropriate. The values of the theoretical
model based standard errors for A  and A  obtained from fitting the model once (see 
Section 6.3.5) are given for each design, along with the values of the sampling standard 
deviation obtained on the 20 parameter estimates. For the six designs where larger 
numbers o f replicates were obtained, similar' values are also given for these analyses.
The standard errors for A i are not given as the main interest was in whether or not the
parameter estimates A  and A  were affected by the inclusion of the missing values in the 
design. For all of the replicates, the results are given below in Table 6.5. The sampling
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standard deviations from the 20 (or larger numbers of) parameter estimates provide an
idea about the true sampling variability for the designs.
Design Param eter Theoretical
standard
erro r
Sampling standard 
deviation obtained 
from 2 0  reps
Sampling standard  
deviation obtained 
from 2 0  reps
A2 « 2 0.0065 0.0052 0.0066
k 0.0058 0.0062 0.0060
B4 « 2 0.0047 0.0050 *
k 0.0042 0.0038 *
C l A 0.0043 0.0045 *
k 0.0047 0.0052 *
D5 A 0.0050 0.0062 0.0052
k 0.0054 0.0056 0.0049
D6 « 2 0.0051 0.0062 *
k 0.0053 0.0058 *
D7 « 2 0.0051 0.0060 0.0050
k 0.0055 0.0053 0.0050
D9 â i 0.0051 0.0060 *
k 0.0055 0.0060
DIO Z%2 0.0051 0.0059 *
k 0.0056 0.0057 *
E l A 0.0028 0.0028 *
k 0.0030 0.0027 *
E 8 A 0.0041 0.0035 *
k 0.0050 0.0035 *
F5 « 2 0.0058 0.0059 *
k 0.0051 0.0051 *
FIO « 2 0.0059 0.0064 *
k 0.0053 0.0055
F12 <%2 0.0062 0.0060 *
k 0.0054 0.0062 *
G2 0.0048 0.0042 0.0051
k 0.0062 0.0050 0.0061
T a b l e  6 .5 :  E s t i m a t e d  s t a n d a r d  e r r o r s  f o r  e a c h  o f  th e  d e s i g n s  ( T h e o r e t ic a l  s t a n d a r d  
e r r o r )  a n d  th e  s a m p l i n g  s t a n d a r d  d e v ia t i o n s  o b t a i n e d f r o m  th e  2 0  ( o r  l a r g e r  n u m b e r s  
o f)  e s t im a te s .  N o te  th a t  in d i c a te s  th a t  o n l y  2 0  r e p l i c a t e s  w e r e  o b t a i n e d  f o r  th a t  
d e s ig n .
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Design Parameter Theoretical
standard
error
Sampling standard 
deviation obtained 
from 20 reps
Sampling standard 
deviation obtained 
from 20 reps
H9 A 0.0049 0.0044 *
Â 0.0046 0.0038 *
H14 â j 0.0049 0.0044 *
k 0.0047 0.0040 *
H21 A 0.0051 0.0049 0.0049
k 0.0048 0.0038 0.0046
12 4 0.0053 0.0045 0.0054
k 0.0054 0.0057 0.0055
18 â i 0.0054 0.0045 *
k 0.0055 0.0055
T a b l e  6 .5  c o n t:  E s t i m a t e d  s t a n d a r d  e r r o r s  f o r  e a c h  o f  th e  d e s i g n s  ( T h e o r e t ic a l  s t a n d a r d  
e r r o r )  a n d  th e  s a m p l i n g  s t a n d a r d  d e v ia t i o n s  o b t a i n e d  f r o m  th e  2 0  ( o r  l a r g e r  n u m b e r s  
o f)  e s t im a te s .  N o te  th a t  in d i c a te s  th a t  o n l y  2 0  r e p l i c a t e s  w e r e  o b t a i n e d  f o r  th a t  
d e s ig n .
The fact that the theoretical standard errors were similar to these sampling standard 
deviations, based on the 2 0  or more replicates, leads to the conclusion that the 
theoretical model based standard errors can be taken as being reasonable. Therefore, the 
results of fitting exponential regression models to the 79 designs in the nine groups can 
be discussed in the next section using the knowledge that the standard errors are 
probably acceptable.
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6.3.5 EXAMINATION OF THE OBSERVED ESTIMATED BIASES AND 
ESTIMATED STANDARD ERRORS FOR THE ALL CASES DESIGNS
IN T R O D U C T I O N
The nine groups that were modelled in the complete cases designs were the basis of the 
exponential regression model fitted for 79 designs on all cases. Table 6 . 6  shows the 
numbers in the four known cells. All of the numbers are in units of a 1000.
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Numbers in known cells
G roup nil Ul2 nil U22
A 2 0 2 0 2 0 2 0
B 2 0 40 50 1 0 0
C 25 35 50 70
D 1 0 1 0 0 50 40
E 15 75 2 0 90
F 40 5 35 1 2 0
G 2 90 1 0 0 8
H 2 0 40 1 0 0 40
I 30 40 60 2 0
T a b l e  6 . 6 : N u m b e r s  in  th e  k n o w n  c e l l s  f o r  th e  n in e  g r o u p s .
Having just shown that the standard errors (s.e.) for these designs appeared to be 
reasonable even though the model that was fitted was incoiTect, it was then possible to 
test informally whether or not the parameter estimates obtained from these 79 designs 
were biased. This was possible by comparing the magnitude of estimated bias with its
approximate estimated standard error. Only the values o f A  and A  were examined 
and the estimated biases ) = (A  “  ^ 2  ) ô(A ) "= (Â “  A  ) presented along 
with the estimated standar d errors se{^6c2 ) and se (^ k  ) •
The overall percentage of observations falling into the five cells with missing factor 
level information is given by ‘% missing’ for each model. The results for the nine 
groups in the three types are now presented separately.
TYPE I -  GROUP A
This group had complete symmetry with equal numbers in the four known cells (Figure 
6 .8).
F2
FI 20 20
20 20
Figure 6.8: Numbers in the
known cells in Group A.
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Table 6.7 gives the numbers in the missing cells and the overall percentage missing in 
both designs in Group A, whilst the estimated biases and standard errors for A  and A  
for the two designs are given in Table 6.8.
Design
Num ber in missing cells
Ul3 U23 »31 U32 U33 %  missing
3
A1 20 20 20 20 20 56
A2 5 10 15 25 35 53 ij-'
T a b l e  6 .7 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  A .
■?
1
Design 0 (A ) ) 1
A1 <0.0001 0.0058 -0.0032 0.0058 t
A2 0.0024 0.0065 -0.0028 0.0058
T a b l e  6 . 8 : E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  A .
There appears to be no evidence of bias in the parameter estimates obtained for this 
group.
TYPE II - GROUP B
This group had equal proportions in the numbers in level 1 of factor F2 for both levels 
n ,,  n .of factor FI, with "21
« 1 1  + « 1 2 «21 + «22
= 0.33. These proportions are the mixing
paiameters r  and s  (Section 6.3.2 and Appendix 9) for weighting the two exponential 
distributions used to generate the observations in the missing cells (l,3) and
(2 ,3 ) respectively. These proportions are observed by examining the breakdown of the 
numbers in the known cells for this group (Figure 6.9).
F2
FI 20 40
50 100
Figure 6.9: Numbers in the
known cells in Group B.
173
J
Table 6.9 gives the numbers in the missing cells for the six designs in Group B.
Design
Number in missing cells
ni3 n23 n3i n32 U33 % missing
B1 100 5 75 150 2 61
B2 40 40 40 40 40 49
B3 20 20 20 20 20 32
B4 5 10 15 25 35 30
B5 15 15 15 15 15 26
B6 5 5 5 5 5 11
T a b l e  6 .9 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s in g  in  G r o u p  B .
The estimated biases and standard errors for the parameter estimates are given in Table 
6.10 for these designs.
Design 6(A ) s e ^ â j  ) b { Â ) s e [ A )
B1 0.0022 0.0045 0.0007 0.0032
B2 0.0007 0.0040 0.0033 0.0039
B3 -0.0007 0.0043 0.0049 0.0042
B4 0.0009 0.0047 0.0052 0.0042
B5 <0.0001 0.0044 0.0048 0.0043
B6 0.0010 0.0047 0.0059 0.0045
T a b l e  6 .1 0 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  B .
Again, there was no evidence of biased parameter estimates.
TYPE II -  GROUP C
This is another group in type II where there were equal proportions of obseiwations for 
level 1 out of the total of factor F2 for both levels of FI (Figuie 6.10).
F2
FI 25 35
50 70
Figure 6.10: Numbers in the
known cells in Group C.
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Table 6.11 gives the numbers in the missing cells and the overall percentages missing. 
The biases and model based standard errors for the parameter estimates are shown in 
Table 6.12.
T a b l e  6 .1 2 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  C.
There was no evidence of bias in the parameter estimates.
It, therefore, appears that for both type I and type II contexts the parameter estimates 
were not biased, despite the fitted model being incorrect. These types have equal
proportions in the known cells for r  = and s "21
« 2 1  + « 2 2
; i.e. r  =  s  (see
« 1 1  + « 1 2
Section 6.3.2 and Appendix 9). In this situation, the expectations in each cell are 
compatible with a proportional hazards model even though the exponential regression 
model is not valid.
For example, the expectation for observations in cell (l,3) is 
exp(- /z)[r + (l -  r) exp(- )] and the expectation for observations in cell (l,l) is 
exp(- j u ) . Therefore, the ratio of the expectations, and hence the hazards for the 
exponential distributions, for cell (l,3) to cell (l,l) is r  + (l -  r) exp(- y  ^).
Similarly, the expectation for the observations in cell (2,3) is
exp(- /z -  « 2  )[‘5' + (l -  j") exp(- y^2 )] and for cell (2 ,l), exp(- /z -  « 2  ). Therefore, the
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Design
N um ber in missing cells
ni3 H23 n3i n32 ns3 %  missing
C l 35 25 5 2 50 39
C2 15 15 15 15 15 29
T a b l e  6 .1 1 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  C .
k
%
Design 6 (A ) z?e( A  ) b { k )
C l 0.0021 0.0043 0.0061 0.0047
C2 0.0013 0.0046 0.0059 0.0044
g
ratio of cell (2,3) to cell (2,l) is 5 + (l -  i-) exp(- y^)= r  + (l -  r) exp(- ) , since r  =  s . 
The ratio of the expectations for cell (3,3) versus cell (3,l) also has the same ratio.
The expectations have the form they would have had if the observations were from an 
additive exponential regression model. Thus, the expectations are proportional even 
though the exponential regression model is not appropriate, with the true hazards not 
being proportional. A sufficient statistic for the maximum likelihood estimate (MLE) is 
the sets of sums of observations in each of the cells. Hence, a MLE will be based solely 
on these quantities and in this case, when the mixing weights are in correct proportions, 
the sums are compatible with an additive exponential model and the estimates would be 
asymptotically unbiased.
TYPE III - GROUP D
The numbers in the known cells for Group D are given in Figure 6.11. 
 ^ F2
FI 10 100
50 40
F ig u r e  6 .1 1 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  D .
Table 6.13 shows the numbers in the missing cells for the designs in this group.
Num ber in missing cells
Design ni3 H23 n3i 1132 n33 %  missing
D1 50 50 5 50 5 44
D2 35 25 5 2 50 37
D3 5 10 15 25 35 31
D4 10 10 10 10 10 20
D5 5 5 5 5 5 11
D6 2 5 10 5 2 11
D7 5 2 5 2 5 9
D8 2 5 2 5 2 7
D9 5 2 2 2 5 7
DIO 2 2 2 2 2 5
T a b l e  6 .1 3 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  % m i s s i n g  in  G r o u p  D .
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The estimated biases and model based standard errors for the parameter estimates are 
presented in Table 6.14.
-
1
Design 6(A) A ) b { k ) s e [ A )
D1 -0.0663 0.0040 -0.0581 0.0051
D2 -0.0440 0.0044 -0.0356 0.0053
D3 -0.0345 0.0049 -0.0622 0.0049
D4 -0.0289 0.0048 -0.0427 0,0052
D5 -0.0129 0.0050 -0.0199 0.0054
D6 -0.0127 0.0051 -0.0252 0.0053
D7 -0.0073 0.0051 -0.0140 0.0055
D8 -0.0063 0.0051 -0.0097 0.0055
D9 -0.0037 0.0051 -0.0069 0.0055
DIO -0.0023 0.0051 -0.0060 0.0056
T a b l e  6 .1 4 .  
G r o u p  D .
E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in
When there was 7% or less of the total missing, there was no evidence of significant 
bias in the parameter estimates. The parameter estimate A  also did not appear to be 
biased when there was 9% missing, but the estimate for p j  was.
I
Note that, as the overall percentage missing increased, the standard errors of A  and A  
decreased. The total sample size was not controlled and, therefore, as more cases were 
added into the missing cells, the overall total numbers of cases increased for the 
particular group design. This led to the standard errors decreasing because the 
parameter estimates were being calculated from more data.
In contrast, as the percentage of missing values increased, so did the magnitude of the 
estimated bias of both A  A , general. To illustrate this, the magnitudes of the 
estimated biases were plotted against the percentage missing for the 10 designs in this 
group (Figure 6.12).
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Estimated bias in estim ates by overall % missing
Group D
0.07 T
0.06
0.04
♦ |B_alp2| 
X 18_bet21
20 25
% missing
F ig u r e  6 .1 2 :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a i n s t  th e  o v e r a l l  p e r c e n t a g e  
m i s s i n g  f o r  G r o u p  D .
TYPE III -GROUPE
The numbers in the known cells in this group were very similar to those of type II since
1 2the proportions in level 1 o f F2 for levels 1 and 2 of FI were — and — respectively,6 11
with the numbers in the known cells given in Figure 6.13.
F2
FI 15 75
20 90
F ig u r e  6 .1 3 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  E .
The numbers in the missing cells are shown in Table 6.15 and the estimated biases and 
standard errors for the parameter estimates from the designs in this group ai’e presented 
in Table 6.16.
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Design ni3
N um ber in missing cells
Ü23 1*31 U32 1133 %  missing
E l 150 150 150 150 150 79
E2 125 125 125 125 125 76
E3 125 150 100 75 150 75
E4 100 100 100 100 100 71
E5 75 75 75 75 75 65
E6 50 50 50 50 50 56
E7 40 40 40 40 40 50
E8 20 20 20 20 20 33
E9 5 5 5 5 5 11
T a b l e  6 .1 5 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  E .
Design b [ a ^ ) se(^a2 ) b { A ) s e [ p )
E l 0.0005 0.0028 -0.0123 0.0030
E2 0.0014 0.0030 -0.0126 0.0032
E3 0.0009 0.0029 -0.0099 0.0036
E4 0.0017 0.0032 -0.0114 0.0035
E5 0.0052 0.0034 -0.0086 0.0038
E6 0.0039 0.0037 -0.0080 0.0042
E7 0.0054 0.0038 -0.0074 0.0044
E8 0.0058 0.0041 -0.0053 0.0050
E9 0.0085 0.0044 -0.0027 0.0056
T a b l e  6 .1 6 :  
G r o u p  E .
E s t i m a t e d  b ia s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in
Despite extensive numbers of cases with missing factor levels (even when there was as 
much as 79% of the total missing), there was no evidence of bias in the parameter 
estimate forctj in any of the designs. However, when there was 65% or more of cases
missing, appeared to be biased, although with 56% or less of the total number of
cases missing, there was no evidence of bias for either â j or •
Figure 6.14 shows a systematic pattern of increasing magnitude of bias for the 
percentage of missing values increased. Although there appears to be a decreasing trend 
for the magnitude of bias of â j with increasing percentage of missing values, there was 
no evidence that any of the biases for were different from zero.
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Estim ated bias in estim ates by overaii % missing
Group E
U i
I  0.008
I 0.004 - -
0.002 - -
♦ |B_alp2j 
X|B_bet2|
20 40
% missing
F ig u r e  6 .1 4 :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a i n s t  th e  o v e r a l l  p e r c e n t a g e  
m i s s i n g  f o r  G r o u p  E .
TYPE III -  GROUP F
The numbers in the known and missing cells for Group F are given in Figure 6.15 and 
Table 6.17 respeetively.
F2
FI 40 5
35 120
F ig u r e  6 .1 5 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  F .
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Design ni3
Number in missing cells
n23 U31 U32 W33 % missing
FI 20 40 100 35 20 52
F2 40 40 40 40 40 50
F3 20 20 20 20 20 33
F4 15 15 15 15 15 27
F5 10 10 10 10 10 20
F6 10 10 10 5 5 17
F7 10 10 5 10 5 17
F8 10 10 5 5 10 17
F9 10 10 5 5 5 15
FIO 10 10 5 2 5 14
F ll 5 5 5 5 5 11
F12 5 2 2 10 5 11
F13 10 5 5 2 2 11
F14 2 2 2 2 2 5
T a b l e  6 .1 7 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  F.
Table 6.18 shows the biases and model based standard errors of â j and
Design b [ a ^ s e [ a 2 ) b { A ) ^ 4 )
FI 0.0111 0.0050 0.0956 0.0041
F2 0.0477 0.0046 0.0687 0.0042
F3 0.0247 0.0053 0.0413 0.0047
F4 0.0197 0.0055 0.0322 0.0049
F5 0.0143 0.0058 0.0219 0.0051
F6 0.0201 0.0059 0.0127 0.0052
F7 0.0189 0.0058 0.0114 0.0052
F8 0.0229 0.0059 0.0061 0.0053
F9 0.0228 0.0059 0.0061 0.0053
FIO 0.0282 0.0059 -0.0016 0.0053
F ll 0.0068 0.0061 0.0134 0.0053
F12 0.0036 0.0062 0.0096 0.0054
F13 0.0184 0.0061 0.0024 0.0054
F14 0.0028 0.0064 0.0062 0.0055
T a b l e  6 .1 8 .  
G r o u p  F .
E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in
%
When there was 20% or more of the total missing, both of the parameter estimates were 
biased in all of the designs. With 17% of the observations were missing, designs F6 and
F7 also had biased parameter estimates, but there was no evidence of bias for for
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design F8. Thus, it appeal's that the distribution of the missing values affected the 
estimation process.
From Figure 6.16, the magnitude of the bias of increased as the percentage of 
missing values increased. No obvious relationship was apparent for the bias of
0.09 +
0.08
„ 0.07 H
§ 0.06 -- I1 0.05
Estimated bias in estimates by overall % missing 
Group F
3 0.04 -- 1E 0.03 
0.02 + 
0,01 
0
*  |B_0lp2| 
x|B„bet2|
30
% missing
F ig u r e  6 .1 6 :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a i n s t  th e  o v e r a l l  p e r c e n t a g e  
m i s s i n g  f o r  G r o u p  F .
TYPE III -  GROUP G
The numbers in the four known cells in this group are given in Figure 6.17. 
  F2
FI 2 90
100 8
F ig u r e  6 . 1 7; N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  G .
Table 6.19 provides the numbers in the missing cells for this group, whilst the estimated 
biases and standard errors for â j  and shown in Table 6.20.
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N um ber in missing cells
Design ni3 U23 n3i U32 U33 % missing
G1 2 2 2 100 100 51
G2 100 50 2 2 2 44
G3 15 15 15 15 15 27
G4 5 5 5 5 5 11
G5 2 2 2 2 2 5
G6 1 1 1 1 1 2
T a b l e  6 .1 9 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  G .
Design s e [ a 2 ) b { A ) s e [ p )
G1 -0.1040 0.0092 -0.1136 0.0091
G2 -0.2213 0.0048 -0.2084 0.0062
G3 -0.2199 0.0069 -0.2346 0.0068
G4 -0,1221 0.0087 -0.1287 0.0087
G5 -0.0634 0.0096 -0.0680 0.0096
G6 -0.0325 0.0100 -0.0366 0.0100
T a b l e  6 .2 0 :  E s t i m a t e d  b ia s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  G .
Despite the fact that design G6 had only 2% of the total number of observations 
missing, both of the parameter estimates for all of the designs were biased.
A quadratic pattern was seen in the plots of the magnitudes of the biases for the two 
parameters against the percentages missing for the different designs (Figure 6.17), again 
suggesting that the distribution of the missing values is important to the estimation 
process.
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Estimated bias In estim ates by overall % missing
Group G
♦ !B_alp2| 
X |B_bet2|
30
% missing
50
F ig u r e  6 .1 8 :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a i n s t  th e  o v e r a l l  p e r c e n t a g e  
m i s s i n g  f o r  G r o u p  G .
■I
TYPE III -  GROUP H
Figure 6.19 and Table 6.21 gives the numbers in the known and missing cells 
respectively.
F2
FI 20 40
100 40
F ig u r e  6 .1 9 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  H
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Design ni3
Number in missing cells
n23 “31 n32 “33 % missing
HI 40 40 40 40 40 50
H2 150 2 5 2 15 47
H3 25 25 25 25 25 38
H4 100 2 5 2 15 38
H5 100 2 5 2 10 37
H6 10 2 5 5 50 26
H7 40 10 5 2 10 25
H8 40 2 5 2 15 24
H9 10 10 10 10 10 20mo 5 10 10 5 5 15
H ll 10 5 5 5 10 15
H12 2 10 2 10 10 15
H13 10 5 5 2 10 14
H14 10 10 5 5 2 14
HIS 10 2 10 5 5 14
H16 10 5 10 2 5 14
H17 10 5 10 5 2 14
H18 10 10 5 2 2 13
H19 5 5 5 5 5 11
H20 10 5 5 2 2 11
H21 2 2 10 2 2 8
H22 2 2 2 2 2 5
T a b l e  6 .2 1 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  H .
The table of results showing the estimated biases and model based standard errors for 
Group H for the parameter estimates are given in Table AlO.l in Appendix 10, along 
with a plot of the magnitudes of the estimated biases against the percentage of missing 
values (Figure AlO.l in Appendix 10).
There was no obvious pattern between whether or not the parameter estimates were 
biased and the overall percentage missing. For example, design H2 had 47% missing
and yet there was no evidence of bias o f , whereas designs H14-H17 had only 14% 
missing, but both of the parameters were biased for these four designs.
When the estimated biases for both parameter estimates were compared when there 
were equal numbers in each of the missing cells (designs H I, H3, H9, HI 9 and H22), 
the magnitude of the biases of the parameter estimates decreased as the numbers in these 
cells decreased (Table A lO.l, Appendix 10).
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TYPE III -  GROUP I
The breakdown of the numbers in the four known cells in this group is shown in Figure 
6.20 and Table 6.22 gives the numbers in the missing cells.
F2
FI 30 40
60 20
F ig u r e  6 .2 0 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  I.
Design “ 13
Number in missing cells
“ 23 “ 31 “ 32 “ 33 % missing
11 10 10 10 10 10 25
12 5 5 5 5 5 14
13 5 5 5 5 2 13
14 5 5 5 2 5 13
15 5 5 5 2 2 11
16 5 2 5 5 2 11
17 2 5 5 5 2 11
18 2 2 2 2 2 6
T a b l e  6 .2 2 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  I.
The estimated biases and standard errors for and for these eight designs in Group 
I are given in Appendix 10 (Table A 10.2). The plot of the magnitudes of the biases 
against the overall percentage missing is also presented in Appendix 10 (Figure A10.2). 
There was a general trend for increasing magnitude of bias in the two parameters with 
increasing overall percentage o f missing values.
C O N C L U S IO N
Except Group E designs, which were similar to type II designs (Groups B and C), all of 
the type III designs had some combinations of numbers in the missing cells that 
produced biased parameter estimates when an exponential regression model was fitted 
to the design.
186
6.3.6 APPLICATION IN THE CONTEXT OF THE BREAST CANCER AUDIT 
DATA
IN T R O D U C T I O N
Following on ftom the investigation into the effects of varying the numbers in both the 
known and missing cells using the 79 designs in the nine groups, six new designs were 
examined. The new analyses were performed to check the general impressions formed 
from the nine groups regarding the parameter estimates remained for datasets with a 
similar missingness structure to the Breast Cancer Audit data. The six designs were 
based on the distributions of subjects with known and missing information for the 
pairwise combinations of the four clinical variables: clinical stage, node status, tumour 
size and ER status. The true numbers in the pairwise combinations for the Breast 
Caneer Audit are given in Tables A4.5 to A4.10 of Appendix 4. Here, however, to 
obtain an estimate of bias in an asymptotic context, the numbers in each of the six new 
designs are scaled up by 1000 in each cell.
The same underlying exponential regression model and methods of simulating data were 
used as in the previous section. As before, it was assumed there was no censoring and 
that the true values of the parameters also remained the same.
T H E  D E S IG N S  A N D  T H E  R E S U L T S
The six designs are C_E (clinieal stage by ER status); C_N (clinical stage by node 
status); C_T (clinical stage by tumour size); E_N (ER status by node status); E_T (ER 
status by tumour size) and N_T (node status by tumour size). Table 6.23 shows the 
numbers, in units of a 1000, in the known cells for these designs.
Numbers in known ceils
Design “ 11 “ 12 “ 21 “ 22
C E 447 278 64 54
C N 363 464 120 28
C T 475 434 30 128
E N 237 244 158 150
E T 267 234 131 186
N T 171 312 269 212
T a b l e  6 .2 3 :  N u m b e r s  in  th e  k n o w n  c e l l s  f o r  th e  s i x  n e w  d e s ig n s .
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The estimated biases and model based standard errors for the parameter estimates 
obtained from the complete cases models for the six new designs are given in Table 
6.24.
Design K 4 ) } s e [ p )
C E 0.0053 0.0031 -0.0007 0.0022
C N 0.0004 0.0029 -0.0015 0.0021
C T 0.0066 0.0028 -0.0026 0.0020
E N 0.0034 0.0023 0.0016 0.0023
E T 0.0024 0.0023 0.0014 0.0022
N T 0.0025 0.0021 0.0022 0.0021
T a b l e  6 .2 4 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  c o m p l e t e  c a s e s  
m o d e l s  f o r  th e  s i x  n e w  d e s i g n s .
As expected, there was little evidence of bias for the complete cases data with the 
possible exception of Clinical stage by Tumour size. Here, the estimated bias fo râ j was 
2.34 standard errors.
For the all cases designs, the numbers in the missing cells and the overall percentage 
missing are shown in Table 6.25. All of the designs had a high percentage of cases 
missing, ranging from 34% to 51%.
Design
Num ber in missing cells
“ 13 “ 23 “ 31 “ 32 “ 33 %  missing
C E 390 69 88 59 170 48
C N 288 39 100 109 108 40
C T 206 29 120 100 97 34
E N 118 83 188 207 234 51
E T 98 74 227 242 160 49
N T 100 120 185 138 112 40
T a b l e  6 .2 5 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s in g .
Based on the finding from the last section, it was anticipated that the model fitted to the 
data in design E_N would produce estimates with less bias, if  any at all, since the 
«11 . «0proportions r «11 1^2 and s  = n^i + «22 (Appendix 9) were very similar for this
design (0.49 and 0.51 respectively). The estimated biases and model based standard 
errors for the parameter estimates for the all cases models are reported in Table 6.26.
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Design 6 (4 ) se(^a2 ) s e [ p )
C E 0.0136 0.0025 0.0010 0.0021
C N -0.0274 0.0026 -0.0204 0.0019
C T 0.0200 0.0026 0.0075 0.0018
E N 0.0014 0.0021 -0.0027 0.0018
E T 0.0074 0.0021 0.0184 0.0018
N T -0.0147 0.0019 -0.0272 0.0018
T a b l e  6 .2 6 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  s i x  d e s i g n s  in  
th e  a l l  c a s e s  a n a l y s e s .
The expected result for design E_N was observed. For the remaining designs, there was
evidence of bias for both of the parameter estimates, except for for design C_E.
However, for all designs the estimated biases were very small in magnitude, both
relatively and absolutely. In fact, the magnitude of b ( a 2 ) for the C_N design was the
largest. The value of 0.0274 represents 5.5% of the true value, 0.5. By contrast, in the 
simulated exercise presented in the last section, the largest percentage bias was 78% in
G3 for b(
S M A L L  S A M P L E  A N A L Y S E S
The simulations so far, both in this section and previously, have been designed to 
investigate bias in a large sample context. The analyses all relied on the large sample 
properties of maximum likelihood estimates theory to obtain the standard errors of the 
parameter estimates. However, in general, there are not usually 100,000 subjects 
available for analysis. It was, therefore, interesting to fit exponential regression models 
to the real sample size of the Breast Cancer Audit, with only 1619 subjects in total, to 
observe the sizes of the biases and standard errors obtained when a relatively small 
sample size was modelled using an incorrect exponential regression model to investigate 
the bias due to the proportional hazards assumption being violated.
The results for all these models are based on 20 replicates, with several designs having 
either 1,000 or 10,000 replicates. The average biases for the estimates based on the 
different numbers of replicates are given in Table 6.27, along with the sampling 
standard error for the average biases of the parameter estimates.
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Design Average 
bias of â j
Standard 
e rro r for the 
average bias 
of â j
Average 
bias of ^
Standard  
e rro r for the 
average bias
of
C E
20 reps. 0.0228 0.0151 -0.0135 0.0146
1000 reps. 0.0159 0.0026 0.0013 0.0020
10,000 reps. 0.0103 0.0008 0.0029 0.0007
C N
20 reps. -0.0363 0.0156 -0.0236 0.0149
10,000 reps. -0.0361 0.0007 -0.0172 0.0006
C T
20 reps. 0.0203 0.0145 0.0063 0.0151
E N
20 reps. -0.0159 0.0168 -0.0082 0.0154
E T
20 reps. -0.0142 0.0183 0.0159 0.0125
1000 reps. 0.0152 0.0018 0.0089 0.0198
10,000 reps. 0.0051 0.0007 0.0197 0.0006
N T
20 reps. -0.0295 0.0115 -0.0366 0.0108
1000 reps. -0.0147 0.0018 -0.0274 0.0018
10,000 reps. -0.0155 0.0006 -0.0272 0.0006
T a b l e  6 .2 7 :  A v e r a g e  b i a s e s  f o r  â j  a n d  f f  w i th  s t a n d a r d  e r r o r s  f o r  th e s e  
e s t i m a t e s  f o r  th e  s i x  d e s i g n s  b a s e d  o n  th e  tr u e  s m a l l  s a m p l e  s i z e s  f o r  v a r y i n g  
n u m b e r s  o f  r e p l i c a t e s  ( r e p s .) .
These data show the extent of bias with the unknown pattern observed in the pairs of 
clinical factors in the Breast Cancer Audit data assuming that the data were exponential. 
As can be seen, there is considerable bias in both parameters when more than 20 
replicates are included in the analysis for all of the designs. There is also evidence of 
bias for both parameter estimates for design N_T when only 20 replicates are included 
in the analysis. For the design C_N, appears to be biased from only 20 replicates.
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6.4 RESULTS FROM FITTING COX REGRESSION MODELS TO THE 
EXPONENTIAL DATASETS
IN T R O D U C T I O N
The parameter estimates obtained from fitting an exponential regression model to data 
which did not satisfy the proportional hazards assumption in the additive main effects 
model situation were biased for some designs (Sections 6.3.5 and 6.3.6). A main effects 
Cox proportional hazards regression model is now fitted to four of the nine groups 
described in Section 6.3.5. The simulated datasets were generated fiom exponential 
distributions as previously and the same true values of the parameters used.
When the Cox regression models were fitted to these designs, it was again assumed that 
there was no censoring. The numbers in the known and missing cells for all of the 
designs in the four groups remained the same so that, for each design, the results from 
fitting a Cox model could be compared to the results obtained from fitting the 
exponential regression model. Note that all of the numbers were in units of 1000 so that 
the large sample context could be examined.
R E S U L T S  F O R  T H E  C O X  M O D E L L IN G
TYPE I - GROUP A
The numbers in this group for the four known cells are given in Figure 6.21. 
 ^ F2
FI 20 20
20 20
F ig u r e  6 .2 1 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  A .
Table 6.28 shows the numbers in the missing cells and the overall percentage missing in 
each design. The estimated biases and estimated standard errors for â j and the 
two designs that were fitted are presented in Table 6.29.
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Design
Number in missing cells
“ 13 “ 23 “ 31 “ 32 “ 33 % missing
A1 20 20 20 20 20 56
A2 5 10 15 25 35 53
T a b l e  6 ,2 8 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  A
Design 6(4) s e ^ â j  ) 6(Â) s e [ p )
AI -0.0116 0.0059 0.0101 0.0058
A2 -0.0123 0.0066 -0.0114 0.0059
T a b l e  6 .2 9 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f r o m  f i t t i n g  th e  C o x  
m o d e l  f o r  th e  d e s i g n s  in  G r o u p  A .
There was no evidence of bias in either and j l j  for each of the two designs.
TYPE II -  GROUP B
The breakdown of the numbers in the known and missing cells for this group are given 
in Figure 6.22 and Table 6.30 respectively.
F2
FI 20 40
50 100
F ig u r e  6 .2 2 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  B .
Design
Number in missing cells
“ 13 “ 23 “ 31 “ 32 “ 33 % missing
B1 100 5 75 150 2 61
B2 40 40 40 40 40 49
B3 20 20 20 20 20 32
B4 5 10 15 25 35 30
B5 15 15 15 15 15 26
B6 5 5 5 5 5 11
Table 6.30: Numbers in the missing cells and % missing in Group B.
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Table 6.31 provides the estimated biases and model based standard errors for the 
parameter estimates for these six designs.
Design 6 (4 ) s e i â j  ) 44) s e [ p )
B1 -0.0113 0.0046 -0.0071 0.0032
B2 -0.0111 0.0040 -0.0035 0.0039
B3 -0.0092 0.0044 0.0001 0.0042
B4 -0.0094 0.0047 -0.0069 0.0043
B5 -0.0078 0.0045 0.0005 0.0043
B6 -0.0033 0.0048 0.0035 0.0046
T a b l e  6 .3 1 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f r o m  th e  C o x  m o d e l  
f o r  th e  d e s i g n s  in  G r o u p  B .
For design B l, with 61% of the observations falling in the missing factor level 
categories, both â j  and were biased, was also biased for designs B2 and B3,
although P 2 was not. There was no evidence of bias for either of the parameter 
estimates when there were 30% or fewer of the observations in the missing levels.
TYPE III  -  GROUP D
The numbers in the known cells for this group are given in Figure 6.23. 
F2
FI ' '10 100
50 40
F ig u r e  6 .2 3 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  D .
The numbers in the missing cells are shown in Table 6.32 and the biases and model 
based standard errors for the parameter estimates presented in Table 6.33.
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Design “ 13
Num ber in missing cells
“ 23 “ 31 “ 32 “ 33 % missing
D1 50 50 5 50 5 44
D2 35 25 5 2 50 37
D3 5 10 15 25 35 31
D4 10 10 10 10 10 20
D5 5 5 5 5 5 11
D6 2 5 10 5 2 11
D7 5 2 5 2 5 9
D8 2 5 2 5 2 7
D9 5 2 2 2 5 7
DIO 2 2 2 2 2 5
T a b l e  6 .3 2 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  D .
Design 6 ( 4 ) ■^^(4) 4 Â )
D1 -0.0718 0.0041 -0.0611 0.0051
D2 -0.0493 0.0045 -0.0385 0.0053
D3 -0.0409 0.0049 -0.0654 0,0050
D4 -0.0329 0.0049 -0.0448 0.0052
D5 -0.0156 0.0051 -0.0214 0.0054
D6 -0.0156 0.0052 -0.0268 0.0054
D7 -0.0097 0.0052 -0.0152 0.0055
D8 -0.0084 0.0052 -0.0108 0.0056
D9 -0.0058 0.0052 -0.0080 0.0056
DIO -0.0040 0.0052 -0.0069 0.0056
T a b l e  6 .3 3 :  E s t i m a t e d  b ia s e s  a n d  s t a n d a r d  e r r o r s  f r o m  th e  C o x  m o d e l  
f o r  th e  d e s i g n s  in  G r o u p  D .
For all of the designs with 11% or more of the observations missing, both of the 
parameter estimates were biased. With 9% missing (D7), there was no evidence of bias
for , although was biased. With only 7% or fewer of observations in the missing 
cells, there was no evidence of bias for either of the parameter estimates.
TYPE III -  GROUP G
The numbers in the known and missing cells for this group are given in Figure 6.24 and 
Table 6.34 respectively.
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F2
FI 2 90
100 8
F ig u r e  6 .2 4 :  N u m b e r s  in  th e  
k n o w n  c e l l s  in  G r o u p  G .
Design “ 13
Num ber in missing cells
“ 23 “ 31 “ 32 “ 33 %  missing
G1 2 2 2 100 100 51 A
G2 100 50 2 2 2 44
G3 15 15 15 15 15 27
G4 5 5 5 5 5 11
G5 2 2 2 2 2 5
G6 1 1 1 1 1 2 1
T a b l e  6 .3 4 :  N u m b e r s  in  th e  m i s s i n g  c e l l s  a n d  %  m i s s i n g  in  G r o u p  G .
The estimated biases and estimated standard eiTors for and shown in Table
6.35.
Design 6 ( 4 ) fg((%2 ) 4 Â )
G1 -0.1076 0.0092 -0.1152 0.0091
G2 -0.2222 0.0048 -0.2086 0.0062
G3 -0.2213 0.0069 -0.2348 0.0068
G4 -0.1231 0.0087 -0.1291 0.0087
G5 -0.0638 0.0097 -0.0682 0.0096
G6 -0.0327 0.0100 -0.0366 0.0100
T a b l e  6 .3 5 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f r o m  th e  C o x  m o d e l  
f o r  th e  d e s i g n s  in  G r o u p  G .
All of the parameter estimates were biased in all situations.
COMPARISON OF RESULTS FOR THE COX AND EXPONENTIAL REGRESSION MODELS 
An interesting observation is that the model based standard eiTors obtained from fitting 
the Cox models are virtually identical to those obtained for the exponential regression 
models (Section 6.3.5) fitted to all of the designs for the four groups. The standard 
errors for the Cox models have been assumed to be valid, as no checks have been made. 
That is, unlike for the exponential regression models (Section 6.3.4), there have been no
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simulations of large numbers of replicates to obtain an estimate of the true sampling
variability for the Cox models.
For Group A, neither of the fits from the exponential regression model nor the Cox 
models produced any biases in the parameter estimates that were signifieantly different 
from zero. For Groups B and D, where some of the parameter estimates were biased, 
the biases were slightly larger for the Cox models than those for the exponential 
regression models, although it is not possible to determine if  these are statistically 
different. It is interesting that the Cox model produced some evidence of bias in Group 
B even though the mixing parameters were equal, i.e. r  =  s  (Appendix 9). The 
parameter estimates were virtually identical for the fits of both the exponential and Cox 
models for Group G.
D IS C U S S IO N
The general compatibility of the results for determining the parameter estimates from 
fitting an exponential regression model and a Cox model to sets of data which were 
generated from exponential distributions is probably because the Cox model is a 
generalisation of the exponential regression model. Thus, the hazard ratios obtained 
fi'om these parameter estimates are similai' for the two regression models. The standard 
errors from the two models were also very similar. It appears that there was no benefit 
gained from fitting the parametric exponential regression model to these data since the 
partial likelihood method of Cox, using the ranks of the deaths times, gave estimates 
that were as efficient at using the information as the maximum likelihood estimate 
technique used by the exponential regression model was.
However, this does not guarantee that there would not have been some benefit gained 
from fitting an exponential regression model had the survival estimates been examined 
instead of simply the parameter estimates. This is because the Cox model only models 
the parameter estimates and not the baseline hazard. This is needed to obtain the 
survival estimate. A parametric exponential model fitted to data generated from 
exponential distributions would probably estimate the baseline hazard, and hence the 
survival estimate, more efficiently.
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It is necessary to remember that these results were for the large sample setting and it was 
assumed that there was no censoring. It is not clear whether similar results would have 
been observed for a small sample problem or if censoring had been taken into account in 
the Cox models.
6.5 GENERAL DISCUSSION
It was shown in Section 6.2.2 that the third level in the two factors exponential 
regression model did not satisfy the proportional hazards assumption when the third 
levels were assumed to be random mixtures of exponential distributions which were 
used to generate the observations falling in the known cells.
The general conclusion from Section 6.3.5, when exponential regression models were 
fitted to each of the designs, was that the bias of the parameter estimates were 
influenced by the inclusion of the extra levels for the unknown values.
However, there were several scenarios where there was no evidence of significant bias 
for the parameter estimates based, on the all cases models. These were:
(i) when the relevant proportions of observations in level 1 of factor F2 for both 
levels of factor FI (Appendix 9) were very similar;
(ii) when the number o f missing values as a percentage of the total numbers of 
cases was small. This was not true in all circumstances for all of the designs, especially 
when the proportions mentioned in (i) were very different (see the results for Group G in 
Section 6.3.5);
(iii) the distribution of the numbers of observations falling in the missing cells 
sometimes made a difference as to whether or not the parameter estimates were biased.
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It would appear that differences among the numbers of observations in the four known 
cells in the designs, along with the appropriate mixing parameters used to obtain the 
observations in the missing cells, greatly influenced the results of the estimation 
procedure. For example, there was no evidence of bias in the parameter estimates for 
Groups A, B and E for any o f the designs where the proportions were the same or very 
similar. This is in contrast to all of the designs in Group G, which showed evidence of 
bias for the parameter estimates.
The results may have been easier to interpret if  the total number in the samples had been 
controlled, so that the variance was controlled. Alternatively, it may have been easier to 
detect patterns if  the missing observations had been introduced into only one factor at a 
time before introducing them into both factors.
It is not clear whether the general conclusions given above based on the large sample 
sizes, apply in the small sample size context. The main observation from fitting 
exponential regression models to small sample sizes was that there was bias observed 
(Section 6.3.6).
From Section 6.4, it appears that in the simulated context examined in this thesis, the 
findings about the effect on the parameter estimates, in terms of bias, based on the 
exponential regression model, could be carried tlirough to the Cox model, in general. 
Here, the data were created to satisfy the exponential regression model for the complete 
data context, but not for the missing cells.
However, there is uncertainty whether different results would be obtained from the two 
models if the complete data were generated to be non-exponential, but still with 
proportional hazai'ds, rather than the constant hazards obtained for the exponential 
regression models, for the known cells. The uncertainty is because the exponential 
regression model assumes a particular parametric form for the baseline hazard function 
whereas the Cox model does not assume any distributional form for this and the only 
assumption made is that the hazards are proportional between the levels of a factor.
198
SECTION C :
FINAL THOUGHTS
CHAPTER 7 DISCUSSION AND CONCLUSIONS
7.1 SUMMARY OF KEY FINDINGS
F R O M  V A R IO U S  R E G IS T R Y  D A T A S E T S
Breast cancer is a major health problem for women throughout the world, with 1 in 12 
women getting the disease at some point in their lifetime. The incidence still appears to 
be rising, although there are some suggestions that the mortality in the UK is beginning 
to fall. Survival from the disease appears to be rising only slightly in Scotland, although 
the relative survival figures for Scotland aie below average when compared to other 
European countries.
F R O M  T H E  B R E A S T  C A N C E R  A  U D IT D A T A
Chapter 4 showed that the presence of missing values in the clinical factors were 
associated with each other, with all two-way interactions, except one, present in the best 
fitting log-linear model. The conclusion from this model was that a woman was more 
likely to have a missing value in one of the four variables if she also had a missing value 
in another of the variables than if she had known information for that variable. The 
exception was for conditional independence between clinical stage and pathological 
node status, given the presence of ER status and tumour size. The clinical interpretation 
of this model appeared to imply that hospitals had agreed protocols, or at least informal 
practice agreements, for management of women with breast cancer.
Having discovered this pattern amongst these unknown values, different methods for 
handling missing values in models were discussed. The methods used in survival 
analyses of several breast cancer studies were then detailed and it was found that only
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the complete cases and additional categories methods were employed in the studies 
examined.
In Chapter 5, the results of the initial survival analysis reported by Twelves et al (1998a) 
were summarised, along with a discussion of the implications of the finding that there 
were significant different survival chances depending on which Health Board the 
women were treated in, but that there appeared to be no significant differences amongst 
the deprivation categories or by sm'gical case load in the Cox model. These findings are 
discussed in relation to other relevant literature. The results of Twelves et al (1998a) 
support the findings from other studies for the need for breast cancer to be managed in 
the setting of a multidisciplinary team. When it was checked whether any interactions 
o f the clinical factors with the Health Board variable were significant, it was not 
possible to conclude that any were necessary and, therefore, none were included in the 
model.
Some model checking on the 'Clinical Full' model revealed that the proportional hazards 
assumption may be in question for ER status, with the increased hazai d of death for 
women having ER negative tumours appearing to weaken over time. However, it is not 
entirely clear how to cany out the time-dependent modelling when then covariates are 
categorieal with more than two levels, rather than binary or continuous. No unique 
method exists for this situation and so the results from the modelling performed have to 
be interpreted with caution.
The presence o f missing values in some of the covariates gave rise to the possibility of 
drawing different conclusions from the results from fitting Cox regression models 
depending on whether, and how, these missing values were included in the models. 
Large absolute differences in survival estimates were observed in some of the tables 
presented in Seetion 5.4.2 which could considerably influence the interpretation of the 
findings.
F R O M  T H E  S IM U L A T IO N  E X E R C IS E  D A T A
In Chapter 6, it was shown that including missing values using the additional categories 
method in an exponential regression model caused the proportional hazards assumption
200
to be violated, when the missing values comprised of a random mixture of observations 
from exponential distributions. When this theoretical finding was examined empirically 
in simulation exercises, some of the parameter estimates obtained appeared to be biased 
due to fitting an incorrect model. Some of the estimated hazard ratios were different 
when exponential and Cox regression models were fitted, for the situations with and 
without the missing data categories (results in Sections 6.3.5 and 6.4). This is 
analogous to the results observed for the Cox modelling of the Breast Cancer Audit data 
(Section 5.4.2). There, it appeared that the hazard ratios for some o f the Health Boards 
compared to Greater Glasgow Health Board were different for the complete cases and 
the all cases models.
7.2 FURTHER RESEARCH POSSIBILITIES
There are several areas of work that it would have been interesting to pursue had there 
been more time available. These include:
(i) modelling the Breast Cancer Audit data using some of the other methods for 
handling the missing values.
It would be interesting to examine the results from using other techniques discussed in 
Section 4.3 to find out whether the interpretations from the models were similar to, or 
different from, those given by the ‘Clinical Full’ model obtained from fitting a Cox 
model to the data using the additional categories method in the initial survival analysis.
(ii) fitting non-proportional hazards models to the Breast Cancer Audit data.
It would be worthwhile to investigate whether the suggested non-proportional hazards 
result for ER status fiom the time-dependent modelling exereise was reasonable by 
fitting some non-proportional hazards models to the data and comparing the results with 
the ‘Clinical Full’ model.
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(iii) exploring the exponential regression and Cox modelling simulation exercises in 
more detail.
It would be useful to examine the findings of these simulation exercises if  censoring had 
been incorporated into the design or if  the artificial datasets had been created to have 
proportional hazards which were not generated from exponential distributions.
(iv) investigating other structures than the random mixtures assumed in this thesis for 
the missing data would also be an interesting exercise to simulate and undertake.
(v) studying a tlireshold for the amount of missing values acceptable in a Cox model in 
terms of clinical significance.
The main message taken from Section 5.4.2 when the all cases (ACM) and the complete 
cases (CCM) models were compared was that the interpretations of the results for these 
models appeared to be very different, although it was not possible to formally test for 
statistical differences between the sets of results. A great deal of fluctuation was 
observed amongst the parameter estimates for the Health Boards obtained for the two 
cohorts and also for the 5-year % suivival estimates for different Health Boards among 
different prognostic groups.
Here, it was seen that having 64% of cases with some missing information in one of the 
four main clinical factors caused differences in results to be clinically significant (when 
compared to magnitudes observed in clinical trials for beneficial treatments; Section 
2.3.2). It is not clear, however, exactly how much missing data was needed to observe 
these clinically significant results, nor whether the results were mainly affected by the 
introduction of missing values in only one variable in particular, or in any of them. 
However, from the work given in Chapter 6, it was found that the influence on the bias 
o f the missing values depended on the context, as well as the overall percentage missing 
and the distribution of the missing values. In some designs, no bias was observed with 
the introduction o f missing values.
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As an alternative to the simulations given in Chapter 6, it would be interesting to 
perform a sensitivity analysis to examine the effect of altering the percentage of missing 
values in some or all of the factors in the ‘Clinical Full’ model for the Breast Cancer 
Audit data. It would be possible to approach this in a couple of ways. The aim in all of 
the techniques suggested below would be to identify at what point the differences 
became clinically non-significant, thus highlighting a threshold whereby the inclusion of 
missing values cease to be important. At this point, it would not matter whether or not 
the missing values were included in the model. The threshold identified could then be 
applied to similar data-sets for breast cancer, and the method used applied in survival 
analyses of other cancers. From Chapter 6, this may not be a straightforward exercise.
U S IN G  T H E  C O M P L E T E  C A S E S  C O H O R T  A S  T H E  B A S E L IN E
Initially the complete cases model (Section 5.4.2) would be fitted and these results used 
as the baseline for all comparisons. One reason for doing this is that the Cox model is 
theoretically correct as the proportional hazards assumption holds. Here, it is 
unimportant that this is a sub-population of the total cohort as this is being used as the 
baseline. Various different strategies could be employed.
(a) Adding a proportion of cases with missing values, without being concerned about 
which variables are missing. This could be done by random simulation of cases, with 
say, 5%, 10%, 25%, 50%, 75% and 100% with missing values in extra cases introduced 
with the complete cases.
(b) Another approach would be to start with one variable only, say ER status, and firstly 
examine the complete cases analysis parameter estimates; then keep only cases with ER 
status known but allow missing values in other variables and examine parameter 
estimates; then keep only cases where other variables known but allow ER status to be 
missing; and finally the all cases model. This method is similar to the two partial cases 
models fitted in Section 5.4.2.
(c) An extension o f (b), whereby cases which have complete information on a subset of 
variables are introduced and the effect o f altering the combinations of variables with 
known and missing information compared.
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APPENDICES
APPENDIX 1 VARIABLES COLLECTED IN THE BREAST CANCER 
AUDIT
The data collected at each of these stages of management of breast cancer are 
discussed separately. The list given below provides an idea of the information 
collected at each stage and is not exhaustive.
Referral Patterns: These included the date the woman saw her GP, the date the 
woman first saw a surgeon, the hospital of initial referral, the date the woman was 
first seen by an oncologist and whether the cancer was detected as part of the 
Screening Programme.
Initial Staging Information: This was collected at the clinic and involved collecting 
the clinical TNM stage and also the menstrual status o f the women. A fine needle 
aspiration could also be performed in the clinic to help to decide whether the lump 
was malignant.
Surgical Procedures: Usually some form of surgeiy was needed to be able to give a 
definitive diagnosis of breast cancer. This could just be a biopsy to investigate 
whether the lump was cancerous or could be definitive surgeiy to remove either just 
the tumour, in breast conservation, or the whole breast, in a mastectomy. Also given 
were details relating to whether surgery was performed on the axilla to remove lymph 
nodes and whether the ovaries were surgically removed. The surgeon performing the 
operation and at which hospital the operation took place were recorded.
Other Forms of Treatment: Details were given relating to the hormone treatment 
administered, including any ovarian suppression, along with any chemotherapy 
regimens the woman was started on. The site as well as dates were given for any 
radiotherapy the women received.
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P a t h o l o g y  D e t a i l s :  This information was normally included as a separate report in 
the case notes, having been sent from the pathology laboratory. The size o f the 
tumour excised was given, when measured in the laboratory, along with details of any 
tumour involvement in the margins of the tissue removed. The number of nodes that 
were found in the sample or clearance of the axilla was given together with the 
number of nodes with tumour involvement. Histological grading information was 
also reported, as was the ER status which was determined tlirough several different 
techniques, whose continuous scores cannot be combined. Thus, either positive or 
negative was also given for BR status, as well as the score from the particular' assay.
F o l l o w - u p  a n d  O u t c o m e  I n f o r m a t i o n :  Dates and sites of the first local, regional and 
distant recurrences were recorded. Also given were details of any clinical trials into 
which the woman had been entered. The status (alive or dead) was noted, with either 
the date of death or the date last seen recorded.
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APPENDIX 2 KEY TO THE HEALTH BOARD CODES
Table A2.1 gives the codes that are usually given for the Health Boards in most 
NHSiS documents. Due to the small numbers of women treated in Orkney, Shetland 
and Western Isles, these Health Boards are represented here by the ‘Health Board’, 
‘the Islands’, to represent off-mainland treatment.
Health 
Board Label
Health Board
A Ayrshire & Arran
B Borders
C Argyll & Clyde
F Fife
G Greater Glasgow
H Highland
I Islands
L Lanarkshire
N Grampian
S Lothian
T Tayside
V Forth Valley
Y Dumfries & Galloway
T a b l e  A 2 .1 :  K e y  to  th e  H e a l th  B o a r d s .
i>
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APPENDIX 3 BREAKDOWNS OF THE VARIABLES USED IN THE 
ANALYSIS OF THE BREAST CANCER AUDIT "I
In all o f the tables, ‘No.’ stands for number.
Clinical Variables:
Age group No. % Clinical stage No. % ER status No. %
< 50  years 476 29.4 I 302 18.7 Positive 599 37.0
50-64 591 36.5 II 813 50.2 Negative 391 24.2
6 5 -7 9 480 29.6 III 187 11.6 Not known 629 38.9
> 80  years 72 4.4 Not known 317 19.6
T a b l e  A 3 .1 :  N u m b e r s  a n d  p e r c e n t a g e s  f o r  e a c h  o f  th e  c l i n ic a l  v a r i a b l e s .
Node status No. % Tumour size No. %
Positive 583 36.0 < 2 cm 625 38.6
Negative 601 37.1 > 2 cm 662 40.9
Not known 435 26.9 Not knovm 332 20.5
T a b l e  A 3 .1  c o n t:  N u m b e r s  a n d  p e r c e n t a g e s  f o r  e a c h  o f  th e  
c l i n i c a l  v a r i a b l e s .
Treatment Variables:
%
Adjuvant
endocrine
therapy
No. % Adjuvant
chemotherapy
No. % Adjuvant
radiotherapy
No. %
Given 1052 65.0 Given 123 7.6 Given 660 40.8
Not given 567 35.0 Not given 1496 92.4 Not given 959 59.2
à
Type of No. % Adjuvant No. %
surgery chemotherapy or
endocrine therapy
Mastectomy 976 60.3 Given 1138 70.3
Conservation 643 39.7 Not given 481 29.7
T a b l e  A 3 .2  c o n t:  N u m b e r s  a n d  p e r c e n t a g e s  f o r  e a c h  o f  th e  
t r e a t m e n t  v a r i a b l e s .
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Service Variables:
Deprivation
group
No. % Referral
to
oncologist
No. % Surgeon 
case load
No. %
Least deprived 404 25.0 No 738 45.6 1 - 9  cases 278 17.2
Intermediate 982 60.7 Yes 852 52.6 10 -29 683 42.2
Most deprived 233 14.4 Not known 29 1.8 Team / 30+ 647 40.0
Not known 11 0.7
T a b l e  A 3 .3 :  N u m b e r s  a n d  p e r c e n t a g e s  f o r  e a c h  o f  th e  s e r v i c e  v a r i a b l e s .  N o te  th a t  
'n o  ‘f o r  r e f e r r a l  to  a n  o n c o l o g i s t  in c l u d e d  th o s e  w o m e n  w h o  s a w  a n  o n c o l o g i s t  a f t e r  
th r e e  m o n th s  o f  d ia g n o s i s .  N o te  th a t  l e a s t  d e p r i v e d  i s  th e  f i r s t  q u in t i l e ,  in te r m e d ia t e  
d e p r i v a t i o n  g r o u p  in c lu d e s  q u in t i l e s  II, I I I  a n d  I V  a n d  m o s t  d e p r i v e d  i s  th e  l a s t  
q u in t i l e .
Health
Board
No. %
A 126 7.8
B 22 1.4
C 107 6.6
F 91 5.6
G 343 21.2
H 72 4.4
I 25 1.5
L 135 8.3
N 186 11.5
S 235 14.5
T 148 9.1
V 68 4.2
Y 61 3.8
T a b l e  A 3 .3  c o n t:  N u m b e r s  a n d  
p e r c e n t a g e s  f o r  H e a l th  B o a r d .
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APPENDIX 4 CROSS-TABULATIONS OF THE PAIRWISE CLINICAL 
VARIABLES AND THE CLINICAL VARIABLES BY SURGEON CASE 
LOAD
In all o f the tables, ‘NK’ stands for unknown.
Cross-tabulations o f the pairwise clinical variables.
C l C II c m C N K Total Total
Number
A <50 25.2 49.8 7.1 17.9 100 476
A 50-64 18.1 51.4 10.8 19.6 100 591
A 65-79 13.3 50.4 16.0 20.2 100 480
A > 80 15.3 41.7 16.7 28.4 100 72
Total 18.7 50.2 11.6 19.6 100 1619
T a b l e  A 4 .1 :  P e r c e n t a g e s  o f  c l i n i c a l  s t a g e  (C ) b y  a g e  (AJ.
E + E - E N K Total Total
Number
A <50 34.5 30.9 34.7 100 476
A 50-64 40.8 25.2 34.0 100 591
A 65-79 36.9 19.4 43.8 100 480
A > 80 23.6 2.8 73.6 100 72
Total 37.0 24.2 38.9 100 1619
T a b l e  A 4 .2 :  P e r c e n t a g e s  o f E R  s t a t u s  (E ) b y  a g e  (A ).
N + N - N N K Total Total
Number
A <50 37.2 43.1 19.7 100 476
A 50-64 39.1 40.1 20.8 100 591
A 65-79 34.0 31.3 34.8 100 480
A >80 16.7 12.5 70.8 100 72
Total 36.0 37.1 26.9 100 1619
T a b l e  A 4 .3 :  P e r c e n t a g e s  o f  n o d e  s t a tu s  (N ) b y  a g e  (A ).
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T < 2 T > 2 T N K Total Total
Number
A <50 39.1 34.2 26.7 100 476
A 50-64 40.1 41.6 18.3 100 591
A 65-79 36.9 45.6 17.5 100 480
A >80 34.7 47.2 18.1 100 72
Total 38.6 40.9 20.5 100 1619
T a b l e  A 4 .4 :  P e r c e n t a g e s  o f  tu m o u r  s i z e  (T ) b y  a g e  (A ).
E + E - E N K Total Total
Number
C l 39.1 20.2 40.7 100 302
C II 40.5 26.7 32.8 100 813
c m 34.2 28.9 36.9 100 187
C N K 27.8 18.6 53.6 100 317
Total 37.0 24.2 38.9 100 1619
T a b l e  A 4 .5 :  P e r c e n t a g e  o f E R  s t a tu s  (E ) b y  c l i n i c a l  s t a g e  (C ).
N + N - N N K Total Total
Number
C l 17.2 47.4 35.4 100 302
C II 38.3 39.5 22.3 100 813
CHI 64.2 15.0 20.9 100 187
C N K 31.5 34.4 34.1 100 317
Total 36.0 37.1 26.9 100 1619
T a b l e  A 4 .6 :  P e r c e n t a g e s  o f  n o d e  s t a tu s  (N ) b y  c l i n i c a l  s t a g e  (C ).
T < 2 T > 2 T N K Total Total
Number
C l 59.9 17.5 22.5 100 302
C II 36.2 46.9 17.0 100 813
c m 16.0 68.4 15.5 100 187
C N K 37.9 31.5 30.6 100 317
Total 38.6 40.9 20.5 100 1619
T a b l e  A 4 .7 :  P e r c e n t a g e s  o f  tu m o u r  s i z e  (T )  b y  c l i n i c a l  s t a g e  (C ).
- A -
Ï
I
' 5;
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N + N - N N K Total Total
Number
E + 39.6 40.7 19.7 100 599
E - 40.4 38.4 21.2 100 391
E N K 29.9 32.9 37.2 100 629
Total 36.0 37.1 26.9 100 1619
T a b l e  A 4 .8 :  P e r c e n t a g e s  o f  n o d e  s t a tu s  (N ) b y  E R  s t a tu s  (E ).
T < 2 T > 2 T N K Total Total
Number
E + 44.6 39.1 16.4 100 599
E - 33.5 47.6 18.9 100 391
E N K 36.1 38.5 25.4 100 629
Total 38.6 40.9 20.5 100 1619
T a b l e  A 4 .9 :  P e r c e n t a g e s  o f  tu m o u r  s i z e  (T ) b y  E R  s t a tu s  (E ).
T < 2 T > 2 T N K Total Total
Number
N  + 29.3 53.5 17.2 100 583
N - 44.8 35.3 20.0 100 601
N N K 42.5 31.7 25.7 100 435
Total 38.6 40.9 20.5 100 1619
T a b l e  A 4 .1 0 :  P e r c e n t a g e s  o f  tu m o u r  s i z e  (T ) b y  n o d e  s t a tu s  (N ).
Cross-tabulations of the clinical variables with surgeon case load.
Note (for Tables A4.11 to A4.15) that for 11 women, the surgeon performing the 
operation was not recorded in the case notes. Therefore, the case load of the surgeon 
was unknown and not included in all analyses.
A <50 A 50-64 A 65-79 A >80 Total
Number
S 1-9 28.8 33.8 30.2 7.2 278
S 10-29 23.9 35.1 35.6 5.4 683
S Team /30+ 35.5 39.4 22.9 2.2 647
Total 29.4 36.6 29.5 4.4 1608*
T a b l e  A 4 .1 1 :  P e r c e n t a g e s  o f  a g e  (A ) b y  s u r g e o n  c a s e  l o a d  (S). 
T h e  P  v a lu e  f o r  th e  t e s t  o f  a s s o c i a t i o n  w a s  < 0 .0 0 1 .
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C Ï C II c m CN K Total
Number
S 1-9 16.9 46.4 10.4 26.3 278
S 10-29 19.0 45.4 11.9 23.7 683
S Team /30+ 19.2 57.0 11.7 12.1 647
Total 18.7 50.2 11.6 19.5 1608*
T a b l e  A 4 .1 2 :  P e r c e n t a g e  o f  c l i n i c a l  s t a g e  (C )  b y  s u r g e o n  c a s e  l o a d  (S). 
T h e  P  v a lu e  f o r  th e  t e s t  o f  a s s o c i a t i o n  w a s  < 0 .0 0 1 . ;
■A
E + E - E N K Total
Number 1
S 1-9 25.9 15.8 58.3 278
S 10-29 28.8 22.7 48.5 683 1
S Team /30+ 50.7 29.2 20.1 647
Total 37.1 24.1 38.7 1608* V’
T a b l e  A 4 .1 3 :  P e r c e n t a g e s  o f  E R  s t a t u s  (E ) b y  s u r g e o n  c a s e  l o a d  (S ). 
T h e  P  v a lu e  f o r  th e  t e s t  o f  a s s o c ia t i o n  w a s  < 0 .0 0 1 .
?
-
y
N + N - N N K Total
Number 1
S 1-9 37.8 32.0 30.2 278 s
S 10-29 31.5 31.5 37.0 683 .1
S Team/30+ 40.3 45.7 13.9 647 1Total 36.1 37.3 26.6 1608*
T a b l e  A 4 .1 4 :  P e r c e n t a g e s  o f  n o d e  s t a tu s  (N ) b y  s u r g e o n  c a s e  l o a d  (S). 
T h e  P  v a lu e  f o r  th e  t e s t  o f  a s s o c i a t i o n  w a s  < 0 .0 0 1 .
T < 2 T > 2 T N K Total
Number
S 1-9 34.9 42.1 23.0 278
S 10-29 38.7 42.2 19.2 683
S Team /30+ 40.6 39.3 20.1 647
Total 38.8 41.0 20.2 1608*
T a b l e  A 4 .1 5 :  P e r c e n t a g e s  o f  tu m o u r  s i z e  (T ) b y  s u r g e o n  c a s e  l o a d  (S). 
T h e  P  v a lu e  f o r  th e  t e s t  o f  a s s o c i a t i o n  w a s  0 .4 2 .
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APPENDIX 5 STANDARD ERROR FOR THE SURVIVAL ESTIMATE 
FROM COX REGRESSION USING THE SPSS STATISTICS PACKAGE
Example (i): From Table 5.20b in Section 5.4.2, the 5-year % suiTival estimates for 
the group E+, N+, T>2 for Health Boards G and T were 76.9% and 61.1% 
respectively. The corresponding standard errors were 2.03% and 3.03% respectively. 
Thus, the 95% CIs for survival are for G: (72.9%, 80.9%) and for T; (55.2%, 67.0%). 
These CIs do not overlap and so informally it appears that there are significant 
differences between these two Health Boards.
However, the hazard ratio for HB T vs G is 1.87 (95% Cl: 0.90, 3.89), which implies 
that HB T is not significantly worse than HB G.
Example (ii): From Table 5.20b, the 5-year % survival estimates for the group E-, 
N+, T < 2 for Health Boards G and Y were 46.0% and 87.1% respectively. The 
corresponding standard eirors were 3.59% and 1.21% respectively. Thus, the 95% 
CIs are for G: (39.0%, 53.0%) and for Y: (79.3%, 89.5%). These CIs do not overlap 
by a wide margin, and so informally it appears that there are significant differences 
between these two Health Boards.
This apparent problem was identified using Version 9.0 of the SPSS statistics package 
during this reseaich when the standai'd errors for some of the HB, prognostic factors 
combinations were obtained and confidence intervals (CIs) given for the 5-year 
survival estimates (Section 5.4.2). The first two examples illustrate why there appears 
to be some uncertainty regarding the estimate of the standard error.
However, the hazard ratio for HB Y vs G is 0.18 (95% Cl: 0.02, 1.29), which implies 
that HB Y is not significantly worse than HB G.
To investigate this apparent inconsistency, SAS Version 6.12 was used to compare the 
results. However, due to the difficulties of fitting categorical factors in SAS 
(especially with HB having 13 levels and an interaction being present in the ‘Clinical
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Fuir model), a much simpler situation was considered where only binary variables 
were modelled in two examples. The product-limit method was used in SAS to 
compute the survivor function estimates. The parameter estimates using this method 
exactly matched those obtained from SPSS. There is only one option available in 
SPSS.
i
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Example (ii:): The binary variable (Y=l, G=0) compared HB Y with HB G with only 
these two Health Boards included in the fit. The corresponding results obtained from 
SAS and SPSS were as follows (Table A5.1):
SAS SPSS
Log hazard ratio for Y vs G -1.311103 -1.3111
Standard error for log hazard ratio 1.00937 1.0094
5-yr suivival estimate for Y 0.91848 0.9185
Standard error for 5-yr survival for Y 0.07807 0.0121
5-yr survival estimate for G 0.72941 0.7294
Standard error for 5-yr survival for G 0.03456 0.0356
T a b l e  A 5 . Î :  R e s u l t s  f o r  th e  C o x  m o d e l s  f i t t e d  b y  th e  tw o  s t a t i s t i c a l  p a c k a g e s  
f o r  E x a m p l e  ( in ).
The number of decimal places for each figure reflect those given by default in the 
output from the two packages exactly.
Thus, showing very different results for the standard errors for the 5-yr suivival 
estimates for HB Y between SAS and SPSS. (The values for G were also different).
For both packages: the hazard ratio for Y vs G was 0.270 with 95% Cl (0.037, 1.949)
NOT DIFFERENT
For SAS: the 5-yr survival estimate for Y was 0.9185 with 95% Cl (0.7655, 1)
for G was 0.7294 with 95% Cl (0.6617, 0.7921) 
NOT DIFFERENT
For SPSS: the 5-yr suivival estimate for Y was 0.9185 with 95% Cl (0.8948, 0.9422)
for G was 0.7294 with 95% Cl (0.6596, 0.7992) 
DIFFERENT
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Thus, the SAS set of figures produced consistent interpretations fi*om the hazard ratio 
and the survival estimates, whereas the SPSS figures did not.
Example (iv): The binary variable (S=l, G=0) compared HB S with HB G with only 
cases for these two Health Boards included in the fit. The corresponding results 
obtained from SAS and SPSS were as follows (Table A5.2):
SAS SPSS
Log hazard ratio for S vs G -0.206406 -0.2064
Standard error for log hazard ratio 0.20589 0.2059
5-yr survival estimate for S 0.78096 0.7810
Standard error for 5-yr survival for S 0.03142 0.0222
5-yr survival estimate for G 0.73792 0.7379
Standard error for 5-yr survival for G 0.03276 0.0258
T a b l e  A 5 . 2 :  R e s u l t s  f o r  th e  C o x  m o d e l s  f i t t e d  b y  th e  t w o  s t a t i s t i c a l  p a c k a g e s  
f o r  E x a m p l e  ( iv ) .
Thus, showing the discrepancies between the two estimates for the standard errors 
from the two packages, but these were not as large as for HB Y vs HB G.
This finding was discussed with members of the Robertson Centre for Biostatistics 
(part of Glasgow University) and, independently, these inconsistencies were replicated 
on a different (much larger) dataset.
I
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C O N C L U S I O N
Due to these findings, it was decided not to use the standard errors until the apparent 
discrepancies had been resolved. Discussions with SPSS Inc. are still on-going and 
the issue remains unresolved.
:
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APPENDIX 6 HAZARD RATIOS AND SURVIVAL ESTIMATES FOR 
VARIOUS SURVIVAL ANALYSES
Variable Hazard Ratio 
(95% Cl)
Age
<50 years 1
5 0 -6 4 1.07 (0.85,1.34)
6 5 - 7 9 1.29 (1.02,1.63)
> 80  years 1.91 (1.28,2.84)
Clinical Stage
Stage I 1
II 1.33 (0.99,1.77)
III 1.90 (1.33,2.71)
Not known 1.34 (0.96,1.87)
ER Status
Positive 1
Negative 2.14 (1.72,2.67)
Not known 1.43 (1.13,1.81)
Node Status by 
Tumour Size
N N K , T < 2 c m 2.55 (1.63,3.99)
N N K , T > 2 4.10 (2.61,6.44)
N N K , T N K 3.50 (2.19,5.62)
N +ve, T < 2cm 4.28 (2.79,6.57)
N +ve, T > 2 4.45 (2.97,6.66)
N + v e , T N K 4.92 (3.11,7.78)
N -ve, T < 2cm 1
N -ve, T > 2 2.82 (1.82,4.37)
N - v e , T N K 1.57 (0.91,2.72)
Health Board
A 1.53 (1.11,2.11)
C 1.50 (1.07,2.12)
F 1.53 (1.04,2.26)
G 1
L 1.21 (0.87, 1.68)
N 0.95 (0.69, 1.32)
S 0.89 (0.65, 1.21)
T 1.35 (0.96, 1.90)
Y 1.09 (0.69, 1.72)
T a b l e  A 6 . I :  H a z a r d  r a t i o s  w i th  9 5 %  C I s  f o r  th e  m o d e l  b a s e d  
o n  1 4 3 2  c a s e s ,  w i t h  H e a l th  B o a r d s :  B , H , I , V  d r o p p e d  f r o m  
th e  A C M . N o te  t h a t  N  a n d  T  s t a n d  f o r  n o d e  s t a t u s  a n d  tu m o u r  
s i z e  r e s p e c t i v e l y .  A ls o ,  N K  s t a n d s  f o r  n o t  k n o w n , + v e  f o r  p o s i t i v e  
a n d  ~ve f o r  n e g a t i v e .
Hrfit'
I
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V ariable
All Cases Complete Cases
5-year %  survival 5-year %  survival
Age
<50 73.3 69.9
50-64 73.8 75.6
65-79 68.1 70.6
>80 48.6 50.0
Clinical Stage
I 83.8 85.2
II 71.1 71.1
III 56.7 62.0
Node Status
Positive 58.8 60.6
Negative 84.5 83.7
T um our Size
Size < 2 cm 80.2 82.0
Size > 2 cm 62.2 64.5
ER  Status
Positive 80.0 82.7
Negative 60.9 56.1
T a b l e  A 6 .2 :  K a p la n - M e i e r  %  s u r v i v a l  e s t im a te s  a t  f i v e  y e a r s  w i t h o u t  
C I s  f o r  th e  tw o  a n a l y s e s .  N o te  th a t  N  a n d  T  s t a n d  f o r  n o d e  s t a tu s  
a n d  tu m o u r  s i z e  r e s p e c t i v e l y .
■•■I
Vf'
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;Variable
All Cases Complete Cases
5-year % survival 5-year % survival
Health Board
A 63.5 75.0
C 63.9 58.4
F 68.1 56.1
G 73.8 72.8
L 67.4 71.9
N 75.8 73.3
S 78.3 78.3
T 66.2 65.2
Y 68.9 90.0
Deprivation Category
Least deprived 73.8 74.5
Intermediate 70.9 73.5
Most deprived 65.7 64.0
Surgical Case load
1 - 9  cases 66.6 61.1
1 0 -2 9  cases 69.1 73.2
Team or > 30 74.7 73.6
Seen by an Oncologist
Yes 70.4 70.6
No 71.5 74.9
Type of Surgery
Mastectomy 68.0 68.2
Conservation 75.1 79.1
Adjuvant Radiotherapy
Given 70.2 70.0
Not given 71.3 74.3
Adjuvant Chemotherapy
Given 61.0 55.9
Not given 71.7 74.7
Adjuvant Endocrine Therapy
Given 70.4 77.4
Not given 71.6 64.0
Adjuvant Chemotherapy or Endocrine Therapy
Given 69.9 74.5
Not given 73.2 67.0
T a b l e  A 6 .2  c o n t:  K a p l a n - M e i e r  %  s u r v i v a l  e s t im a te s  a t  f i v e  y e a r s  w i t h o u t  
C I s  f o r  th e  tw o  a n a l y s e s .
I%
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It
(i) Node status and tum our 
size known
(ii) Three pathological 
factors known
V ariable H azard
Ratio
95% C l for 
H azard Ratio
H azard
Ratio
95%  C l for 
H azard Ratio
Age
< 50 1 * 1 *
50-64 1.05 (0.80, 1.37) 0.93 (0.67, 1.28)
65-79 1.05 (0.78, 1.40) 1.00 (0.70, 1.43)
> 80 2.20 (1.23,3.95) 2.10 (0.50, 8.78)
Clinical Stage
I 1 * 1 *
II 1.64 (1.09,2.48) 1.68 (1.01,2.78)
III 2.08 (1.28,3.38) 1.80 (0.98, 3.30)
E R  Status
Positive 1 * 1 *
Negative 2.51 (1.91,3.31) 2.72 (2.05, 3.62)
Node Status by 
Tum our Size
N +T<2 3.95 (2.63, 5.91) 4.62 (2.82, 7.57)
N + T > 2 4.52 (3.08, 6.61) 4.40 (2.74, 7,07)
N- T<2 1 * 1 *
N - T > 2 2.72 (1.81,4.09) 2.82 (1.70, 4.65)
Health Board
A 1.13 (0.70, 1.81) 1.24 (0.75, 2.05)
C 1.91 (1.24,2.94) 2.33 (1.40,3.86)
F 2.04 (1.27,3.28) 2.50 (1.47, 4.25)
G 1 » 1 *
L 1.11 (0.71, 1.75) 0.99 (0.54, 1.81)
N 1.18 (0.80,1.73) 1.21 (0.77, 1.88)
S 0.83 (0.57, 1.20) 0.84 (0.56, 1.24)
T 1.30 (0.78, 2.17) 1.97 (1.02,3.82)
Y 0.34 (0.11, 1.08) 0.18 (0.02, 1.29)
I '
T a b l e  A 6 .3 :  H a z a r d  r a t i o s  (H R ) w i t h  9 5 %  C I s  f o r  th e  f u r t h e r  tw o  a n a l y s e s .  N o te  
t h a t  N  a n d  T  s t a n d  f o r  n o d e  s t a tu s  a n d  tu m o u r  s i z e  r e s p e c t i v e ly .
%
■if..
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APPENDIX 7 DERIVATION OF THE NORMAL EQUATIONS FOR TWO 
FACTORS IN AN EXPONENTIAL REGRESSION MODEL WITH 
COMPLETE CASES ONLY
1
D E S I G N  W IT H O U T  M IS S IN G  V A L U E S
Here, the two factors have only two levels with observations which are taken to satisfy 
an exponential regression model. It is assumed that there is no interaction between 
the factors in an additive model. Suppose there are observations falling in
cell (A:, Z), where A: = 1, 2 and / = 1, 2 represent the levels of factors FI and F2 
respectively. Let these observations be denoted by with =1, ..., .
Then the basic design can be represented by Figure A7.1.
F2
1 2
FI
/7]i 1^2
2^1 ^22
F ig u r e  A 7 .1 :  D ia g r a m  to  r e p r e s e n t  th e  d e s i g n  
w i t h o u t  m i s s i n g  v a lu e s  in  th e  tw o  f a c t o r s .
The pdf for the observations falling in cell (A:,/) is given by
f { y u ,n ^  ) = ^  exp(- K i y u , , , , ) . 
for A: = 1, 2 and / -  1, 2 , where
and the constraints and = 0 are imposed.
The a,^ parameters are main effects related to factor FI and the parameters are 
main effects related to factor F2.
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By the independence assumed between observations falling in each of the separate 
cells, the joint pdf for the observations falling in cell (A:,/) is given by
By the independence between the cells, the overall joint pdf for the four cells is 
therefore given by
'hi
(4 )"" exp
V
for A: = 1, 2 , 7 = 1 ,2  and n \ ,  ~  1, .
The subscript C on f c { y \ ^  is given here to demonstrate that only the complete cases 
(i.e. the known values) are included.
11I
i i
1
The likelihood fmiction can be obtained from the joint pdf and taking logs gives the 
log-likelihood function as
"k!
^cU) = IcigA^ / + Z i “
k, i  k j \  1 /
where d  does not depend on X .
The aim here is to obtain the parameter estimates / /u , « 2  Â  • Therefore, the 
are replaced by their values given above. Thus, the log-likelihood function 
becomes
^c(™) ~ ^11 (Ai) ^ 1 2  (Mi 7 2^ ) ^2 1 (Mi ^ 2 ) ^  ^ 2 2  (Mi ^ 2  ^ 2 )
-[exp(/i„ +a2)]l];'2i„„ -[exp(ft, +«2 +A)]£y22„,.
%
I
ii
'if 
„ 3|
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The three normal equations obtained are:
â l , ( A )
^11 1^2 2^1^  , .,+"22 -[exp(Â i)]Z j'ii»„ -[exp{A i + Â )]£)',2 .
- [e x p (A ,+ « : ) ] £ )^ 2I„,., -[exp(A i + A  + Â ) ] £ J'22,,,,,
= + " 2 2  -[exp(A, + » : ) ] £ ;^ 2w„ -[exp(A i + « 2  + Â ) ] £ % 2.
=  0
à / c i â )
and -  «J2 + 2^2 exp(Ai + Â ) ] Ë ^ i 2,»„ -[exp(Ai + « 2  + Â ) ] £ ) '22»„
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APPENDIX 8 DERIVATION OF THE NORMAL EQUATIONS FOR TWO 
FACTORS IN AN EXPONENTIAL REGRESSION MODEL FOR ALL CASES
D E S I G N  W IT H  M IS S IN G  V A L U E S
When the missing values are also included in the exponential regression model, with 
the missing values being incorrectly taken to satisfy the model, the derivation of the 
normal equations proceeds in the same manner as for the context without the missing 
values (Appendix 7). The assumption of independence in an additive model is again 
made. Here there are now obseivations falling in cell (A:,/), where A: = 1, 2, 3 and 
7 = 1, 2, 3. The new design can be represented diagrammatically by Figure A8.1.
’a-:-r
F2
1 2 3
1 « 11 ^ 1 2 ^ 1 3
FI 2 ^ 2 1 ^ 2 2 ^ 2 3
3 « 3 1 « 3 2 « 3 3
F ig u r e  A 8 .1 :  D ia g r a m  to  r e p r e s e n t  th e  d e s i g n  f o r  th e  
t w o  f a c t o r s  w h e n  m i s s i n g  v a lu e s  a r e  in c lu d e d .
Since the observations falling into cells (l,3) ,(2,3), (3 ,l), (3,2) and (3,3) are taken 
here to be exponential then the pdfs for all nine cells is given by
f{yk lm u  ) "  A/ sxp^- ) )
for A: = 1, 2, 3 and 7 = 1, 2, 3, where
h i  =exp[/2„ + P ]
and represent the hazard functions for the nine cells with the constraints = 0 
and = 0 still imposed.
■:N
■f-
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Again, by independence assumed between observations falling in the same cell, the 
joint pdf for the observations in cell ( k .  I) is still given by
n'%=i
Therefore, by independence between observations in different cells, the overall joint 
pdf for the nine cells is given by
k j
i h i T "  exp ^kl Z^yklnm  '"w=l /
with A: = 1, 2, 3 , 7 = 1,2,  3 and =1, ..., % .
The subscript A here is given to show that all of the cases (i.e. known and missing 
values) have now been included. This is in contrast to the C used before for the 
complete cases in Appendix 7.
Therefore, the log-likelihood function for all cases is given by
_    + e ,
k, i  V 1 J
where e  does not depend on X .
f
A (&) ~  Z  «W A/ + Z  “  A / Z  yklm^.,
k J  , l  \   /
To obtain the normal equations, it is necessary to replace the by the linear 
combinations of the parameter estimates of interest. Differentiation of 7^  ( A) with
respect to the parameter estimates A n  Â , « 3  and Â  yields five normal 
equations which need to be solved simultaneously once they are all set equal to zero. 
The five normal equations for the design with missing values in the two factors case 
are:
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and
^ L i é
— «11 «12  «13 «21 « 2 2  « 2 3  «31 « 3 2  « 33 -[exp(Ai)]Z>'u,»„
exp rti + A  2 ,7 ,2
«13
exp Ml + A  Z .T i3./«i3
-[exp(A , + A )]£ 7 2 „ ,,, -[exp(A i + « 2  + Â )]Z 722
-  exp(Ai + « 2  +Â)1E723,„„ -[exp(A i +«3)]£73i.,J 1 1
-  [exp( A , + « 3 + Â ) j £  732»,,
'«22
«33
e x p U / i i + a j + A  Z,T33)'»33
=  0
= «21 +«22 +«23 -[eXp(Al +»2)]£72,.,„ “ eXp(A, +«2 +Â )]Z 722
exp A, + a ,  + A  Zj723)"'23
0
^ ^ ^  = «,2 +«22 +«32 -[exp(Ai + Â )]E 7 i2,»„ -[exp(Ai +«2 +Â)]£722,„„
OP2 1 1
exp Mi +^^3+A 2-.T32i ' « 3 2
=  0
(7 A(~) r ( '' M’sc f A  I
 - =  « 3 1  +  « 3 2  +  « 3 3  -  [ e X p ( M l  +  « 3  j j Z T 3 1 ; i , 3 ,  “  [ ^ X P ^ M l  +  « 3  +
«32
T32,,2 f IZ-J ^ i2m^ 2 
1
T33,«'33[exp(Ai + « 3  + Â )]Z  
0
— «13 +«23 +«33 |eXp^Al + Â ) j ^ 7,3»,,] eXp^Al + 2^ + Â ] 723,«2,
"3 3
[exp(Ai +(%3 +AjjAT33,«,,
=  0
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APPENDIX 9 DETERM INING TH E MIXING PARAMETERS FO R 
GENERATING THE MISSING VALUES FO R THE TW O FACTORS DESIGN
A sequence of randomly generated uniform numbers was utilised to decide which 
exponential distribution to use to generate the observations falling in the missing cells. 
The appropriate probabilities were chosen based on the relative frequencies of the 
cases in the known levels. The missing value was then generated from the appropriate 
exponential distribution.
The following probabilities for the five missing cells are:
For cell (1 ,3 ) ,  the mixing paiameter was r  = ----- -— , with an observation coming
«11 «12
from an jEx(exp(//jj )) distribution when the attached random uniform number had a 
value < r  ; otherwise the observation was generated from an Ex(exp(^u + A ))
distribution. Similarly, for cell (2,3), the mixing parameter was s  = ----- --— , with
« 2 1  « 2 2
a similar use made of the attached uniform numbers. For cells (3,l) and (3,2), the cut­
offs were t  ~ -----  —  and u  = -------— respectively, again with similar use o f the
«11 « 2 1  « 1 2  « 2 2
attached uniform random numbers.
For cell(3,3), however, tliree probabilities were needed. These were at
« . . + « . 2  . T h e
«11 ”^ « 1 2  « 21  " ^ « 2 2  «11 «1 2  «21  " ^ « 2 2  «11 « 1 2  « 2 1  ”**«22 
observations in this cell were generated from the four possible distributions depending 
on the values of the uniform random numbers attached to each observation. For a 
uniform number of value < a , the observation in cell (3,3) was generated from an
Ex:(exp(//]j)) distribution. When the number lay in the interval ( a , b \  or (&,c], the 
distribution used was an£x(exp(//,i + A ) )  or Er(exp(//^ + (^ 2 ) )  respectively.
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Otherwise, the observation was generated from an fic( exp(//,, + « 2  + A  )) 
distribution. I
I
■H.
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APPENDIX 10 FURTHER RESULTS FROM FITTING AN EXPONENTIAL 
REGRESSION MODEL TO DIFFERENT DESIGNS WITH TWO FACTORS 
AND MISSING VALUES PRESENT
From Section 6.3.5:
GROUP H
Table A 10.1 gives the estimated biases and standard errors for the parameter estimates 
for Group H.
Design s e ( a 2  ) b f )
HI -0.0519 0.0041 -0.0631 0.0040
H2 -0.0160 0.0049 -0.0088 0.0048
H3 -0.0373 0.0044 -0.0431 0.0042
H4 -0.0158 0.0049 -0.0087 0.0048
H5 -0.0145 0.0049 -0.0082 0.0048
H6 -0.0114 0.0050 -0.0080 0.0047
H7 -0.0317 0.0046 -0.0136 0.0047
H8 -0.0148 0.0049 -0.0083 0.0048
H9 -0.0179 0.0049 -0.0199 0.0046
HIO -0.0145 0.0050 -0.0127 0.0047
H ll -0.0090 0.0050 -0.0134 0.0047
H12 -0.0098 0.0051 -0.0091 0.0047
H13 -0.0155 0.0050 -0.0082 0.0048
H14 -0.0197 0.0049 -0.0117 0.0047
HIS -0.0116 0.0050 -0.0119 0.0047
H16 -0.0162 0.0049 -0.0101 0.0047
H17 -0.0162 0.0050 -0.0133 0.0047
H18 -0.0137 0.0049 -0.0073 0.0048
H19 -0.0082 0.0050 -0.0081 0.0047
H20 -0.0102 0.0050 -0.0062 0.0048
H21 -0.0048 0.0051 -0.0058 0.0048
H22 -0.0020 0.0051 -0.0016 0.0048
T a b l e  A  1 0 .1 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  H .
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No clear pattern could be determined from a plot of magnitude o f bias and percentage 
of missing values (Figure AlO.l).
f
Estimated bias in estimates by overall % missing 
group H
0.07 T
0.03
0.02
♦ |B_alp2| 
x|B_bet2|
25
% missing
45
F ig u r e  A l O . l :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a in s t  th e  o v e r a l l  
p e r c e n t a g e  m i s s i n g  f o r  G r o u p  H .
GROUP I
Table A10.2 gives the estimated biases and standard errors for the parameter estimates 
for Group I.
Design s e { a 2 )
11 -0.0202 0.0051 -0.0261 0.0052
12 -0.0116 0.0053 -0.0129 0.0054
13 -0.0116 0.0053 -0.0128 0.0054
14 -0.0106 0.0053 -0.0095 0.0054
15 -0.0106 0.0053 -0.0095 0.0054
16 -0.0076 0.0053 -0.0115 0.0054
17 -0.0103 0.0053 -0.0125 0.0054
18 -0.0060 0.0054 -0.0060 0.0055
T a b l e  A  1 0 .2 :  E s t i m a t e d  b i a s e s  a n d  s t a n d a r d  e r r o r s  f o r  th e  d e s i g n s  in  
G r o u p  I.
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The amount of missing values seemed to affect whether or not the parameter estimates 
were biased, with 14% or more missing leading to biased estimates (Figure A10.2). 
Models 13 and 14 both had 13% missing with model 13 having biased parameter
estimates, whereas there was no evidence of bias of A  for model 14, although was
biased.
0.015
0.005
Estimated bias In estimates by overall % missing 
Group I
% missing
♦ |B„alp2| 
X |B_bet2|
F ig u r e  A 1 0 .2 :  P l o t  o f  th e  m a g n i tu d e  o f  th e  e s t i m a t e d  b ia s  a g a in s t  th e  o v e r a l l  
p e r c e n t a g e  m i s s i n g  f o r  G r o u p  I.
iIfii'i
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